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Outline of the introduction 
 
The research performed as part of this doctoral thesis aimed to gain novel insights into the 
molecular mechanisms driving T-cell acute lymphoblastic leukemia (T-ALL) and to identify 
new therapeutic strategies for patients with T-ALL. In this first introductory chapter, the topics 
covered in the thesis are introduced. The state-of-the-art knowledge and broader context 
provided in Chapter 1 allow a critical reading of the results and discussion. 
In part I, the disease T-ALL and its current treatment are described. The short-comings and 
side effects of the current treatment strategies indicate that there is still room for 
improvement. Within T-ALL, several subgroups can be distinguished. The main focus in this 
doctoral thesis was on the early immature subgroup, a subgroup associated with a poor 
prognosis. Searching new treatment strategies for these patients by investigating the 
molecular mechanisms that play a role in this subgroup was the goal of this work.  
One way to find more effective and targeted therapies is increasing our knowledge on the 
genetic and epigenetic alterations present in T-ALL. In that way, druggable targets can be 
identified. Part II of the introduction discusses therefore the genetic and epigenetic factors 
that play a role in the pathogenesis of T-ALL and the opportunities for targeted therapies. A 
detailed description of ZEB2 (zinc finger E-box binding homeobox 2), KDM1A (lysine 
demethylase 1A) and BET (bromodomain and extraterminal) proteins is given since these 
were central to the research performed in this thesis. The transcription factor ZEB2 is an 
oncogenic driver of early immature T-ALL and the determination of its interaction partners 
was part of our objectives. One of the newly identified interaction partners, KDM1A, turned 
out to be druggable. Consequently, KDM1A inhibition was one of the treatment strategies 
evaluated in this thesis. BET bromodomain inhibitors were also studied in this work and are 
thus also discussed in detail in this part of the introduction. 
Part III deals with the role of apoptosis, a form of programmed cell death, in cancer. The 
pathways of apoptosis are described and ways to exploit apoptosis in cancer therapy are 
given. The emphasis is on the intrinsic pathway of apoptosis, a pathway that is governed by 
the B-cell lymphoma 2 (BCL-2) family of proteins, since inhibition of the anti-apoptotic factor 
BCL-2 was the subject of two publications that are part of this PhD thesis. 
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PART I Description and contemporary treatment of T-cell acute 
lymphoblastic leukemia 
 
1. What is T-cell acute lymphoblastic leukemia (T-ALL)? 
 
Cancer is a genetic disease because the transformation of a healthy cell to a cancer cell is 
caused by changes in genetic material. This transformation is a multistep process during 
which the cells acquire capabilities that enable them to become malignant. The hallmark 
capabilities that allow cancer cells to survive, proliferate and disseminate are sustaining 
proliferative signaling, evading growth suppressors, resisting cell death, enabling replicative 
immortality, inducing angiogenesis and activating invasion and metastasis1. Leukemias are 
cancers of the white blood cells and depending on the type of cell that becomes malignant, 
several types of leukemias can be distinguished.  
Blood cells are lifelong produced from hematopoietic stem cells (HSCs) residing in the bone 
marrow. These HSCs have the capacity of self-renewal and to differentiate in any type of 
blood cell. During this differentiation process, progenitor cell intermediates are formed 
(Figure 1)2.  
Figure 1. Schematic representation of human hematopoiesis. HSCs in the bone marrow (left) can 
differentiate via several progenitor cell intermediates to terminally differentiated blood cells (right). Via the cluster 
of differentiation (CD) cell surface markers, a distinction between the different progenitors can be made. 
Multilymphoid progenitors (MLPs) also possess myeloid, but not erythroid and megakaryocytic potential. 
Accumulation of mutations in a T-cell progenitor can cause T-cell acute lymphoblastic leukemia (T-ALL). HSC: 
hematopoietic stem cell; MPP: multipotent progenitor; MLP: multilymphoid progenitor; ETP: early thymic 
progenitor, CMP: common myeloid progenitor; GMP: granulocyte-monocyte progenitor; MEP: megakaryocyte-
erythroid progenitor; Lin: cocktail containing cell surface markers for all terminally differentiated populations. 
Adapted from Doulatov et al.
2
. 
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All the mature blood cells, with the exception of T cells, are formed in the bone marrow. For T 
cell development, bone marrow-derived thymus seeding progenitors (TSPs) home to the 
thymus. Within the thymus, the cells migrate via a defined pattern through several signaling 
microenvironments and differentiate to mature T cells (Figure 2)3. When during this 
differentiation process mutations occur in a lymphoid progenitor cell (lymphoblast), this cell 
can become malignant. The resulting cancer is called acute lymphoblastic leukemia (ALL) if 
more than 25% of the nucleated cells in the bone marrow are lymphoblasts4, 5. ALL arising 
from T cell progenitors is called T-ALL while transformation of B cell precursors (BCP) leads 
to BCP-ALL. Most symptoms in patients with these diseases are a result from the shortages 
of normal blood cells. Thrombocytopenia leads to bruising or bleeding, anemia causes 
fatigue and pallor while neutropenia can lead to infections. Leukemic cells may also infiltrate 
the liver, spleen, lymph nodes, mediastinum and central nervous system6. 
 
Figure 2. T cell development in the thymus. The thymus provides the necessary microenvironment for the 
development of T cells. Four compartments can be distinguished in a thymus: the subcapsular zone (SCZ), the 
cortex (in blue), the corticomedullary junction (CMJ) and the medulla (in yellow). In the SCZ mainly cortical thymic 
epithelial cells (cTECs) are present. In the cortex a mix of cTECs, fibroblasts and macrophages (MՓ) can be 
found while the medulla is populated by medullary thymic epithelial cells (mTECs) and dendritic cells (DCs). TSPs, 
derived from HSC in the bone marrow, enter the thymus at the CMJ where a dense network of endothelial cells is 
present. They progress to the ETP stage upon contact with the cTECs and differentiate via progenitor cell 
intermediates to mature T cells while migrating through the thymus via a defined pattern. The progenitors are in 
the beginning negative for both the co-receptors CD4 (cluster of differentiation 4) and CD8 and are therefore 
called double negative (DN). Next, they mature to CD4
+
 and CD8
+ 
double positive (DP) cells and finally to mature 
CD4
+
 or CD8
+
 single positive (SP) cells that leave the thymus via blood vessels. Adapted from Koch and Radtke
7
. 
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2. Incidence 
 
Leukemia is the most common cancer type in children under 15 years old. 80% of the 
leukemia diagnoses in this age group are ALL8. The peak prevalence in children is between 
the ages of 2 to 5 years while most adults with ALL are older than 659, 10. Moreover, ALL is 
more common in children than in adults with two-thirds of ALL cases being diagnosed in 
children10. T-ALL accounts for about 15% of childhood and 25% of adult ALL cases11. For 
Belgium this means that about 10-15 children (0-14 years) receive the diagnosis of T-ALL 
each year12. Remarkably, there is a gender bias in T-ALL with more boys than girls being 
affected13. 
 
3. T-ALL subgroups 
 
T-ALL can be subdivided into subgroups based on several criteria, including gene expression 
profiles, genetic rearrangements and immunophenotype. Molecular-cytogenetic and gene 
expression profiling studies demonstrated the existence of 6 distinct molecular subgroups13-17 
(Figure 3): early immature, T-cell leukemia homeobox 1 (TLX1), T-cell leukemia homeobox 3 
(TLX3), TAL/LIM domain only (LMO), homeobox A cluster (HOXA) and the proliferative 
cluster.  
 
 
 
 
 
 
 
Figure 3. Frequencies of molecular subgroups in pediatric T-ALL. Pie chart based on data presented in
14, 17
. 
Each subgroup shows aberrant activation of specific T-ALL transcription factor oncogenes. 
Early immature T-ALLs are characterized by high levels of the transcription factors LYL1, 
LMO2 and myocyte enhancer factor 2 (MEF2C) and high expression of genes expressed in 
early immature thymocytes. The TLX1 and TLX3 clusters have an aberrant expression of 
TLX1 and TLX3 respectively, often caused by genetic rearrangements. In the TAL/LMO 
subgroup, high expression of LMO1/2/3 and/or the basic helix-loop-helix transcription factors 
TAL1/2 is found, often as a result of translocations. Activation of HOXA genes is observed in 
cases with CALM-AF10, SET-NUP214 or mixed lineage leukemia (MLL)-fusions and in 
cases with rearrangements that directly activate HOXA genes. T-ALLs belonging to the 
proliferative cluster display strong expression of proliferation genes together with ectopic 
expression of NK2 homeobox 1 (NKX2-1) or NK2 homeobox 2 (NKX2-2), which is the result 
of rearrangements. The NKX2-1/NKX2-2 rearranged T-ALL cases cluster together with 
TLX1-rearranged cases suggesting related pathogenic mechanisms.  
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Figure 4. Schematic representation of T cell development and the association of T-ALL subgroups with the arrest at a particular developmental stage. Multipotent 
progenitor cells travel from the bone marrow to the thymus (thymus seeding progenitors, TSPs) and differentiate via several progenitor cell intermediates to mature T cells. The 
cluster of differentiation (CD) cell surface markers can be used to distinguish between the different progenitors. In the beginning, T cell progenitors are negative for the 
glycoproteins CD4 and CD8 and are therefore called ‘double negative (DN)’. Once CD1a is expressed, the cells are T cell commi tted which means that the potential to become 
another blood cell type is eliminated. TCR rearrangements at TCRD, TCRG,TCRB and TCRA loci take place during the differentiation process and result in the formation of 
either T cells with TCRαβ or TCRγδ. In the TCRαβ-lineage, cells become positive for both CD4 and CD8 (double positive, DP) and finally undergo a positive and negative 
selection that determines whether the cell matures into CD4
+
 or CD8
+
 single positive (SP) T cells. ISP: immature single positive (CD4
+
). Figure based on data and figures 
presented in
14, 15, 17, 18
. 
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Interestingly, these genetic subtypes relate to an arrest at a particular stage of T cell 
development that can be recognized via immunophenotypic markers (Figure 4). The 
immunophenotypical classification of T-ALL is shown in Table 1 and indicated in Figure 4. 
Table 1. Immunophenotypical classification of T-ALL based on the classification of the European Group 
for the Immunological Characterization of Leukemias (EGIL)
19, 20
. TCR: T cell receptor. 
T-ALL CATEGORY IMMUNOPHENOTYPIC PROFILE 
PRO-T-ALL only intracellular CD3
+
 and CD7
+
 
PRE-T-ALL ≥ 1 of CD2
+
,CD5
+
, CD8
+
 
CORTICAL-T-ALL CD1a
+
 
MATURE T-ALL 
Α/Β
+
 T-ALL (GROUP A) 
Γ/Δ
+
 T-ALL (GROUP B) 
membrane CD3
+
, CD1a
- 
anti-TCR α/β
+ 
anti-TCR γ/δ
+ 
 
Several studies have described early immature T-ALLs based on different criteria. There is a 
large overlap between LYL1+ signature cases15, T-ALLs with absence of biallelic TCRγ locus 
deletion (ABD)21, MEF2C-dysregulated T-ALLs22 and the so-called early T-cell precursor 
ALLs (ETP-ALLs), which are immunophenotypically defined as CD1a-, CD8-, CD5weak with 
stem-cell/myeloid markers such as CD13, CD117, CD33 and CD34. Furthermore, ETP-ALLs 
have a transcriptional program related to early T cell precursors (ETPs)23.  
 
4. Treatment 
 
The treatment for children with ALL consists of 3 phases of chemotherapy that take in total 2 
to 3 years. First, induction therapy is given for 4 to 6 weeks. The drugs included in this phase 
are a glucocorticoid (prednisone or dexamethasone), vincristine, asparaginase and optionally 
an anthracycline. For patients with T-ALL, often cyclophosphamide is added to the regimen. 
The goal of this phase is to achieve remission, which is successful in 98% to 99% of children. 
However, stopping the treatment after this phase would lead to relapse. Therefore, the 
induction phase is followed by a consolidation/intensification phase in which intensive 
combination chemotherapy is given. The most widely used strategy is delayed intensification 
with asparaginase, vincristine and dexamethasone with or without anthracycline, 
mercaptopurine and methotrexate. For patients with T-ALL, repeated courses of extended 
intravenous infusion over 24 hours of high doses methotrexate are widely used. The last 
phase of treatment is the maintenance period taking 18 to 30 months. Daily oral 
mercaptopurine or thioguanine is combined with weekly low-dose methotrexate. Sometimes 
also pulses of glucocorticoids and vincristine are included6, 9, 24. An overview of the working 
mechanisms of the conventional chemotherapeutics is given in Table 2 and Figure 5. For all 
treatment phases, no real consensus exists on what the optimal regimen is24. Intrathecal 
chemotherapy (central nervous system directed therapy) is also given during the treatment in 
order to kill leukemic cells that might have spread to the brain and spinal cord. In the past, 
this was pursued via cranial irradiation, a practice that is now abandoned or limited in most 
protocols due to the adverse side effects25. 
 
 
Chapter 1: Introduction 
9 
  
Table 2. Overview of conventional chemotherapeutics used in the treatment of ALL and their working mechanism. 
 
 
 
 
 
                 
Figure 5. Conventional chemotherapeutics used in ALL
33
.
TYPE OF 
CHEMOTHERAPY 
DRUGS USED IN 
ALL 
WORKING MECHANISM 
GLUCOCORTICOIDS prednisone, 
dexamethasone 
Bind to glucocorticoid receptor. This arrests growth 
and induces apoptosis in lymphoid tissue
26
. 
VINCA ALKALOIDS vincristine Bind to tubulin leading to the disruption of the mitotic 
spindle microtubules organization. Cell cycle is 
inhibited at metaphase of mitosis
27
. 
ENZYMES L-asparaginase Leukemic cells can’t make their own asparagine. 
Asparaginase converts free asparagine to aspartic acid 
leading to starvation
28
. 
ANTHRACYCLINES doxorubicin, 
daunorubicin 
Intercalate with DNA and interfere with the function of 
Topoisomerase II. At high drug levels free radicals are 
formed that induce DNA damage
29
. 
ALKYLATING 
AGENTS 
cyclophosphamide Alkylate and crosslink DNA which induces DNA 
damage and apoptosis. Low doses promote antitumor 
immunity
30
. 
ANTIFOLATES methotrexate Inhibit DNA biosynthesis via the partial depletion of 
reduced folates and direct inhibition of folate 
dependent enzymes
31
. 
NUCLEOSIDE 
ANALOGUES 
6-mercaptopurine, 
thioguanine, 
cytarabine, 
nelarabine, 
clofarabine 
Incorporate into DNA resulting in synthesis inhibition 
and chain termination. Some also inhibit enzymes 
involved in the generation of nucleotides and RNA 
synthesis
32
. 
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Besides chemotherapy, an allogeneic hematopoietic stem cell transplantation (HSCT) 
belongs to the treatment options. HSCT is only used in 5 to 10% of children during primary 
therapy while more than half of the children that relapse receive a transplantation6. 
These pediatric intensive chemotherapy regimens are also recommended for adolescents 
and young adults (AYA) with T-ALL34. Older patients do not tolerate intensive chemotherapy 
as well as AYA. For them, optimized supportive care, targeted therapies, moderately 
intensified consolidation and reduced-intensity stem cell transplantation are the most 
promising approaches for the future. It will be important to discriminate between fit and unfit 
patients35. 
15% to 20% of childhood ALL patients and about 50% of adult ALL patients relapse36, 37. 
Relapses occur the most often during treatment or within the first two years after completing 
the treatment. The major site where relapse occurs is the bone marrow and this may or may 
not be combined with involvement of other sites such as the central nervous system or testes. 
Isolated central nervous system, testicular or other extramedullary relapses occur also but 
are less frequent36. Pediatric patients with an early marrow relapse or T-ALL are considered 
as high-risk relapse patients. Their treatment generally consists of multidrug chemotherapy 
followed by HSCT while low-risk or standard-risk relapse patients receive about 2 years of 
chemotherapy38. The chemotherapy that is currently used to treat relapsed ALL consists 
mostly of different combinations of the same agents used in frontline therapy36. The U.S. 
Food and Drug Administration (FDA) approved the use of the drugs nelarabine (Arranon) and 
clofarabine (Table 2) for treatment of ALL patients with refractory or relapsed disease after 
earlier chemotherapy. Nelarabine is only approved to use in T-ALL patients while clofarabine 
can only be used after at least two prior regimens36, 39. Patients with central nervous system 
relapse are treated with radiotherapy and systemic chemotherapy. Radiotherapy is often also 
used for the treatment of extramedullary relapse while an orchiectomy may be performed in 
case of testicular relapse36, 38. 
The contemporary treatment regimens are accompanied by acute and long-term side effects. 
Long-term toxicities associated with childhood ALL include cardiac dysfunction, 
osteonecrosis, neurocognitive impairment and second malignant neoplasms40. Still, 2-4% of 
pediatric patients die from treatment-related complications, which are mainly caused by 
infections, often preceded by chemotherapy-induced neutropenia, bleeding, thrombosis or 
tumor burden complications and organ toxicity41. Moreover, a high rate of illness due to 
chronic health conditions was found in survivors of childhood cancer42.  
All the chemotherapeutic agents used nowadays for the treatment of T-ALL are non-specific, 
affecting general mechanisms like DNA synthesis and cell division. Therefore, not only 
cancer cells are killed but often also normal healthy cells which causes side effects. A better 
understanding of the molecular mechanisms that cause T-ALL or contribute to the 
development of the disease can lead to the development of molecularly targeted therapies. 
These targeted therapies target specific molecules that are involved in the pathogenesis of 
the disease. By targeting cancer-specific molecules, targeted therapies may have less toxic 
effects on normal cells. 
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5. Prognosis 
 
The cure rate for childhood ALL has gradually increased over the past decades thanks to the 
fine-tuning of combination chemotherapy and better understanding of the disease biology. 
Nowadays, the survival rates reach approximately 85%24, 43, 44. Although these numbers are 
high, the outcome for children that fail induction therapy or suffer from relapsed disease 
remains extremely poor with only 7-23% of relapsed T-ALL patients surviving beyond 3 to 5 
years after the initial diagnosis38. Compared to childhood leukemia, the clinical picture for 
adult ALL is even worse with high relapse rates and 5-year overall survival rates of 35-48%37, 
45-48. Minimal residual disease (MRD), i.e. the residual leukemic cells during or after treatment 
is an important prognostic indicator. MRD can be detected using immunophenotyping by flow 
cytometry (sensitivity of 10-3 to 10-4) and/or quantitative real-time polymerase chain reaction 
(qPCR; sensitivity of 10-4 to 10-5). Follow-up of MRD during treatment can identify patients at 
high risk of relapse and patients with a good response allowing less intensive 
chemotherapy49. In a large cohort of pediatric T-ALL patients, an MRD of more than 10-3 at 
day 78 was the most important predictor for relapse50. The survival chances of ALL patients 
after relapse are influenced by several factors. The outcome is especially poor if relapse 
happens less than 18 months from the initial diagnosis51, 52. 
Most publications describing ETP-ALL reported an inferior outcome with a high proportion of 
remission failure or hematological relapse when using standard intensive chemotherapy23, 53-
56. Also research groups studying LYL1+ early immature T-ALL15, T-ALL with ABD21 and early 
immature adult T-ALL defined on the basis of gene expression data57 found an association 
between early immature T-ALLs and poor prognosis15, 21, 57. However, some studies question 
the prognostic relevance of early immature T-ALL22, 58. A recent study on a large cohort of T-
ALL patients treated on a contemporary protocol failed to find significant differences in 
outcome between ETP-ALL and other T-ALL cases58. 
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PART II The genetic and epigenetic landscape of T-ALL 
 
1. T-ALL development is a multistep process  
 
T-ALL arises from the malignant transformation of T cell progenitor cells. This transformation 
is a multistep process in which thymic progenitor cells gradually accumulate genetic and 
epigenetic changes59. A hierarchical model of T-ALL development has been proposed with 
the formation of pre-leukemic stem cells (pre-LSCs) as first step. Pre-LSCs are long-lived 
cells with self-renewal properties that allow clonal expansion. They harbor some but not all of 
the mutations present in the diagnostic clone. In contrast to fully transformed leukemic cells, 
pre-LSCs retain the ability to differentiate into the full spectrum of mature daughter cells. Pre-
LSCs are often resistant to chemotherapy and can be the origin of relapse. The clonal 
expansion of these pre-LSCs allows the acquisition of oncogenic events leading eventually to 
cancer59, 60. For example, mutations in the DNA methyltransferase (DNMT) DNMT3A were 
found as an early event in acute myeloid leukemia (AML) leading to a clonally expanded pool 
of pre-LSCs from which AML evolves61.  
In T-ALL, the combined overexpression of TAL1 and LMO1 in DN3 mouse thymocytes, the 
double negative stage in T cell development where T lineage commitment driven by 
NOTCH1 takes place, reprograms the DN3 thymocytes into self-renewing pre-LSCs with 
retained differentiation capacity. For this reprogramming, high physiological levels of 
NOTCH1 were critically required. Moreover, overexpression of LYL1 and LMO1 results in a 
similar reprogramming62. Previously, McCormack et al.63 already detected the formation of 
pre-LSCc upon overexpression of Lmo2 in the thymus from mice. An essential factor in this 
reprogramming was LYL164. Again, the self-renewal capacity was restricted to the DN3 
population63.  
Altogether, activation of TAL1 or LYL1 together with LMO1 or LMO2 can drive oncogenic 
reprogramming of DN3 thymic precursors into self-renewing pre-LSCs. These proteins are all 
part of the basic helix-loop-helix transcription factor complex. The transcription factors LMO1 
and LMO2 are recruited to DNA by the basic helix-loop-helix factor TAL1 or LYL159, 60. 
Whether other T-ALL specific transcription factor oncogenes have the capacity to induce self-
renewal remains to be established.  
 
2. Genetic alterations and opportunities for targeted therapies in T-ALL 
2.1. Overview of genetic alterations in T-ALL  
 
T-ALL is a genetically heterogeneous disease in which multiple oncogenes and tumor 
suppressors cooperate to alter the normal mechanisms that control differentiation, growth 
and survival during thymocyte development.  
Constitutive activation of NOTCH1 signaling is identified in over 50% of T-ALL patients13. 
Moreover, deletions of the CDKN2A (cyclin-dependent kinase inhibitor 2A) locus in 
chromosome band 9p21, which encompasses the p16/INK4A and p14/ARF suppressor 
genes, are present in more than 70% of all T-ALL cases13. Thus, constitutive activation of 
NOTCH1 signaling cooperates with loss of p16/INK4A and p14/ARF in T-cell transformation 
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and constitutes the core of the oncogenic program in the pathogenesis of T-ALL. 
Furthermore, aberrant expression of specific transcription factor oncogenes defines the 
distinct molecular-genetic subgroups in T-ALL as described in part I. In addition, whole-
genome T-ALL profiling has provided a fairly complete and comprehensive list of additional 
genetic defects that are shared among the different genetic subclasses and activate a 
plethora of oncogenic signaling cascades, including interleukin-7 receptor (IL7R)/Janus 
kinase (JAK)/signal transducer and activator of transcription (STAT), phosphoinositide-3-
kinase (PI3K)/AKT/mechanistic target of rapamycin (mTOR) and RAS/RAF/mitogen-
extracellular signal-regulated kinase (MEK)/extracellular signal-regulated kinase (ERK) 
signaling65. Hyperactivation of mTOR explains, at least in part, the addiction of T-ALL cells to 
cap-dependent translation in which the eukaryotic initiating factors (eIF) eIF4E and eIF4A 
play an important role66, 67.  
The tyrosine kinase ABL1 is frequently activated via ABL1 genomic rearrangements. 
Additionally, activation of the oncogenic transcription factors MYC and MYB is often found in 
T-ALL. MYC is a critical NOTCH1 direct target gene but can also be activated via rare 
translocations while MYB can be overexpressed in T-ALL via translocations or focal 
duplications. On the other hand, the transcription factor tumor suppressor genes WT1 (Wilms 
tumor 1), LEF1 (lymphoid enhancer binding factor 1) and BCL11B (B-cell CLL/lymphoma 
11B) are often inactivated by mutations or deletions13. De Keersmaecker et al.68 recently 
identified mutations in CCR4-NOT transcription complex subunit 3 (CNOT3), which is part of 
a complex that regulates gene transcription, and in the ribosomal genes RPL5 and RPL10. 
Genetic alterations in early immature T-ALL subtypes  
Early immature T-ALLs are characterized by a high degree of genetic heterogeneity including 
genetic alterations in hematopoietic transcription factors such as RUNX1 (runt related 
transcription factor 1), GATA3 (GATA binding protein 3) and ETV6 (ETS variant 6), activating 
mutations in critical mediators of cytokine receptor and RAS signaling and mutations in 
myeloid specific oncogenes and tumor suppressors69, 70. Given the myeloid mutational 
spectrum and gene expression signature of these tumors, myeloid-directed therapies have 
been suggested for poor prognostic early immature/ETP T-ALL69. 
Adults versus children  
A recent genome-wide sequencing study68 reported a correlation between age at diagnosis 
and number of somatic mutations in T-ALL and showed that particular genes are 
preferentially affected in adults versus children. For example, the newly identified mutations 
in CNOT3 were mainly present in adults, whereas mutations affecting the ribosomal protein 
RPL10 were almost exclusively found in children68. Another example is the plant 
homeodomain finger 6 (PHF6) gene. Van Vlierberghe et al.71 identified PHF6 as an X-linked 
tumor suppressor in T-ALL carrying truncating or missense mutations in about 15% of 
pediatric and 40% of adult T-ALLs. 
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2.2. Opportunities to target genetic alterations in T-ALL  
 
The NOTCH1 signaling pathway gains a lot of attention as a rational molecular target. 
NOTCH1 is a class I transmembrane receptor that regulates T cell development. Upon 
interaction between NOTCH1 and its ligands, the extracellular domains of the receptor are 
cleaved by the ADAM10 metalloprotease. Next, the γ-secretase complex cleaves the 
transmembrane region of the receptor releasing the intracellular portion of NOTCH1 (ICN1) 
which then translocates into the nucleus and activates gene expression of target genes72. 
Most of the NOTCH1 activating mutations identified in T-ALL result in ligand-independent 
receptor activation or stabilization of the cytoplasmic ICN172, 73. Small molecule γ-secretase 
inhibitors (GSIs) block the proteolytic cleavage of NOTCH1 and inhibit the release of ICN1. 
Preclinical studies were promising and GSIs entered phase I clinical trials for patients with T-
ALL72. However, dose-limiting gastrointestinal toxicities were observed and the responses in 
the clinic were limited and not durable74, 75. The use of GSIs in combination with 
chemotherapy or targeted therapies could increase the antileukemic effects of GSIs as 
exemplified by several preclinical studies76-79. In addition to GSIs, blocking NOTCH1 
signaling with NOTCH1 inhibitory antibodies80, 81, preventing the assembly of the ICN1 
transcriptional complex by using the stapled peptide SAHM182 and inhibition of the 
sarco/endoplasmic reticulum calcium ATPase (SERCA) channels to impair the maturation of 
mutated NOTCH1 receptors83, are possible therapeutic options to target oncogenic NOTCH1 
signaling (Table 3). 
As almost 50% of T-ALL patients carry activating mutations in the JAK/STAT, 
PI3K/AKT/mTOR or RAS/RAF/MEK/ERK signaling pathways84, targeting these pathways 
might be an interesting therapeutic strategy. An overview of available inhibitors for these 
pathways and other opportunities for targeted therapies in T-ALL is given in Table 3.  
 
Table 3. Opportunities to target genetic alterations in T-ALL. 
 
 
PATHWAY THERAPIES 
NOTCH1 
- NOTCH1 inhibitory antibodies and stapled peptides (e.g. SAHM1) 
- γ-secretase inhibitors (e.g. PF-03084014) 
- SERCA inhibitors (e.g. thapsigargin) 
JAK/STAT 
- JAK1/JAK2 inhibitors (e.g. ruxolitinib) 
- JAK3 inhibitors (e.g. tofacitinib) 
PI3K/AKT/mTOR 
- PI3K inhibitors (e.g. BKM120) 
- AKT inhibitors (e.g. MK-2206 dihydrochloride) 
- Dual PI3K/mTOR inhibitor (e.g. NVP-BEZ235 (dactolisib)) 
- mTOR inhibitors (e.g. rapamycin) 
RAS/RAF/MEK/ERK 
- MEK inhibitors (e.g. trametinib) 
- ERK inhibitors (e.g. GDC-0994) 
ABL1 KINASE - ABL1 inhibitors (e.g. imatinib) 
CAP-DEPENDENT 
TRANSLATION 
- eIF4A inhibitors (e.g. silvestrol) 
- eIF4E inhibitors (e.g. 4EGI-1) 
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2.3. The transcription factor ZEB2 as an oncogene in early immature T-ALL 
 
ZEB2: a transcriptional repressor or activator ? 
The zinc finger E-box binding homeobox 2 protein (ZEB2/SIP1) belongs to the ZEB family, 
consisting of the two highly homologous proteins ZEB1 and ZEB2. These molecules are 
large multidomain transcription factors that bind with their C-terminal and N-terminal clusters 
of zinc fingers to bipartite E-box motifs in the DNA. Depending on the cellular context and 
target gene, ZEB proteins can act as transcriptional repressors or activators. The availability 
and interactions with other transcription factors and cofactors play an important role in this. 
For ZEB2, interactions with receptor-activated SMADs, the nucleosome remodeling/histone 
deacetylating (NuRD) complex, the transcriptional co-repressor CtBP (C-terminal binding 
protein) and the histone acetyltransferases p300 and p/CAF have been described. 
Furthermore, SUMOylation by the polycomb group protein Pc2 can regulate the 
transcriptional activity of ZEB285, 86 (Figure 6). Additionally, export of the ZEB proteins to the 
cytoplasm in a temporal- and/or tissue-specific manner can also control their functionality86. 
 
 
Figure 6. Schematic representation of the domains and known interaction partners of the ZEB2 
transcription factor. The N- and C-terminal clusters of zinc fingers (ZF) are important for DNA binding while the 
homeodomain (HD), CtBP interacting domain (CID) and Smad binding domain (SBD) are mainly used for protein-
protein interactions with other transcription factors and cofactors with repressor or activator activities. The 
polycomb group protein Pc2 has SUMO E3 ligase activity and SUMOylates (indicated with S in the figure) ZEB2 
at the 390-IKTE-393 sequence. Figure based on
85-87
. 
 
A large intron with an internal ribosomal entry site is present in the 5’ untranslated region 
(UTR) of ZEB2. When the natural antisense transcript ZEB2-AS1 is transcribed, the splicing 
of this intron is blocked with a stronger expression of the ZEB2 protein as result85.  
ZEB2 in epithelial-mesenchymal transition  
ZEB2 is one of the master regulators driving epithelial-mesenchymal transition (EMT). During 
EMT, epithelial cells lose their cell-cell junctions and apical-basal polarity, reorganize their 
cytoskeleton, change their shape and reprogram their gene expression profile to undergo a 
transition to mesenchymal cells. Mesenchymal cells are more motile and are able to degrade 
extracellular matrix proteins enabling them to invade tissues. This process is implicated in 
both normal embryonic development and tumorigenesis88. In several cancer types, such as 
glioma89, colorectal cancer90, renal cell carcinoma91 and ovarian cancer92, ZEB2 
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overexpression is an unfavorable factor that may promote migration and invasion. In 
melanoma, the situation is different. Normal melanocytes do not belong to the epithelial 
lineage and they express already the EMT-inducing transcription factors ZEB2 and SNAIL2 
(snail family transcriptional repressor 2). These factors behave as tumor-suppressor proteins. 
A switch from ZEB2/SNAIL2 to ZEB1/TWIST1 (twist family bHLH transcription factor 1) 
expression was found as a major risk factor for poor outcome in melanoma and was 
associated with a gain in invasive properties93. 
ZEB2 in hematological malignancies  
Zeb2 is abundantly expressed in the hematopoietic system and is essential for differentiation 
and mobilization of hematopoietic stem cells during murine embryonic development94. In 
addition, Zeb2 inactivation in the adult murine hematopoietic system leads also to severe 
differentiation defects95. However, the role of ZEB2 in normal human T cell development and 
hematologic malignancies has not been thoroughly investigated.  
Goossens et al.96 identified the translocation t(2;14)(q22;q32) as a rare but recurrent genetic 
event in early immature T-ALL. Detailed cytogenetic analysis allowed mapping of the 
translocation breakpoint at 14q32 within the BCL11B locus and within close vicinity of the 
ZEB2 gene at chromosomal band 2q22. Notably, juxtaposition of BCL11B near putative 
oncogenes has been previously reported for a number of T-ALL oncogenes including TLX3, 
NKX2-5 and PU.197, 98. Therefore, this work suggested that sustained expression of the EMT 
regulator ZEB2 could act as a molecular driver of immature T-ALL development. It is also 
interesting to note that BCL11B haploinsufficiency has also been implicated in T cell 
leukemogenesis, as exemplified by the loss-of-function BCL11B deletions and mutations 
identified in primary T-ALLs99, 100. Therefore, this particular chromosomal translocation might 
execute a dual function toward malignant T cell transformation with concomitant loss of 
BCL11B and gain of ZEB2, a concept that also applies for the other BCL11B-driven 
translocations mentioned above. Furthermore, ZEB2 was higher expressed in human 
immature T-ALL patients than in other T-ALL patients. Using a conditional ROSA26-based 
Zeb2 gain-of-function mouse model, Goossens et al.96 showed that hematopoietic 
overexpression of Zeb2 resulted in spontaneous thymic lymphoma development starting at 5 
months of age, indicating that Zeb2 can act as a bona fide oncogene in hematologic T cell 
malignancies. Furthermore, breeding of this tumor model in a tumor-prone p53 null 
background revealed that Zeb2 overexpression shortens tumor latency and drives a gene 
expression profile that resembles early immature T-ALL, including the early T cell/stem-cell 
markers c-Kit, Baalc (brain and acute leukemia, cytoplasmic) and Lyl1. Similar activation of a 
stem-cell-like transcriptional program has previously been described in a CD2-Lmo2tg mouse 
model101, in which preleukemic thymocytes acquired Lmo2-driven self-renewal capacity as a 
prerequisite of full clonal T cell transformation63. Similarly, transplantation experiments using 
Zeb2-overexpressing lymphoblasts in immunodeficient mice showed that Zeb2-driven tumors 
contained a higher fraction of leukemia-initiating cells as compared with controls96, 
suggesting some putative commonalities between the Zeb2- and Lmo2-driven tumor models 
as described above. Interestingly, ZEB proteins also bind tandem E-boxes102, suggesting a 
potential overlap or competition for the same regulatory sequences with the above-described 
LYL1/LMO2 transcriptional regulatory complex103. Zeb2 tumors were also characterized by 
enhanced JAK/STAT signaling through transcriptional activation of IL7R96. This association 
between ZEB2 and IL7R/JAK/STAT activation is in line with other recent studies that 
reported alternative in vivo models for early immature T-ALL. Indeed, bone marrow 
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transplantation of precursor cells expressing gain-of-function IL7R104 or JAK3105 mutations 
resulted in the development of a transplantable murine early immature T-ALL, reminiscent of 
the human disease. Altogether, this study96 convincingly identified ZEB2 as a novel 
oncogene implicated in early immature T-ALL, but the molecular mechanisms by which ZEB2 
regulates leukemic stem cell activity, in addition to the spectrum of direct ZEB2 target genes 
that modulate disease initiation or progression, remains to be established. 
Recently, the importance of ZEB2 in the development of acute myeloid leukemia (AML) was 
also identified using shRNA screens. ZEB2 is highly expressed in AML and knockdown of 
ZEB2 in AML cells impaired their proliferation and resulted in aberrant differentiation106. 
 
3. Epigenetic alterations and opportunities for targeted therapies in T-ALL 
3.1. Overview of epigenetic alterations in T-ALL 
 
Changes in transcriptional regulation, which occur independent of the genomic DNA 
sequence, are studied in the field of epigenetics. The dynamic interplay between histone 
modifications and DNA methylation defines the chromatin structure of the human genome 
and serves as a conceptual framework to understand transcriptional regulation. In a recent 
landmark study, Huether et al.107 sequenced 633 epigenetic regulatory genes in over 1000 
pediatric tumors representing 21 different cancer subtypes and found T-ALL to be among the 
tumors with the highest frequency of mutations in genes that encode proteins involved in 
epigenetic regulation. Indeed, over the last 5 years, genome-wide and candidate-approach 
based studies have identified recurrent genomic lesions in a variety of genes involved in 
DNA methylation and post-translational histone modifications in T-ALL. Therefore, disruption 
of epigenetic homeostasis in normal T cells might act as a core component of hematopoietic 
T cell transformation108.  
An overview of epigenetic alterations detected in T-ALL is presented in Table 4. 
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Table 4. Epigenetic alterations in human T-ALL. Table adapted from Peirs et al.
108
 
GENE DEFECT INCIDENCE IN 
T-ALL 
REFERENCES 
DNA METHYLATION    
     DNMT3A
a 
mutation 4-19% 70, 109-112 
     DNMT3B aberrant transcripts NA 113 
     TET1 mutation 6-14% 68, 114 
     IDH1
a
 mutation 2-6% 70, 115 
     IDH2
a
 mutation 5-9% 70, 110 
HISTONE METHYLATION    
     EZH2 mutation/deletion 11-18% 57, 69, 116 
     SUZ12 mutation/deletion 6-11% 57, 69, 116 
     EED mutation/deletion 10% 69 
     JARID2 mutation 1/11 110 
     UTX mutation 5% 68, 107 
     JMJD3 overexpression NA 117 
     MLL1 rearrangements 5% 118 
     MLL2 mutation 10% of ETP-ALL 111 
     DOT1L mislocated 10% 119 
     SETD2 mutation/deletion 8% of ETP-ALL 69 
HISTONE ACETYLATION    
     CREBBP mutation NA 120 
     EP300 mutation 2% 107 
     HDACs  elevated expression  NA 121, 122 
     HDAC5 mutation 1% 107 
     HDAC7 mutation 4% 107 
a Only detected in adults. 
NA: not available 
 
DNA methylation  
DNA methylation is executed by the DNA methyltransferases DNMT1, DNMT3A and 
DNMT3B (Figure 7). This DNA modification controls transcription and chromatin structure, 
maintains genomic stability and regulates X chromosome inactivation123. Aberrant patterns of 
DNA methylation are a characteristic feature of human cancer. The cancer epigenome 
displays global DNA hypomethylation of CpG-poor regions in combination with local 
hypermethylation of CpG-rich promoter regions. The general DNA hypomethylation is 
thought to trigger chromosomal instability, whereas local DNA hypermethylation mediates 
repression of a specific set of tumor suppressor genes124.  
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Figure 7. Schematic representation of DNA (de)methylation with indication of alterations found in T-ALL. 
DNA methylation is carried out by DNA methyltransferases on a cytosine in the context of CpG dinucleotides. 
Methylation of CpG islands at transcriptional start sites is associated with gene silencing while gene body 
methylation was found to correlate with active transcription. DNMT1 is a maintenance DNMT while DNMT3A and 
DNMT3B are responsible for de novo DNA methylation. Furthermore, DNMT3A is needed for the maintenance of 
the methylation canyons which are enriched in genes dysregulated in leukemias. Enzymes from the Ten-Eleven 
Translocation (TET) protein family catalyze the conversion of methylated cytosine to 5-hydroxymethyl-cytosine, 
which promotes DNA demethylation. Neomorphic mutations in isocitrate dehydrogenases (IDH) inhibit the activity 
of TET enzymes via the production of the oncometabolite 2-hydroxyglutarate
108
. 
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Mutations targeting DNMT3A have been identified in up to 19% of human T-ALL and are 
mainly associated with immature T-ALL subtypes57, 111. Similar to what has been observed in 
AML125, 126, DNMT3A mutations are associated with poor prognosis in the context of T-ALL57, 
109. Interestingly, Kramer et al.127 demonstrated with the help of mouse models that DNMT3A 
is required for normal T cell development and acts as a T-ALL tumor suppressor. DNMT3B 
produces several isoforms due to alternative splicing123 and aberrant DNMT3B transcripts 
encoding truncated proteins have been observed in cancer cell lines including the T-ALL cell 
line JURKAT113. Notably, the oncogenic property of one particular isoform was firmly 
established in transgenic mice suggesting that DNMT3B mediated redistribution of DNA 
methylation might be involved in carcinogenesis128. 
It has been postulated that the initial steps of active DNA demethylation are promoted by the 
conversion of 5-methyl-cytosine to 5-hydroxymethyl-cytosine by dioxygenases of the Ten-
Eleven Translocation (TET) protein family which includes TET1, TET2 and TET3129, 130 
(Figure 7). TET1 mutations have been detected in a fraction of human T-ALLs68, 114. TET 
enzymes require 2-oxoglutarate that can be derived from several sources including isocitrate. 
Isocitrate dehydrogenases (IDH) catalyze the decarboxylation of isocitrate to 2-
oxoglutarate131 (Figure 7). IDH1 and IDH2 mutations have not been identified in pediatric T-
ALL132 but seem to occur exclusively in adult T-ALL70, 110, 115. Moreover, and similar to what 
has been observed for DNMT3A mutations, IDH1 or IDH2 mutant adult T-ALL patients show 
characteristic expression of myeloid antigens (CD13 and/or CD33) and a gene expression 
profile reminiscent of HSCs and myeloid progenitors70. 
Histone acetyltransferases and deacetylases  
Histone acetyltransferases (HATs) and histone deacetylases (HDACs) regulate acetylation of 
both histone and non-histone proteins. These enzymes are part of multiprotein complexes 
that determine their substrate specificity and lysine preference. In general, histone 
acetylation releases the chromatin structure and acts as a molecular scaffold for 
transcription-related proteins to trigger active gene transcription133. CREBBP (CREB binding 
protein) and EP300 (E1A binding protein p300) are transcriptional coactivators with HAT 
activity that share significant amino acid homology and have established roles in 
hematopoiesis134. Deletions or loss-of-function mutations in the CREBBP gene have been 
identified in about 20% of relapsed ALL cases and included missense mutations targeting the 
HAT domain and frame-shift or nonsense mutations resulting in truncated CREBBP protein. 
Enrichment of CREBBP mutations at relapse suggests that loss of CREBBP is implicated in 
therapy resistance, possibly through impaired regulation of glucocorticoid responsive 
genes120. In this study, CREBBP mutations were also identified in 3 primary T-ALL samples 
and different T-ALL cell lines120. Notably, heterozygous Crebbp deficient mice show an 
increased incidence of hematopoietic tumors, further confirming the tumor suppressive 
properties of CREBBP in leukemia development135. Although EP300 mutations in relapsed 
ALL were sparse120, independent screening efforts did identify recurrent EP300 mutations in 
about 5% of childhood ETP-ALLs69. Moreover, other studies also reported EP300 mutations 
in a small fraction of pediatric107 and adult110 T-ALL.  
Finally, the oncogenic or tumor suppressive potential of HDACs in the context of T-cell 
transformation remains controversial. Although some studies reported elevated expression 
levels121, 122 or enhanced activity of particular HDACs136 in primary T-ALL, Huether et al.107 
reported somatic mutations in HDAC5 or HDAC7 in about 5% of childhood T-ALL. 
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Histone methyltransferases and demethylases  
The polycomb repressive complex 2 (PRC2) mediates transcriptional gene repression by 
writing the repressive H3K27me3 histone mark at specific loci throughout the genome. Loss-
of-function mutations and deletions targeting the core components of this complex (EZH2 
(enhancer of zeste 2 PRC2 subunit), SUZ12 and EED (embryonic ectoderm development)) 
have been identified in both pediatric69 and adult57, 116 T-ALL. The role of PRC2 as a tumor 
suppressor in the T cell lineage has been confirmed using xenografts of human T-ALL cell 
lines116 and a conditional Ezh2 knockout mouse model110. Although the H3K27 specific 
histone demethylase UTX (ubiquitously transcribed tetratricopeptide repeat, X chromosome) 
and the PRC2 complex seem to exert opposite functions on gene transcription, recent exome 
sequencing analysis unraveled recurrent loss-of-function mutations targeting UTX in about 5% 
of T-ALLs 68, 107, suggesting that both chromatin remodelers can exert tumor suppressive 
functions during T-cell transformation. In contrast, the  H3K27 demethylase JMJD3 (jumonji 
domain containing 3) was shown to be overexpressed in primary T-ALL samples and in a 
mouse model of NOTCH1-induced T-ALL117. 
In T-ALL, rearrangements of the H3K4 methyltransferase MLL1 are found in about 5% of 
patients118 and most frequently result in the expression of MLL1-AF4 or MLL1-ENL fusion 
transcripts137. The leukemic cells of these MLL1-rearranged T-ALLs are characterized by an 
increased level of HOXA expression and show an early arrest in thymocyte differentiation or 
commitment towards the γδ-lineage16, 137. Translocations directly targeting the HOXA locus16, 
138 or genetic rearrangements that result in CALM-AF10 or SET-NUP214 fusion transcripts 
show a similar activation of HOXA gene expression16, 119, 137, 139. Notably, MLL fusion 
proteins140-143 as well as CALM-AF10141, 144 and SET-NUP214119 chimeric proteins recruit the 
H3K79 DOT1-like histone lysine methyltransferase (DOT1L) which results in elevated levels 
of H3K79 methylation at the HOXA locus and concomitant upregulation of HOXA gene 
expression. In addition, MLL2 mutations have recently been identified in 10% of immature 
adult T-ALL111. 
Trimethylation of lysine 36 at histone H3 (H3K36me3) is generally associated with active 
gene transcription and is mainly detected in gene bodies of its target genes145. The enzymes 
NSD1 and NSD2 (nuclear receptor binding SET domain protein 1 and 2) act as H3K36 
mono- and dimethylases, whereas SETD2 (SET domain containing 2) mediates H3K36 
trimethylation. SETD2 functionally connects H3K36me3 with transcriptional elongation 
through binding with RNA polymerase II145. SETD2 mutations and deletions were identified in 
8% of childhood ETP-ALL cases, while no mutations were observed in mature subtypes of 
human T-ALL 69. 
Noncoding RNAs  
Both oncomirs and tumor suppressor miRNAs that negatively regulate the expression of 
respectively tumor suppressor genes and oncogenes have been identified in T-ALL. 
Moreover, the role of long noncoding RNAs in the context of T-ALL is starting to be explored. 
For more details, the reader is referred to an excellent review that was recently published146. 
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3.2. Opportunities to target epigenetic alterations in T-ALL 
 
The overwhelming evidence that inappropriate regulation of epigenetic factors serve as an 
intrinsic part of the molecular circuitry that is perturbed during malignant transformation, 
created an enormous interest in pharmacological intervention of epigenetic processes. 
Indeed, development of targeted therapies against epigenetic modifiers as new treatment 
modalities for human leukemia is currently ongoing and epigenetic opportunities for targeted 
therapy that might be relevant for the treatment of human T-ALL are summarized in Table 5. 
 
Table 5. Putative epigenetic therapies for the treatment of human T-ALL. Updated table from Peirs et al.
108
 
CTCL: cutaneous T-cell lymphoma; PTCL: peripheral T-cell lymphoma; MM: multiple myeloma; MDS: 
myelodysplastic syndromes. 
 
3.3. Inhibition of BRD4 to repress the transcription of oncogenes 
. 
BRD4 and super-enhancers  
Bromodomains (BRDs) are protein interaction modules that recognize acetylation of lysine 
residues. The bromodomain and extra-terminal (BET) family of proteins are critically involved 
in transcriptional regulation and consist of BRD2, BRD3, BRD4 and BRDT151.  
BRD4 is an important BET family member that associates with positive transcription 
elongation factor b (P-TEFb) and Mediator in a transcriptional co-activator complex that 
recruits the transcriptional apparatus to acetylated chromatin. Recent studies identified 
TARGET RATIONALE FOR USE IN T-ALL EXAMPLES OF INHIBITORS 
HDACs 
Increased expression levels and enhanced activity 
of HDACs in T-ALL. Several studies described the 
induction of apoptosis by HDAC inhibitors in T-ALL 
cell lines and T-ALL patient blasts 147-149.  
 
- Vorinostat and Romidepsin 
(FDA approved for refractory 
CTCL) 
- Panobinostat (FDA approved for 
refractory MM) 
- Belinostat (FDA approved for 
relapsed or refractory PTCL) 
DOT1L 
MLL-rearranged, CALM-AF10-positive and SET-
NUP214-positive leukemias recruit the DOT1L  
enzymatic activity to drive elevated expression of 
genes important in leukemogenesis.  
 
- EPZ-5676 (phase I trial in AML 
and ALL with MLL rearrangements) 
JMJD3 
JMJD3 is overexpressed in primary T-ALL cells. 
Evidence supporting a role for JMJD3 in the 
maintenance of T-ALL has been obtained. GSKJ4 
showed anti-tumorigenic activity in T-ALL cell lines 
and in primary T-ALL cells
117
. 
 
- GSKJ4  
(dual JMJD3/UTX inhibitor) 
DNMTs 
The DNMT inhibitor decitabine enhances 
chemosensitivity of ETP-ALL patient-derived 
samples
150
. 
- Azacitidine and Decitabine 
 (FDA approved for MDS) 
 
IDH1/2 
14% of immature adult T-ALLs carry a mutation in 
IDH1 or IDH2. 
-  AG-120 and AG-221 (mutant 
IDH1/2 inhibitors; phase I in 
IDH1/2-mutated positive 
hematologic malignancies) 
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extreme large enhancers that are co-occupied by the transcriptional co-activators BRD4 and 
mediator complex subunit 1 (MED1) and drive expression of lineage identity genes152, 153 or 
prominent proto-oncogenes in human cancer154. In addition, these so-called super-enhancers 
show broad binding of traditional enhancer associated histone marks including H3K27ac and 
H3K4me1152, 153. In the context of T-ALL, a fraction of functional NOTCH1 binding sites are 
located near super-enhancer regions in the vicinity of genes critically involved in normal and 
malignant T cell development including MYC and IL7R 155, 156. Since super-enhancers are 
often associated with critical oncogenes, it has been postulated that the establishment of a 
super-enhancer catalogue of human cancer could trigger the discovery of novel oncogenes 
that are critically involved in tumor development153, 154. In that respect, recent work identified 
super-enhancer sequences in the T-ALL cell lines JURKAT, DND-41 and RPMI-8402. These 
analyses confirmed the presence of super-enhancer sequences near putative T-ALL 
oncogenes, including MYB, MYC, ERG, GFI1 (growth factor independent 1), CCND3 (cyclin 
D3), CDK6 (cyclin dependent kinase 6), TAL1 and NOTCH1153. However and most notably, 
super-enhancers were also identified near genes with a well-established tumor suppressor 
function in the pathogenesis of T-ALL, including ETV6, WT1, LEF1, GATA3 and RUNX1153. 
Therefore, identification of super-enhancers seems to provide a snapshot of critical 
mediators of normal T cell differentiation that can execute both oncogenic as well as tumor 
suppressive functions in the context of T cell neoplasms. Nevertheless, these analyses on 
human T-ALL cell lines should be further extended towards a more in-depth and 
comprehensive characterization of super-enhancers in molecular genetic subgroups of 
primary human T-ALL and refined subpopulations of normal T cells. 
Small molecules targeting BET bromodomains  
Over the last years, small molecules that target the binding of acetylated lysines to members 
of the BET family of proteins have been developed. These acetylated lysine mimetics 
competitively engage the bromodomain pocket and cause displacement of BRD2, BRD3, 
BRD4 and BRDT from chromatin. Notably, these pan-BET inhibitors have shown therapeutic 
effects in a variety of hematological malignancies including AML, multiple myeloma and 
lymphoma157. The anti-tumoral properties of these molecules are at least in part mediated by 
super-enhancer inhibition near genes that are critically involved in tumor maintenance, such 
as MYC or BCL2 (B-cell lymphoma 2)154. Nevertheless, given the broad impact of BET 
inhibition on transcriptional regulation, concerns have been raised regarding tolerability and 
toxicity in humans. Therefore, selective inhibition of individual BET proteins could avoid 
adverse side effects when these molecules are moved into clinical trials158. Notably, elegant 
studies recently suggested that MYC regulates the leukemia initiating capacity of malignant T 
cells156, 159. Therefore, therapeutic targeting of MYC by BET inhibitors could represent a 
valuable strategy for targeted therapy in human T-ALL156, 159, 160. Indeed, King et al.156 
reported dose-dependent growth inhibition of T-ALL cell lines and primary human T-ALL 
samples upon treatment with the BET inhibitor JQ1. Moreover, treatment of NOTCH1-driven 
primary mouse T-ALL using CPI203, a JQ1 derivative with enhanced bioavailability, resulted 
in rapid reduction of leukemia burden confirming the therapeutic potential of this compound 
in vivo156. Importantly, the in vivo relevance of pharmacological BRD4 inhibition by JQ1 was 
further confirmed in immunodeficient mice xenografted with primary human T-ALL160 and a 
Tal1/Lmo2 driven murine T-ALL tumor model159. Moreover, relapsed or induction failure 
primary T-ALL cells responded in vitro to short-term JQ1 treatment, confirming that BET 
inhibition could also serve as a valuable therapeutic strategy for clinically challenging 
subtypes of human T-ALL159, 161. Obviously, BET inhibition not only results in MYC or MYCN 
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inactivation, but will also affect other prominent T-ALL oncogenes including IL7R, MYB and 
BCL2162, 163. Besides the use of small molecule BRD4 inhibitors as single agents, some 
studies have also evaluated potential synergisms with other therapeutic agents in the context 
of T-ALL. For example, the combination of γ-secretase inhibitors, which block NOTCH1 
signaling, with JQ1 showed synergistic in vivo anti-tumor effects in mice xenografted with 
primary T-ALLs164.  
All validated BRD4 antagonists interact with one BRD while BET proteins have tandem 
BRDs. Therefore, bivalent inhibition could increase the potency of the inhibitors. Indeed, 
Tanaka et al.165 developed the bivalent BET inhibitor MT1 which showed greater efficacy 
than JQ1 in leukemia mouse models. In 2015, a new innovative strategy to target the BET 
family of proteins was published in Science. Instead of inhibiting the BRDs of BET proteins, 
BET proteins can be targeted for degradation. The authors conjugated a phthalimide moiety 
to JQ1 and obtained the bifunctional dBET1. Similar to JQ1, dBET1 binds to BET BRDs. 
Next, the phthalimide moiety hijacks the cereblon E3 ubiquitin ligase and targets the BET 
protein for proteasomal degradation. Interestingly, dBET1 induced even more pronounced 
antileukemic effects in human AML cells than JQ1166.  
Several BET bromodomain inhibitors are evaluated in clinical trials for solid tumors and 
hematological malignancies (Table 6). For example, the small-molecule BRD2/3/4 inhibitor 
OTX015 is currently evaluated in a phase I dose-escalation clinical trial for acute leukemia. 
Some patients (3/41) achieved complete remission167. 
 
Table 6. Overview of BET bromodomain inhibitors in clinical trials. Clinicaltrials.gov was consulted on 28
th
 of 
December 2016. 
 
 
 
 
COMPOUND CLINICAL TRIAL STAGE
 
FT-1101 Phase I in AML and myelodysplastic syndrome (MDS) 
CPI-0610 
Phase I in hematological malignancies 
Phase II in peripheral nerve sheath tumors 
GSK525762 (I-BET762) Phase I/II in hematological malignancies and solid tumors 
ZEN003694 Phase I in prostate cancer 
OTX015/MK-8628 
Phase I in solid tumors and hematological malignancies 
Phase II in recurrent glioblastoma multiforme patients 
BMS-986158 Phase I/II in solid tumors 
GSK2820151 Phase I in solid tumors 
TEN-010 Phase I in solid tumors, AML and MDS 
BAY1238097 Phase I in solid tumors and lymphoma 
INCB057643 Phase I/II in solid tumors and hematological malignancies 
INCB054329 Phase I/II in solid tumors and hematological malignancies 
RVX000222 (RVX-208, 
APABETALONE) 
Phase III in high-risk type 2 diabetes mellitus subjects with coronary artery 
disease 
GS-5829 Phase I/II in solid tumors and lymphoma 
ABBV-075 Phase I in solid tumor and hematological malignancies 
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3.4. Targeting the lysine demethylase KDM1A as a therapeutic strategy in 
many cancers 
 
The role of KDM1A in transcriptional regulation 
Histone posttranslational modifications, including phosphorylation, acetylation, methylation 
and ubiquitination, regulate the chromatin structure and the binding of non-histone proteins to 
regulate gene expression168. Methylation of histones is carried out by methyltransferases 
while demethylases remove methyl groups. The lysine demethylase 1A (KDM1A, synonym 
LSD1) is an amino oxidase that oxidatively removes the methyl groups from mono- and 
dimethylated lysine 4 on histone 3 (H3K4me1 and H3K4me2) with the help of its cofactor 
flavin adenine dinucleotide (FAD). The amine oxidase domain (AOD) of the protein has two 
sites to bind the methylated substrate and FAD169, 170. H3K4 methylation is generally 
associated with transcriptional activation, with H3K4me3 located at active promoters and 
H3K4me1 at active enhancers171. Therefore, KDM1A acts as a co-repressor by 
demethylating H3K4 (Figure 8). Interestingly, KDM1A interacts via its Tower domain with 
interaction partners. Interaction with the CoREST and NuRD complex, which are involved in 
transcriptional repression, has been described. Remarkably, when KDM1A binds to the 
androgen (AR) or estrogen (ER) nuclear receptors, its substrate specificity changes to 
H3K9me1 and H3K9me2169, 170. Since methylation of H3K9 is mainly associated with 
transcriptional silencing168, KDM1A acts here as a co-activator 169, 170 (Figure 8). Moreover, 
KDM1A can also be part of the ELL (elongation factor for RNA polymerase II) complex, 
containing the P-TEFb transcriptional elongation factor, and MLL super-complex170. 
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Figure 8. Structure and demethylating activity of KDM1A. KDM1A contains three protein domains. The 
SWIRM domain and AOD are together responsible for the enzymatic activity while the TOWER domain is 
involved in protein interactions. KDM1A catalyzes the demethylation of mono- and dimethylated H3K4 and H3K9. 
Although H3K4me1 and me2 are the primary substrates, KDM1A can also demethylate H3K9me1 and me2 when 
it is bound to the androgen (AR) or estrogen receptor (ER). Therefore, KDM1A can act as a transcriptional co-
repressor or co-activator depending on its substrate and interaction partners. Figure based on
170
. 
 
Lysine residues at non-histone proteins can also be demethylated by KDM1A. Demethylation 
of the dimethylated K370 residue of tumor suppressor p53 by KDM1A inhibits the pro-
apoptotic activity of p53. Another substrate of KDM1A is MYPT1 (myosin phosphatase target 
subunit 1), a phosphatase that regulates retinoblastoma protein 1. MYPT1 loses its stability 
upon demethylation by KDM1A. This may enhance the phosphorylation and consequent 
inactivation of retinoblastoma protein 1, allowing cell cycle progression. Furthermore, 
demethylation of DNMT1 by KDM1A protects it from degradation. Likewise, the protein 
stability of the E2F1 transcription factor increases after demethylation of K185169, 170. 
The activity and function of KDM1A can further be regulated through interactions with 
proteins, alternative splicing, non-coding RNAs and posttranslational modifications172. 
Phosphorylation173-175, deacetylation176 and deubiquitylation174 of KDM1A have been reported.  
KDM1A is also important in developmental processes170. The protein is highly expressed and 
plays a key role in human embryonic stem cells (ESCs). In these cells, KDM1A regulates the 
balance between self-renewal and differentiation by controlling H3K4 methylation levels of 
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bivalent domains in the promoters of a subset of developmental genes. KDM1A activity is 
essential to maintain the silencing of these genes and to keep the cells in an undifferentiated 
state. During differentiation, KDM1A expression is progressively downregulated177. An 
interesting role for KDM1A at enhancer sites during ESC differentiation was found in mouse 
ESCs. There, KDM1A binds active enhancers as part of the NuRD complex together with 
ESC master transcription factors that recruit histone acetyltransferases. However, no 
demethylation of H3K4 occurs because the activity of KDM1A is inhibited in the presence of 
acetylated histones. Only during differentiation, when the level of acetylated histones is 
decreased, KDM1A is able to demethylate H3K4me1 at enhancers of ESC-specific genes178. 
KDM1A is also involved in EMT-related epigenetic reprogramming179. Noteworthy, the EMT-
inducing transcription factors SNAIL1 and ZEB1 can both recruit KDM1A88.  
Another essential function of KDM1A is controlling the differentiation of several cell types170. 
In the hematopoietic system, KDM1A can be recruited by the homologous transcriptional 
repressors GFI1 and GFI1B180 or TAL1181 to mediate transcriptional repression and to control 
hematopoietic differentiation. Conditional inactivation of Kdm1a in the hematopoietic system 
of mice fetuses resulted in pancytopenia in newborns while deletion of Kdm1a during adult 
hematopoiesis was associated with a lack of myeloid progenitor cells. Furthermore, a defect 
in HSC self-renewal and terminal differentiation of granulocytes and erythroid cells was 
detected in absence of Kdm1a182.  
KDM1A in cancer  
KDM1A is overexpressed in various solid human cancers, including bladder cancer183, small 
cell lung cancer (SCLC)183, non-small cell lung cancer (NSCLC)184, prostate cancer185, ER-
negative breast cancer186, colorectal cancer183, neuroblastoma187, 188, oral cancer189 and 
cervical cancer190. In many of these cancers, an association between high KDM1A 
expression and shorter survival was found183-185, 187-189. Knockdown or pharmacological 
inhibition of KDM1A decreased cell growth in several cancer cell lines indicating that KDM1A 
contributes to human carcinogenesis183, 184, 186, 188, 189. As mentioned before, KDM1A plays a 
role in EMT, which can also contribute to the aggressiveness of a cancer. Indeed, Liu et al.190 
observed EMT in cervical cancer upon ectopic expression of KDM1A, resulting in the 
promotion of invasion and metastasis. 
In addition to the solid tumors, KDM1A overexpression was also identified in a substantial 
part of myeloproliferative neoplasms, myelodysplastic syndromes, AML, chronic myeloid 
leukemia (CML), ALL and lymphomas191. In human AML, translocations involving the 
methyltransferase MLL occur frequently. Harris et al.192 identified KDM1A as an essential 
factor to sustain the oncogenic potential of MLL-AF9 AML cells. Knockdown of Kdm1a in 
AML cells from mice with MLL-AF9 leukemia resulted in the loss of their colony-forming cell 
and leukemic stem cell potential. Moreover, differentiation and apoptosis of the cells was 
induced. Their work supports a model in which KDM1A acts at genes bound by the MLL-AF9 
fusion oncoprotein to maintain low levels of H3K4me2 relative to H3K4me3, allowing 
transcription required for oncogenic transformation. Upon knockdown of Kdm1a, a selective 
increase of H3K4me2 was observed that was associated with the downregulation of these 
genes192. Finally, inhibition of KDM1A does not only elicit anti-tumor responses in MLL-
rearranged AML192, 193, but also in other AML subtypes194. 
Chapter 1: Introduction 
28 
  
Since KDM1A is also strongly expressed in T-cell lymphoblastic leukemia/lymphoma (T-LBL), 
Wada et al.195 studied the protein in this context. Of the four known KDM1A isoforms, two 
were detected in normal human and murine hematopoietic cells and primary T-LBL samples. 
Overexpression of the shortest human KDM1A isoform in mouse bone marrow cells induced 
the expression of the HoxA family and increased the self-renewal of HSCs in vivo and in vitro. 
Most notably, overexpression of the shortest human KDM1A isoform in a transgenic mouse 
model led to focal hyperplasia of T lymphocytes but not to hematological malignancies. 
Nevertheless, irradiation of KDM1A-overexpressing mice resulted in the accelerated 
development of T-LBL compared to control mice, indicating that KDM1A overexpression 
generates preleukemic HSCs195. Other elements pointing towards an important role for 
KDM1A in T cell leukemogenesis are the described interactions with NOTCH1196 and 
TAL1181, 197, two factors that are often aberrantly activated in T-ALL. KDM1A plays a dual role 
in NOTCH1 signaling. In the absence of NOTCH1, KDM1A is associated with the CSL-
repressor complex and demethylates the activating H3K4me2 mark at NOTCH1-target genes. 
On the other hand, in the context of the NOTCH-activation complex, the catalytic activity of 
KDM1A changes to function as a NOTCH1 coactivator that triggers H3K9me2 
demethylation196. 
Inhibitors of KDM1A  
Plenty of irreversible and reversible KDM1A inhibitors with a wide variety in chemical 
structures have been developed198, 199. 
The first small molecules that were evaluated as KDM1A inhibitors, were inhibitors of the 
homologous monoamine oxidase (MAO). Tranylcypromine (2-PCPA) is the most 
representative one in this category. Tranylcypromine forms a covalent adduct with the FAD 
cofactor in the active cavity of KDM1A and irreversibly inhibits KDM1A activity. Interestingly, 
tranylcypromine is able to enhance all-trans-retinoic acid (ATRA)-induced differentiation in 
AML cells and the combination of these two drugs has a potent anti-leukemic effect in vivo 
and in vitro200. Later on, more potent and selective derivatives of MAO inactivator based 
inhibitors were developed198, 201. In the study of Harris et al.192, tranylcypromine and two 
analogs induced loss of clonogenic potential and differentiation in MLL leukemia cells. 
Moreover, treatment of mice transplanted with mouse MLL-rearranged AML cells completely 
blocked the progression of the leukemia into the circulation. Oryzon Genomics and 
GlaxoSmithKline each have a tranylcypromine derivative, ORY-1001 and GSK2879552 
respectively, that entered clinical trials. GSK2879552 was developed and tested on cell lines 
from different cancer types by Mohammad et al.202. Especially the proliferation of SCLC and 
AML cell lines was inhibited and in vivo treatment of SCLC xenografts was promising202.  
An overview of the KDM1A inhibitors that are currently evaluated in clinical trials is given in 
Table 7. Very recently, a novel irreversible KDM1A inhibitor T-3775440 was published203. T-
3775440 achieves anti-leukemic and transdifferentiation activity in acute erythroleukemia and 
acute megakaryoblastic leukemia by disrupting the interaction between KDM1A and 
GFI1B203. 
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Table 7. Overview of KDM1A inhibitors in clinical trials. clinicaltrials.gov and EU Clinical Trials Register were 
consulted on 3th of January 2017. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
COMPOUND WORKING MECHANISM CLINICAL TRIAL STAGE
 
TRANYLCYPROMINE  
(2-PCPA) 
MAO inhibitor, forms covalent 
adduct with FAD 
Phase I/II in AML and MDS in 
combination with ATRA 
GSK2879552  Tranylcypromine derivative Phase I in AML and SCLC 
ORY-1001 (RG-6016) Tranylcypromine derivative Phase I in acute leukemia 
IMG-7289 Not reported 
Phase I in AML and MDS in 
combination with and without ATRA 
INCB059872 Not reported Phase I/II in advanced malignancies 
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PART III Targeting apoptosis in cancer 
 
1. Apoptosis: programmed cell death 
 
A cell can die in many different ways and this may happen in a controlled or uncontrolled 
manner. Apoptosis is the major form of programmed cell death. It plays a crucial role in the 
formation and deletion of structures during development and in the regulation of cell numbers. 
In addition, apoptosis protects us against unwanted and potentially dangerous cells204. The 
process of apoptosis can be triggered by various stresses such as DNA damage, loss of 
growth factor signaling, energy stress and hypoxia. Cancer cells also suffer from various 
apoptosis-inducing stresses, including signaling imbalances resulting from elevated levels of 
oncogenic signaling, DNA damage linked to hyperproliferation and of course also stresses 
coming from chemotherapy during treatment. In spite of all these stresses, cancers can often 
still develop and even resist therapy. Resisting cell death is therefore one of the hallmarks of 
cancer as previously mentioned in part I. Cancer cells can develop mechanisms to escape 
apoptosis including upregulation of anti-apoptotic factors and downregulation of pro-apoptotic 
factors1, 205.  
Apoptosis is mediated by caspases, a class of cysteine proteases. Two distinct but 
congregating pathways, the intrinsic/mitochondrial pathway and the extrinsic/death receptor-
mediated pathway of apoptosis can lead to the activation of caspases (Figure 9). Initiator 
caspases (caspase-8, -9, and -10) are first activated. In turn, executioner caspases 
(caspase-3, -6 and -7) are activated via an initiator caspase206. These proteases cleave 
numerous proteins, ultimately resulting in apoptosis characterized by cell shrinkage, nuclear 
fragmentation, chromatin condensation and membrane blebbing. The dying cell is 
recognized by phagocytes and cleared207. 
 
Figure 9. An intrinsic or extrinsic pathway can activate caspases resulting in apoptosis
206
. 
 
Since apoptosis is a nonlytic mode of cell death that causes minimal inflammation, it is an 
attractive target for cancer therapy208. 
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2. Intrinsic pathway of apoptosis 
2.1. BCL-2 family of proteins governs the intrinsic pathway of apoptosis 
 
The B-cell lymphoma 2 (BCL-2) family of proteins regulates the intrinsic (mitochondrial) 
pathway of apoptosis and consists of both pro- and anti-apoptotic proteins. The balance 
between these members determines whether a cell goes into apoptosis or not209. All the 
proteins belonging to the BCL-2 family contain blocks of sequence homology (BH domains). 
The pro-survival proteins and the pro-apoptotic effectors share four of these BH domains 
(BH1, BH2, BH3, BH4) while the BH3-only pro-apoptotic family members only have the BH3 
domain. The interactions between the family members occur mainly on the mitochondrial 
outer membrane (MOM). In response to cytotoxic stresses, BH3-only pro-apoptotic proteins 
are stimulated transcriptionally or post-translationally. Activator BH3-only proteins can 
directly activate the pro-apoptotic effectors BAX (BCL-2 associated X) and BAK (BCL-2 
homologous antagonist/killer) leading to the initiation of apoptosis. The pro-survival proteins 
can however prevent apoptosis by binding the BH3 domains of the BH3-only proteins or by 
binding activated BAX or BAK. Furthermore, while sensitizer BH3-only proteins can not 
activate apoptosis directly, they are able to neutralize the pro-survival proteins (Figure 10). 
Moreover, there is some selectivity in these interactions. Not all the BH3-only proteins can 
bind to all the pro-survival proteins and not all the pro-survival proteins are able to interact 
with BAK210, 211.  
Upon activation, BAX and BAK undergo a conformational change from monomers into homo-
oligomers that can permeabilize the MOM211. This process is called Mitochondrial Outer 
Membrane Permeabilization (MOMP) and is, in most cases, a point of no return for cell 
survival. Apoptogenic proteins are released from the intermembrane space into the cytosol. 
The binding of cytochrome c (cyt c) to apoptotic protease-activating factor 1 (APAF1) leads 
to conformational changes and oligomerization and eventually to the formation of the 
apoptosome. From here, the proteolytic cascade starts with the consecutive activation of 
initiator and effector caspases (Figure 10).  
The well-known tumor suppressor p53 can regulate the expression and activity of BCL-2 
family proteins. Stress-activated p53 directly induces transcription of pro-apoptotic factors 
such as BAX, PUMA (p53 upregulated modulator of apoptosis) and NOXA and represses 
transcription of anti-apoptotic BCL-2 family genes including BCL2 and BCL2-like 1 (BCL2L1;  
encoding BCL-XL) in some settings. In addition, p53 can also have transcription-independent 
effects in the cytoplasm. In response to stress, p53 accumulates in the cytosol or 
mitochondria and interacts with members of the BCL-2 family. It has been suggested that 
p53 acts like a BH3-only protein. However, the relevance of these transcription-independent 
activities for p53-mediated apoptosis is under debate212-215. 
Posttranslational modifications add an extra layer of complexity to the regulation of the BCL-
2 family members. Phosphorylation of BIM by ERK and AKT targets the protein for 
proteasomal degradation while phosphorylation by c-JUN enhances its pro-apoptotic 
activities216. MCL-1 (BCL-2 family apoptosis regulator) is stabilized through phosphorylation 
of the PEST domain by ERK1/2 but this phosphorylation primes MCL-1 for phosphorylation 
by glycogen synthase kinase-3 beta (GSK3B) which enhances the polyubiquitination and 
degradation of MCL-1217. BCL-2 itself can also be phosphorylated and this happens for 
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example during mitosis. Phosphorylated BCL-2 binds BIM and BAK with a higher affinity, 
which enhances its anti-apoptotic activity218.  
Figure 10. The BCL-2 family of proteins controls the intrinsic (mitochondrial) pathway of apoptosis. 
Proteins belonging to the BCL-2 family can be divided into four groups that execute pro- or anti-apoptotic 
functions. Whether PUMA can function as a real activator, is still under debate. When the effector pro-apoptotic 
proteins BAX or BAK are activated, mitochondrial outer membrane permeabilization (MOMP) occurs. Apoptogenic 
factors such as cytochrome c (cyt c), second mitochondria-derived activator of caspase (SMAC) and OMI are 
released. Cyt c interacts with APAF1, resulting in the formation of the apoptosome and the activation of caspase 9. 
Caspase 9 activates on its turn the effector caspases 3 and 7, ultimately leading to apoptosis. The release of OMI 
and SMAC inhibits the caspase inhibitory function of X-linked inhibitor of apoptosis protein (XIAP). Figure is based 
on
207, 210, 211
.  
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2.2. BH3 profiling 
 
The group of dr. Anthony Letai developed a technique, called BH3 profiling, that allows to 
determine how cancer cells evade the intrinsic pathway of apoptosis. The technique uses 
synthetic peptides that are derived from the BH3 domains of BH3-only proteins. Exposing 
mitochondria to these peptides and measuring the induction of MOMP gives information 
about the apoptotic blocks present in the cell219, 220.  
A first way to evade intrinsic apoptotic signaling is the loss of functional BAX and BAK. Cells 
without functional BAX and BAK are apoptotically incompetent and will not respond to both 
sensitizer and activator BH3 peptides. Secondly, cells that induce MOMP in response to the 
addition of activator peptides but not to the addition of sensitizer peptides, have an intact 
effector arm but are unprimed. This means that the anti-apoptotic proteins in these cells are 
not occupied by activator BH3-only proteins. Consequently, the binding of sensitizer peptides 
to the anti-apoptotic proteins will not release activator BH3-only proteins that can activate 
BAX/BAK. The upstream activation of BH3-only proteins might be inhibited in these cells.  
Lastly, cells that respond to both activator and sensitizer peptides are primed for apoptosis 
and they depend on the expression of anti-apoptotic proteins for their survival220, 221. Since 
the anti-apoptotic protein is in primed cells largely occupied by activator BH3-only proteins, 
adding sensitizer peptides will induce MOMP by competitively binding the anti-apoptotic 
protein and displacing the activator BH3-only protein219. The fact that each anti-apoptotic 
BCL-2 family member has a selective affinity for the different sensitizer BH3-only proteins 
makes it possible to determine to which anti-apoptotic BCL-2 family member a cell is 
addicted. BCL-2 has affinity for BAD (BCL2 associated agonist of cell death) but not for HRK 
(harakiri) and NOXA, while MCL-1 does not bind BAD and HRK but does bind NOXA. 
Furthermore, BCL2A1 (BCL2 related protein A1) binds none of the sensitizers except for 
PUMA while BCL-XL has a high affinity for HRK. Therefore, depending on the pattern of 
peptides that are capable to induce MOMP, one can deduce the addiction to a particular anti-
apoptotic protein219. 
Over the past years, the technique has evolved and improved. In the beginning, mitochondria 
had to be isolated to perform the technique219. Now, methods that permeabilize the plasma 
membrane without permeabilizing the mitochondrial membranes are used to allow peptide 
diffusion into the cell. In addition, instead of measuring the release of apoptogenic factors via 
antibody staining, ELISA or Western blot, the collapse of the transmembrane mitochondrial 
potential can be used as a measure for MOMP. The change in the potential can be 
visualized with potentiometric dyes allowing MOMP to be detected with flow cytometry or 
plate-based assays222. The newest method, intracellular BH3 profiling (iBH3), uses 
formaldehyde fixation after the exposure to BH3 peptides. By fixing the cells, variance due to 
the time sensitivity of potential measurements is removed, infectious particles in the sample 
are killed and samples can be analyzed on a later time point. Upon MOMP, cyt c escapes the 
mitochondria and also the permeabilized cell while intact mitochondria will stain positively for 
cyt c, a feature that can be detected with flow cytometry223. 
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2.3. Chemotherapy and apoptosis 
 
Cancer cells are often more sensitive to chemotherapeutic agents than normal cells. This 
can be explained by the fact that they are already closer to the “apoptotic threshold” and 
“primed for death”. As mentioned above, cancer cells endure already death signaling 
triggered by all the intrinsic stresses they experience. Although anti-apoptotic proteins can 
sequester these pro-apoptotic factors and prevent cell death, their anti-apoptotic reserve is in 
the meantime decreased making them more sensitive to chemotherapy. Whether a cell is 
“primed for death” or not, can be measured using BH3 profiling210, 219. Most notably, the 
clinical response of cancer patients to chemotherapy correlates with the pretreatment 
proximity of the tumor cells to the apoptotic threshold. Mitochondria from patients with 
chemosensitive cancer are more “primed for death” than those from chemoresistant cancer 
and normal tissues224. 
Most conventional chemotherapeutic agents trigger the intrinsic pathway of apoptosis225. 
Nevertheless, it is important to realize that also the extrinsic pathway of apoptosis and even 
nonapoptotic modes of cell death such as autophagy and necrosis can be responsible for the 
cell death caused by cytotoxic agents226. The conventional chemotherapeutic agents used for 
the treatment of T-ALL induce DNA damage, microtubule damage or deprive cancer cells of 
important nutrients. These are all “intrinsic stresses” that can trigger the intrinsic apoptotic 
pathway225.  
Glucocorticoids directly regulate genes involved in apoptosis. They control gene transcription 
through activation of the glucocorticoid receptor, which then functions as a transcription 
factor. The resulting upregulation of BCL2L11 (encoding BIM) and downregulation of BCL2 
can cause apoptosis. BCL2L11 is also indirectly upregulated due to the downregulation of 
the miR17-92 cluster by glucocorticoids26. 
The fact that most chemotherapeutic agents execute their cytotoxic effect via the intrinsic 
pathway of apoptosis implicates that defects in apoptosis can produce multidrug 
resistance225. 
2.4. Pathways that contribute to the evasion of apoptosis in T-ALL   
 
The PI3K/AKT/mTOR, IL7R/JAK/STAT and RAS/RAF/MEK/ERK pathway (Figure 11) are 
frequently hyperactivated in T-ALL. Canté-Barrett et al.84 identified activating mutations in 
one of these pathways in 49% of their pediatric T-ALL patients. All three pathways lead to 
growth and prevention of apoptosis and they can interact and cross-regulate each other227. 
Activation of these pathways helps cancer cells to escape from apoptosis. Consequently, 
these pathways are interesting to target therapeutically. In addition, overexpression of RBP2 
(retinoblastoma-binding protein 2) can upregulate BCL2 in T-ALL228.  
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Figure 11. Overview of the PI3K/AKT/mTOR, RAS/RAF/MEK/ERK and JAK/STAT pathway. The ligation of a 
growth factor or cytokine to its receptor activates the signaling pathways. Upon activation of RAS, RAF is 
recruited to the membrane and activated. RAF kinases phophorylate MEK which phophorylates and activates on 
its turn ERK1 and ERK2. ERK1 and ERK2 phosphorylate and activate a variety of substrates that regulate gene 
transcription. In addition, RAS can also activate the PI3K/AKT/mTOR pathway. PI3K consists of an 85-kDa 
regulatory subunit and a 110-kDa catalytic subunit. PI3K converts phosphatidylinositol 4,5-bisphosphate (PIP2) to 
phosphatidylinositol 3,4,5-trisphosphate (PIP3) which recruits PDK1 and AKT to the plasma membrane. PDK1 
phophorylates and activates AKT. Activated AKT phosphorylates numerous proteins that play a role in the 
regulation of gene transcription or in the regulation of protein translation. mTOR is a key downstream protein that 
phosphorylates components of the protein synthesis machinery. An important negative regulator of the 
PI3K/AKT/mTOR pathway is the phosphatase PTEN. Another pathway activated after receptor ligation is the 
JAK/STAT pathway. Upon activation of cytokine receptors, receptor homodimers and heterodimers are formed 
which allows transphosphorylation of receptors and the activation of the associated JAKs (JAK1, JAK2, JAK3, 
TYK2) and STATs (STAT1, STAT2, STAT3, STAT4, STAT5a, STAT5b, STAT6). The phosphorylation of STATs 
by JAK proteins results in the formation of STAT dimers that move to the nucleus, bind DNA and activate 
transcription. Phosphorylation events that enhance the activity are shown by a black P in a white circle while 
phosphorylation events that inhibit activity are visualized by a white P in a black circle. Figure from Steelman et 
al.
227
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PI3K/AKT/mTOR pathway  
In response to many types of cellular stimuli, the kinase PI3K is activated and converts 
phosphatidylinositol 4,5-bisphosphate (PIP2) to phosphatidylinositol 3,4,5-trisphosphate 
(PIP3). PIP3 recruits the serine/threonine kinase AKT to the plasma membrane where it is 
activated (Figure 11). One of the important downstream target proteins of AKT is the 
serine/threonine kinase mTOR229. This pathway plays a key role in cell survival, apoptosis, 
drug resistance and many other processes229 and is frequently hyperactivated in T-ALL230. 
Silva et al.231 reported PI3K/AKT/mTOR pathway hyperactivation in 87.5% of primary T-ALL 
samples.  
In addition to activating mutations in PI3K and AKT itself232, 233, aberrations in phosphatase 
and tensin homolog (PTEN) lead to an overactivation of the pathway in T-ALL. The 
phosphatase PTEN is an important tumor suppressor that negatively regulates the 
PI3K/AKT/mTOR pathway by converting PIP3 to PIP2 (Figure 11). Deletions, mutations or 
posttranslational mechanisms that inactivate PTEN are frequently found in T-ALL patients231-
234. Moreover, activating mutations in NOTCH1, occuring in more than 50% of T-ALLs73, and 
IL7R235, 236 also stimulate the PI3K/AKT/mTOR pathway. NOTCH1 downregulates PTEN via 
HES1 (hes family bHLH transcription factor 1)237 while interleukin-7 (IL7)/IL7R is known to 
activate the PI3K/AKT/mTOR pathway in human thymocytes and T-ALL cells238, 239. 
Oncogenic PI3K/AKT/mTOR signaling can regulate BCL-2 family members. Examples of 
downstream effects include the direct phosphorylation of BAD (BCL-2 associated agonist of 
cell death) and BIM by AKT, resulting in inhibition or degradation of the respective pro-
apoptotic factor. AKT can also phosphorylate GSK3B which suppresses its ability to 
phosphorylate MCL-1 and promote the degradation of MCL-1. Furthermore, AKT can repress 
the expression of BCL2L11 (encoding BIM), NOXA and PUMA via phosphorylation of 
forkhead box O proteins (FOXO) and can upregulate MCL1 and BCL2 expression via the 
activation of cAMP response element-binding protein (CREB). In addition, AKT can activate 
the E3 ubiquitin-protein ligase MDM2, a negative regulator of p53161, 227, 240. PI3K, AKT and 
mTOR are druggable factors and some of the small molecule inhibitors against them are now 
evaluated in clinical trials229. Also in T-ALL, targeting the PI3K/AKT/mTOR pathway is 
investigated as a treatment strategy241-244. Interestingly, inhibitors working at different levels 
of the PI3K/AKT/mTOR pathway can show synergistic activities in the context of T-ALL241. 
Indeed, Hall et al.245 demonstrated the use of the dual PI3K/mTOR inhibitor BEZ235 to 
enhance the antileukemic effects of glucocorticoids in T-ALL. BEZ235 in combination with 
dexamethasone was capable to increase BIM levels and induce apoptosis in T-ALL models. 
Furthermore, in another illustrative study, PI3K/AKT/mTOR signaling was found to be 
induced in nelarabine-resistant T-ALL cells upon treatment with nelarabine. The combination 
of pan-PI3K inhibition and nelarabine in resistant T-ALL cell lines resulted in the reduction of 
BCL-2 and BCL-XL expression and in the concomitant increase of BAX and BAK expression. 
Notably, this combination synergistically induced apoptosis in nelarabine-resistant relapsed 
patient samples246.  
IL7R/JAK/STAT pathway  
IL7 is a cytokine produced in the bone marrow and thymus that is required for normal human 
T cell development. However, the IL7R is also an oncogene since the aberrant activation of 
IL7R signaling contributes to the development of T-ALL. The two main downstream pathways 
activated by IL7/IL7R are the JAK/STAT5 and PI3K/AKT/mTOR pathway247 (Figure 11).  
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Around 10% of T-ALL patients harbor somatic gain-of-function IL7R mutations that lead in 
most cases to constitutive signaling235, 236. Moreover, gain-of-function mutations in the 
downstream signaling molecules JAK1, JAK3 and STAT5 frequently occur and are mutually 
exclusive69, 84, 248. Especially in ETP-ALL, aberrant activation of the IL7R/JAK/STAT pathway 
is frequent249 with about 20% of pediatric ETP-ALL cases harboring activating mutations in 
IL7R or in the downstream JAK1 and JAK369. Interestingly, IL7R/JAK/STAT promotes T-cell 
survival by inducing the expression of the anti-apoptotic factors BCL-2, MCL-1 and BCL-XL
248, 
250, 251. Notably, NOTCH1 regulates IL7R and triggers this pathway also252. 
Upregulation of anti-apopotic BCL-2 family members via this pathway can be combat with 
JAK/STAT pathway inhibitors. In patient-derived murine xenograft models of ETP-ALL, the 
JAK1/2 inhibitor ruxolitinib displayed strong antileukemic effects249. 
Very recent work of Li et al.253 described the association of mutations in IL7R signaling 
molecules (IL7R, JAK1, JAK3, NF1 (neurofibromin 1), NRAS, KRAS and AKT genes) with 
steroid resistance and reduced survival in pediatric T-ALL patients. Overexpression of 
mutant IL7R, JAK1 or NRAS, as well as overexpression of wild-type NRAS or AKT in steroid-
sensitive T-ALL cell lines, could indeed render the cells resistant to steroids by upregulating 
the anti-apoptotic MCL-1 and BCL-XL and inactivating the pro-apoptotic BIM and its regulator 
GSK3B. By using small molecule inhibitors that target MEK/ERK or PI3K/AKT/mTOR 
signaling, the steroid response in most primary T-ALL samples could be increased253, 254. 
RAS/RAF/MEK/ERK pathway  
After stimulation of the appropriate receptor by growth factors, cytokines or mitogens, RAS is 
activated and a kinase cascade is initiated with the RAF, MEK and ERK kinases (Figure 11), 
resulting in the promotion of cell survival and proliferation216. RAS is activated in 50% of T-
ALL cases255 and activating mutations in the pathway (NRAS, KRAS, BRAF, NF1, FLT3 (fms 
related tyrosine kinase 3) and PTPN11 (protein tyrosine phosphatase non-receptor type 11)) 
are recurring in T-ALL69, 84.  
Notably, the RAS/RAF/MEK/ERK pathway regulates the activity of several members of the 
BCL-2 family. Especially BIM is a key factor downstream of the pathway. Activated ERK1/2 
phosphorylates the transcription factor FOXO3A leading to its proteasomal degradation and 
the prevention of FOXO3A-dependent expression of BCL2L11 (encoding BIM). Additionally, 
the direct phosphorylation of BIM by ERK1/2 inhibits the interaction of BIM with BAX and pro-
survival proteins and targets BIM for proteasomal degradation216, 217. The expression of the 
anti-apoptotic factors BCL-2, BCL-XL and MCL-1 is also upregulated by the pathway and the 
MCL-1 protein is even stabilized through direct phosphorylation by ERK1/2217.   
Interestingly, drugs used in leukemia therapy, such as doxorubicin, can activate the 
RAS/RAF/MEK/ERK pathway. Treatment with doxorubicin results in the generation of 
reactive oxygen species (ROS) that can activate the pathway at multiple points. This 
activation can play a role in drug resistance216.  
Compounds targeting components of the pathway, such as RAF, MEK and ERK inhibitors 
are available and some are approved for the treatment of BRAF-mutant metastatic 
melanoma256. Moreover, the combination of MEK and PI3K-AKT inhibitors exerted 
synergistic effects on half of the primary T-ALL samples tested by Canté-Barrett et al.84 and 
could therefore be a promising therapeutic option in T-ALL.  
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TYK2/STAT1/BCL2 pathway  
A significant fraction of T-ALLs depends on tyrosine kinase 2 (TYK2) for survival. TYK2 is a 
member of the JAK kinase family and was shown to phosphorylate and activate STAT1 
leading to the upregulation of BCL2 expression. The TYK2/STAT1/BCL2 pathway can be 
activated by activating TYK2 mutations, present in about 20% of T-ALL cell lines, or by IL10 
signaling (Figure 12). The TYK2-dependent T-ALL cells can be pushed into apoptosis by 
using JAK kinase inhibitors that also exhibit activity against TYK2257. Another interesting 
therapeutic strategy is to disrupt TYK2 protein stability by pharmacological inhibition of heat 
shock protein 90 (HSP90) with NVP-AUY922 (AUY922), a small molecule inhibitor that is 
currently under investigation in clinical trials against several cancers. Treatment of T-ALL 
cells with AUY922 did not only result in the downregulation of BCL-2, also an upregulation of 
BIM and BAD was observed258. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 12. TYK2 signaling in T-ALL upregulates BCL2 expression. Adapted from Fontan and Melnick
259
. 
 
RBP2 
An additional mechanism for the upregulation of BCL2 in T-ALL was recently discovered. 
Wang et al.228 investigated the role of the histone demethylase RBP2 in the context of adult 
ALL. RBP2, also known as lysine-specific demethylase 5A (KDM5A) or jumonji/ARID 
domain-containing protein 1A (JARID1A), is a member of the JARID protein family that 
demethylates tri- and di-methylated lysine 4 of histone H3. High RBP2 expression was found 
in both de novo and relapsed ALL. Notably, BCL2 was upregulated by RBP2 and identified 
as a new direct target gene of RBP2228. 
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3. Extrinsic pathway of apoptosis 
 
The extrinsic pathway of apoptosis (Figure 13) is initiated by the binding of a ligand to a 
death receptor (DR). DRs all belong to the tumor necrosis factor (TNF) receptor superfamily 
and include type 1 TNF receptor (TNFR1), FAS, TNF-related apoptosis-inducing ligand 
receptor (TRAILR) 1 and 2, DR3 and DR6. These DRs have a cytoplasmic death domain that 
allows interaction with cytoplasmic adapter proteins. FAS and TRAILR recruit the FAS-
associated protein with death domain (FADD) upon ligand binding. In the case of activated 
TNFR1, the mechanism is more complex. The adapter protein TNFR1-associated death 
domain protein (TRADD) is first bound which can ultimately also interact with FADD.  
Subsequently, procaspase-8 and the related procaspase-10 are recruited by FADD and a 
death-inducing signaling complex is formed resulting in activation of the initiator caspases 
(Figure 13)260.  
Caspase-8 does not only activate the executioner caspases but also cleaves the BH3-only 
protein BID which results in the formation of truncated BID (tBID) that can induce MOMP 
(Figure 13). In this way, the extrinsic and intrinsic pathway of apoptosis are linked. Moreover, 
MOMP induces the release of SMAC which antagonizes the XIAP-mediated inhibition of  the 
executioner caspases. Some cells require this tBID-induced MOMP to undergo DR-induced 
apoptosis260. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 13. The extrinsic pathway of apoptosis is connected with the intrinsic pathway of apoptosis. Upon 
the binding of a ligand to a death receptor, the extrinsic pathway of apoptosis is initiated. The caspase-8-mediated 
cleavage of BID can induce the intrinsic pathway of apoptosis
261
. 
Chapter 1: Introduction 
40 
  
4. Strategies to target apoptosis pathways in cancer 
4.1. Targeting the anti-apoptotic BCL-2 family 
 
Instead of targeting the pathways that lead to the upregulation of anti-apoptotic BCL-2 family 
members, one could also target the anti-apoptotic proteins itself (Table 8).  
Antisense oligonucleotides  
A first strategy to target anti-apoptotic proteins is the use of antisense oligonucleotides 
(ASOs). ASOs are oligonucleotides that are complementary to a sequence of a specific 
mRNA and inhibit its expression by degrading the mRNA via an RNAse H-dependent 
mechanism or by sterically blocking the initiation of protein translation262. Oblimersen sodium 
(G3139, Genasense), an antisense phophorothioate DNA oligonucleotide targeting the first 
six codons of human BCL2 mRNA, showed very promising preclinical results in several 
cancer types including lymphoma and melanoma263. In contrast, clinical trials in solid tumors 
and hematological malignancies with Oblimersen alone or in combination with conventional 
agents failed to demonstrate clear clinical benefit210. 
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Table 8. Overview of molecules targeting anti-apoptotic BCL-2 family members. Clinicaltrials.gov was consulted on 28
th
 of December 2016. NHL: non-Hodgkin lymphoma, 
FL: follicular lymphoma, MM: multiple myeloma, DLBCL: diffuse large B-cell lymphoma, AML: acute myeloid leukemia.  
  
 
 
 
 
 
COMPOUND TARGET WORKING MECHANISM CLINICAL TRIAL STAGE
 
OBLIMERSEN SODIUM 
(G3139, GENASENSE) 
BCL-2 Antisense oligonucleotide 
Phase I, II and III trials in several solid tumors and hematological 
malignancies have been unconvincing. Not approved by FDA. 
AT101  
(R(-)-GOSSYPOL) 
BCL-2,  BCL-XL, MCL-1 BH3 mimetic Phase I and II trials in solid and hematological malignancies 
OBATOCLAX 
BCL-2, BCL-XL, BCL-W, 
BCL-B, BFL-1, MCL-1 
BH3 mimetic Phase I and II studies in solid and hematological malignancies 
ABT-737 BCL-2, BCL-XL, BCL-W BH3 mimetic 
Preclinical 
Poor physiochemical and pharmaceutical properties 
ABT-263 
(NAVITOCLAX) 
BCL-2, BCL-XL, BCL-W BH3 mimetic 
In phase I and II clinical studies as monotherapy or as part of combination 
therapies for lymphoid malignancies and solid tumors 
ABT-199 
(VENETOCLAX, GDC-
0199 
BCL-2 BH3 mimetic 
In clinical studies as monotherapy or as part of combination therapies for 
NHL, FL, DLBCL, AML, MM  
FDA approved for CLL patients with 17p deletion and at least one prior 
therapy 
S-055746 BCL-2 BH3 mimetic Phase I studies in hematological malignancies 
PNT-2258 BCL-2 DNAi Phase I and II studies in solid and hematological malignancies 
WEHI-539  BCL-XL BH3 mimetic Preclinical 
A-1155463 BCL-XL BH3 mimetic Preclinical 
S63845 MCL-1 BH3 mimetic Preclinical 
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BH3 mimetics  
Another strategy to target these pro-survival proteins is the development of small molecules 
that mimic the function of BH3-only proteins. These small molecules, called “BH3 mimetics”, 
bind to and inhibit the anti-apoptotic proteins to prevent the sequestration of pro-apoptotic 
factors264. Gossypol, a compound from cotton seed extracts, was found to inhibit BH3 binding 
to BCL-XL in a screen on natural products using NMR-based binding assays and 
fluorescence polarization displacement assay265. Gossypol is a pan-BH3 mimetic with 
modest affinities to BCL-2, BCL-XL and MCL-1. The R(-)-gossypol enantiomer (AT-101) has 
better pro-apoptotic and antitumor activities than the enantiomeric mixture. Nevertheless, AT-
101 demonstrated only limited efficacy in clinical trials266. Another pan-BH3 mimetic, 
obatoclax (GX15-070), binds to all the pro-survival BCL-2 family members with modest 
affinity267. Although obatoclax was able to activate the intrinsic pathway of apoptosis in 
preclinical studies, induction of autophagy and necroptosis were also reported, suggesting 
the presence of additional targets outside the BCL-2 family268-271. Similar to Oblimersen and 
AT-101, obatoclax showed disappointing results in clinical trials205, 210, 272. 
Besides the molecules identified in screens, several BH3 mimetics were rationally designed 
to competitively inhibit the binding of pro-apoptotic proteins to the hydrophobic groove of a 
particular anti-apoptotic protein210. The first rationally designed BH3 mimetic was ABT-737, 
binding BCL-2, BCL-XL and BCL-W with high affinity
273. To improve its physiochemical and 
pharmaceutical properties, ABT-737 was optimized resulting in the orally bioavailable 
inhibitor ABT-263 that entered clinical trials274. An on-target dose-limiting toxicity of 
compounds targeting BCL-XL is thrombocytopenia since BCL-XL plays a critical role in 
platelet survival275. To circumvent this toxicity in cancers that depend on BCL-2, the highly 
selective BCL-2 inhibitor ABT-199 was developed276. Not all the cells that express BCL-2 will 
be sensitive to treatment by ABT-199. Several studies demonstrated the requirement for 
BCL-2 complexed to BIM in order to sensitize cells to BCL-2 inhibition by BH3 mimetics276-278. 
In cells where BCL-2 is unoccupied, binding of ABT-199 can reduce the anti-apoptotic 
reserve but will not likely cause MOMP as a single agent. The situation is different when 
BCL-2 is occupied by the pro-apoptotic factor BIM. Adding ABT-199 to these cells will 
displace BIM and induce MOMP (Figure 14)210.  
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Figure 14. Schematic representation of the effect of ABT-199 in insensitive and sensitive cells. (Top) In 
cells with largely unoccupied BCL-2, ABT-199 can bind to BCL-2 but can not release enough pro-apoptotic factors. 
Therefore, BAX/BAK remains inactive and there is no induction of apoptosis. (Bottom) In cells with a high 
occupation state of BCL-2, BIM will be released when ABT-199 competes for the BH3 binding site on BCL-2. Next, 
the released BIM can activate BAX/BAK and induce MOMP. This is true in case that there are no resistance 
mechanisms like high expression of other anti-apoptotic factors that can sequester the released BIM. Figure 
based on
210
. 
 
In the first small clinical trial with ABT-199, platelets were indeed spared but patients suffered 
from tumor lysis syndrome (TLS)276. TLS occurs when cancer cells lyse and release their 
contents into the bloodstream. This leads to hyperkalemia, hyperphosphatemia, 
hyperuricemia and hypocalcemia and can cause renal insufficiency, cardiac arrhythmias, 
seizures or even death due to multiorgan failure279. ABT-199 is highly effective and destroys 
cancer cells rapidly. To avoid TLS, stepwise increases in dose (ramp-up) were used in the 
subsequent clinical trials280, 281. A large part (79%) of patients with relapsed or refractory 
chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) had a response to 
ABT-199 in a phase I dose escalation study. 20% of the patients even gained complete 
remission with a monotherapy of ABT-199280. ABT-199 received three separate 
Breakthrough Therapy Designations (BTDs) from the FDA which is exceptional. BTDs allow 
the FDA to accelerate the review of a drug for serious or life-threatening conditions. ABT-199 
was granted a BTD for previously treated patients with CLL with 17p deletion, for patients 
with relapsed/refractory CLL in combination with rituximab and for the combination with 
hypomethylating agents for patients with first-line AML who can’t receive high-dose 
chemotherapy. Since April 2016, ABT-199 is FDA-approved for the treatment of patients with 
CLL with 17p deletion and who have been treated with at least one prior therapy. Another 
BCL-2 specific inhibitor is S55746, which is currently evaluated in phase I clinical trials264. 
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The development of small molecules that specifically target MCL-1 or BCL-XL has been 
challenging. Lessene et al.282 were the first to discover and develop a highly potent and 
selective BCL-XL inhibitor, WEHI-539. Soon afterwards, the same group developed the more 
potent inhibitor A-1155463 with better physicochemical properties than WEHI-539. In 
addition, they could demonstrate in vivo activity and tumor growth inhibition in mice283. Very 
recently, the highly potent and MCL-1-specific inhibitor S63845 was designed and 
successfully tested in preclinical mouse models of diverse hematological malignancies. 
Interestingly, S63845 was tolerated in mice at efficacious doses suggesting that a suitable 
therapeutic window is achievable284. 
DNA interference  
A new strategy to target the BCL2 gene is DNA interference (DNAi). By using single-
stranded unmodified sequences of DNA that are complementary to non-coding genomic 
DNA upstream of gene transcription start sites, gene expression can be modulated. Two 
possible working mechanisms have been described: binding of the DNA oligonucleotide to 
noncoding regions of the target gene prevents transcription or the oligonucleotide binds 
directly to transcription factors preventing the transcription262. 
PNT2258 is a 24-base DNA oligonucleotide sequence that is complementary to a region of 
the BCL2 gene and encapsulated in protective amphoteric liposomes285. This DNAi 
therapeutic entered clinical trials.  
4.2. SMAC mimetics 
 
XIAP belongs together with the cellular inhibitor of apoptosis proteins (cIAP) and others to 
the family of inhibitor of apoptosis (IAP) proteins. As mentioned before, XIAP inhibits both the 
intrinsic and extrinsic pathway of apoptosis by binding and inhibiting caspase-3, -7 and -9. 
Other members of the IAP family also inhibit apoptosis but are not potent direct inhibitors of 
caspases. For example, cIAP1 and cIAP2 have a domain that acts as E3 ubiquitin ligase. 
The ubiquitination carried out by cIAP1 and cIAP2 promotes pro-survival NF-κB signaling 
pathways and blocks the assembly of pro-apoptotic protein signaling complexes286, 287. 
IAP proteins are overexpressed in various human cancers and are often associated with a 
poor prognosis. Therefore, a lot of interest exists in developing drugs that target these 
proteins286, 287. As SMAC is an endogenous antagonist of IAP proteins, SMAC mimetics are 
promising small molecule inhibitors. Several SMAC mimetics are currently evaluated in early 
clinical trials as monotherapy or as part of combination therapies in solid tumors and 
leukemias287.   
SMAC mimetics could also be used in the treatment of T-ALL. Hundsdoerfer et al.288 
detected a high expression of XIAP protein in childhood ALL compared to control bone 
marrow. Notably, increased expression of XIAP was associated with glucocorticoid 
resistance in T-ALL patients and in vitro treatment of ALL cells with a SMAC mimetic 
increased glucocorticoid-induced apoptosis288. Moreover, ex vivo drug response profiling of 
relapsed or refractory ALL cases identified a subset of patients with high sensitivity to the 
SMAC mimetic birinapant. Complete responses in the blood were even achieved with 
birinapant in patient-derived xenograft models. Intriguingly, birinapant activated 
simultaneously apoptosis and necroptosis in the sensitive high-risk ALL samples289. 
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4.3. Recombinant TRAIL and TRAIL receptor agonists 
 
TRAIL is the ligand of the death receptors TRAILR1 and TRAILR2 and can induce the 
extrinsic pathway of apoptosis. Interestingly, a variety of tumor cells are very sensitive to 
TRAIL-induced apoptosis as opposed to normal cells 290. TRAIL is therefore a promising 
candidate for cancer therapeutics. Recombinant human TRAIL proteins and agonistic 
monoclonal antibodies specific for TRAILR1 and TRAILR2 have been developed and 
evaluated in many clinical trials for solid cancers. Although strong objective clinical 
responses have been reported, most patients showed no or only limited responses. In 
addition, multiple mechanisms of TRAIL resistance have been identified. It will be of crucial 
importance to find the right combination regimens and to select those patients that will most 
likely respond208, 290, 291. 
Resistance to in vitro treatment with human recombinant TRAIL was found in some human 
T-ALL cell lines and patient samples. The low expression of TRAILR1 and TRAILR2 in T-ALL 
can be responsible for this observed resistance292. Treatment with GSI resulted in increased 
TRAILR expression and an enhancement of TRAIL-induced apoptosis in the T-ALL cell line 
JURKAT293.   
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Research objectives 
Although the overall survival rates of children diagnosed with ALL are nowadays reaching 
85%, there is still a substantial part of children that does not respond to therapy or relapses 
and presents therefore with very dismal survival perspectives. For adults, the survival rates 
are lower and risk of relapse higher. Moreover, the current high-dose multi-agent 
chemotherapy treatment schedules are very intensive and are associated with acute and 
long-term side effects. Therefore, there is an urgent need for more effective and less toxic 
therapies for the treatment of ALL. 
In the lab of Prof. Pieter Van Vlierberghe, we focus on T-cell acute lymphoblastic leukemia 
which accounts for 15% of childhood and 25% of adult ALL cases. By in-depth investigation 
of genetic and epigenetic alterations in T-ALL, a better understanding of the disease can be 
obtained. Unraveling the pathways and biological processes related to these alterations can 
lead to the identification of new druggable targets and eventually to the development of 
therapies that are less toxic and more effective than the current ones. The aim of this thesis 
was to gain novel molecular insights in the disease and to evaluate novel molecular 
therapies for the treatment of T-ALL. Moreover, the main focus was on early immature T-
ALLs because this subgroup has been associated with a poor prognosis and is therefore in 
need of more effective treatment strategies. The objectives of this research were: 
Objective 1: Evaluate BCL-2 inhibition as a novel therapy in T-ALL  
The early immature T-ALL subgroup shows a high genetic diversity, making it difficult to find 
a common genetic alteration that can be targeted to treat patients with this disease. 
Therefore, we analysed gene expression profiles of T-ALL patients to discover genes that 
are differentially expressed in these early immature T-ALL patients compared to other 
subtypes. The finding that the anti-apoptotic factor BCL2 was overexpressed in the early 
immature group of T-ALL urged us to test BCL-2 inhibition as a novel therapy in human T-
ALL (paper 1, Blood 2014). For this purpose, the potent and selective BCL-2 inhibitor ABT-
199 (Venetoclax) was used. The antileukemic effects of ABT-199 were evaluated in several 
T-ALL subtypes by using a panel of human T-ALL cell lines and primary patient samples. 
Furthermore, using a xenograft mouse model, its potential for the treatment of T-ALL could 
also be proven in vivo.  
Objective 2: Identification of successful combination therapies with the BCL-2 
inhibitor ABT-199 in T-ALL  
After the encouraging results with ABT-199 as monotherapy in T-ALL, research on this topic 
was continued. Since monotherapy with a drug always raises the concern of resistance, 
synergistic combination therapies with ABT-199 were searched for. In a first step, 
combinations with conventional chemotherapeutic agents were tested to investigate whether 
adding BCL-2 inhibitors to the current treatment schedule could be useful (paper 1, Blood 
2014). Second, a screen in primary patient samples was performed in which ABT-199 was 
combined with several clinically relevant drugs. The BET bromodomain inhibitor JQ1 was 
identified as the most promising combination with ABT-199. Subsequently, this combination 
was thoroughly investigated, both in T-ALL cell lines and primary patient samples as well as 
in xenograft models. Moreover, the working mechanism of JQ1 was studied and mechanistic 
insights in the synergism were obtained (paper 2, Leukemia 2017). 
 Chapter 2: Research objectives 
64 
  
Objective 3: Identification of the interaction partners of the oncogenic transcription 
factor ZEB2 in T-ALL  
Early immature T-ALLs express high levels of ZEB2 compared to other T-ALL subtypes. 
Moreover, ZEB2 is an oncogenic driver of early immature T-ALL. ZEB2 has several domains 
that mediate protein-protein interactions and these interactions with other transcription 
factors or cofactors play an important role in determining its function. Therefore, identifying 
the interaction partners of ZEB2 in the context of T-ALL could help to clarify how ZEB2 
contributes to the development of T-ALL. Furthermore, targeting interaction partners that are 
essential for ZEB2’s oncogenic properties could potentially be used as a novel therapy to 
treat ZEB2-positive T-ALL. In our study, we identified the interaction partners of ZEB2 via 
protein complex pull-down experiments on nuclear extracts of Zeb2-overexpressing mouse 
T-ALL cell lines (paper 3, Blood 2017). 
Objective 4: Evaluation of the pharmacological inhibition of the interaction partner 
KDM1A as a novel therapy in ZEB2-positive T-ALL   
One of the newly identified interaction partners of ZEB2, was the lysine demethylase 1A 
(KDM1A). Also in the human T-ALL cell line LOUCY, a cell line characterized by high ZEB2 
levels and a transcriptional profile resembling early immature T-ALLs, this interaction was 
confirmed. Since KDM1A is a druggable target for which specific inhibitors are available and 
being tested in clinical trials, we decided to determine the efficacy of KDM1A inhibition in T-
ALL. The sensitivity of ZEB2-positive and –negative cells to the KDM1A-specific inhibitor 
GSK2879552 was evaluated in mouse and human T-ALL cell lines. Finally, xenograft mouse 
models were used to study the in vivo effects of GSK2879552 in T-ALL (paper 3, Blood 
2017).   
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PART I The BCL-2 inhibitor ABT-199 as monotherapy and part of 
combination therapies for the treatment of T-ALL 
 
Paper 1: ABT-199 mediated inhibition of BCL-2 as a novel therapeutic strategy in T-cell 
acute lymphoblastic leukemia (published in Blood, 2014) 
Paper 2: Targeting BET proteins improves the therapeutic efficacy of BCL-2 inhibition in T-
cell acute lymphoblastic leukemia (published in Leukemia, 2017) 
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Key Point 
High levels of the anti-apoptotic factor BCL-2 can be therapeutically exploited by the BH3 
mimetic ABT-199 in human T-ALL.  
 
Abstract 
T-cell acute lymphoblastic leukemia (T-ALL) is a high-risk subtype of ALL with gradually 
improved survival through introduction of intensified chemotherapy. However, therapy-
resistant or refractory T-ALL remains a major clinical challenge. Here, we evaluated BCL-2 
inhibition by the BH3 mimetic ABT-199 as a new therapeutic strategy in human T-ALL. The 
T-ALL cell line LOUCY, which shows a transcriptional program related to immature T-ALL, 
exhibited high in vitro and in vivo sensitivity for ABT-199 in correspondence with high levels 
of BCL-2. In addition, ABT-199 showed synergistic therapeutic effects with different 
chemotherapeutic agents including doxorubicin, L-asparaginase and dexamethasone. 
Furthermore, in vitro analysis of primary patient samples indicated that some immature, 
TLX3- or HOXA- positive primary T-ALLs are highly sensitive to BCL-2 inhibition, whereas 
TAL1 driven tumors mostly showed poor ABT-199 responses. Because BCL-2 shows high 
expression in early T-cell precursors and gradually decreases during normal T-cell 
differentiation, differences in ABT-199 sensitivity could partially be mediated by distinct 
stages of differentiation arrest between different molecular genetic subtypes of human T-ALL. 
In conclusion, our study highlights BCL-2 as an attractive molecular target in specific 
subtypes of human T-ALL that could be exploited by ABT-199. 
 
Introduction 
T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive hematological cancer that 
occurs in children and adolescents. Despite significant insights in T-ALL biology, only limited 
therapeutic options are available for patients with primary resistant or relapsed disease. 
Current T-ALL treatment schedules consist of high-dose chemotherapy and are often 
associated with acute and chronic life-threatening and debilitating toxicities1-3. Consequently, 
there is an urgent clinical need for optimized treatment stratification and more effective 
antileukemic drugs for the treatment of human T-ALL3.  
Genetic studies have collectively shown that T-ALLs can be divided into subgroups that are 
characterized by unique gene expression signatures and relate to stages of T-cell 
differentiation at which the leukemic cells arrest. Each molecular subgroup has characteristic 
genetic abnormalities that cause aberrant activation of specific T-ALL transcription factor 
oncogenes, including LYL1/MEF2C, HOXA, TLX1, TLX3 and TAL1/LMO2 driven T-ALL3-6. 
Notably, the recently described early T-cell precursor (ETP)-acute lymphoblastic leukemia 
(ALL) patients7 have leukemic cells that show an early block in T-cell differentiation and 
significantly overlap with LYL1-positive T-ALL4 and MEF2C-dysregulated immature T-ALL5,8. 
These immature T-cell leukemias often express myeloid markers such as CD13 and CD33, 
and show a transcriptional program related to hematopoietic stem cells and myeloid 
progenitors5. Importantly, these tumors are associated with poor prognosis and reduced 
overall survival7,9,10. Preclinical mouse models of LMO2-dependent T-cell neoplasia are 
thought to recapitulate at least some features of early immature human T-ALL including a 
pre-leukemic T-cell differentiation arrest11. In general, T-ALLs can be classified in pro-T 
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(CD7+, CD2-, CD5-), pre-T (CD7+, CD2+, CD5±), cortical-T (CD1a+) and mature T-cell stages 
(sCD3+, CD1a-) according to the European Group for the Immunological Characterization of 
Leukaemias classification system12. 
In an effort to improve patient prognosis and survival, targeted therapeutics are beginning to 
emerge as powerful agents against hematological malignancies. One such example is the 
small molecule ABT-199, a highly potent, orally bioavailable B-cell lymphoma (BCL)-2 
specific inhibitor13. The anti-tumor effects of ABT-199 have been reported in a growing 
number of tumor entities, including acute myeloid leukemia (AML)14,15, chronic lymphocytic 
leukemia (CLL)16, multiple myeloma17, estrogen receptor-positive breast cancer18 and 
lymphoma19. Currently, phase-I clinical trials of ABT-199 in CLL are ongoing and the first 
preliminary results show a high overall response rate. Notably, some patients included in this 
trial experienced tumor lysis syndrome as a result of the massive cell death induced by ABT-
19920. 
Given these promising antitumor results for ABT-199, we sought to establish the extent and 
level of BCL-2 expression across different T-ALL molecular subgroups and evaluated the 
therapeutic potential of the BCL-2 inhibitor ABT-199 in the context of human T-ALL. 
 
Methods 
Patient samples, cell lines and mouse tumor cells  
The cell lines were purchased from the DSMZ repository (Braunschweig, Germany) and 
cultured in RPMI 1640 medium supplemented with 10% or 20% fetal bovine serum (FBS), 
100 U/ml penicillin, 100 µg/ml streptomycin, 100 µg/ml kanamycin sulfate and 2 mM L-
glutamine at 37°C with 5% CO2.  
Bone marrow lymphoblast samples from 64 T-ALL patients (15 immature, 25 TAL/LMO, 17 
TLX1/TLX3 and 7 HOXA) were collected with informed consent according to the declaration 
of Helsinki from Saint-Louis Hospital, Paris, France, and the study was approved by the 
Institut Universitaire d’Hematologie Institutional Review Board. This primary T-ALL cohort 
was previously investigated21 and the high-quality RNA samples from this cohort were used 
for gene expression profiling.  
Primary T-ALL cells for in vitro ABT-199 treatment and xenograft studies were acquired by 
informed consent from the Department of Pediatric Hemato-Oncology at Ghent University 
Hospital. These primary T-ALL samples were assigned to a specific molecular genetic 
subclass based on qPCR of SIL-TAL1 or MLL fusion transcripts, TLX1/TLX3 expression 
analysis by quantitative polymerase chain reaction or fluorescence in situ hybridization 
analysis of the LMO2 locus.  
Leukemic T-cells obtained from splenic tissue derived from secondary transplanted tumors 
that originally developed in the Lck-Lmo2 mouse model (K.R. & T.H.R., manuscript in 
preparation) were a kind gift of T.H.R.  
Isolation of thymocyte subsets from human thymus tissue  
Human thymocytes were extracted from thymus tissue from children undergoing cardiac 
surgery and were obtained and used according to the guidelines of the Medical Ethical 
Commission of the Ghent University Hospital, Beglium. The thymus was dissected into small 
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pieces and the released cell suspension was passed through a 40 µm cell strainer. 
Enrichment of viable mononuclear cells was done by a Lymphoprep density gradient.  
CD34-positive cells were isolated by magnetic activated cell sorting (MACS) and purified by 
fluorescence-activated cell sorter (FACS)-mediated cell sorting. For the isolation of immature 
single positive cells (CD4+ CD8- CD3-), the cells were first labeled with an unlabeled anti-
glycophorin-A monoclonal antibody, and subsequently with unlabeled anti-CD8 and anti-CD3 
monoclonal antibodies for depletion of residual red blood cells and CD8+ and CD3+ cells. 
Magnetic anti-mouse immunoglobulin-coated Dynabeads were used to obtain a CD3, CD8 
and red blood cell depleted thymocyte fraction by means of the DynaMag Magnet. This 
fraction could then be further purified into pre- and post-β-selection CD4+CD3-CD8-CD28- 
and CD4+CD3-CD8-CD28+ subsets by staining the cells with anti-human CD4, CD3, CD34, 
CD8 and CD28 antibodies followed by FACS. Isolation of double-positive and single-positive 
thymocytes was performed by staining the cells with CD4, CD8 and CD3 antibodies followed 
by FACS analysis. T-cell receptor (TCR)γδ+ cells were isolated via MACS by labeling the 
thymocytes with anti-TCRγδ Hapten antibodies and adding MACS Anti-Hapten MicroBeads 
fluorescein isothiocyanate. To separate immature and mature TCRγδ+ cells, the MACS-
enriched cells were stained with CD3 and CD1 monoclonal antibodies and sorted via FACS. 
Gene expression profiling of primary T-ALL samples and T-cell subsets  
Total RNA was isolated using the miRNeasy or RNeasy mini kit (Qiagen) and the RNA 
quality was evaluated on the Agilent 2100 bioanalyzer (Agilent Technologies, Santa Clara, 
CA). Whole human genome expression profiling was performed using the GeneChip Human 
Genome U133 2.0 Plus arrays (Affymetrix, Santa Clara, CA) according to standardized 
procedures at the IGBMC (www.igbmc.fr, Strasbourg, France). Normalization of microarray 
intensities was done using the variance stabilization and calibration (VSN) R package in R. 
Differential expression analysis was done using the Comparative Marker Selection module in 
GenePattern22. Microarray data have been deposited in the NCBI Gene Expression Omnibus 
(GEO) with accession number GSE62156. An independent and publically available5 cohort of 
human T-ALL samples was used to validate the findings about BCL-2 expression levels. 
Treatment of cells with ABT-199 followed by viability or apoptosis assay  
Cells from T-ALL cell lines (Supplementary Table 1) were plated at 100 000 cells per well in 
96-well plates. The cells were incubated for 48 hours in 100 µl medium with 10% FBS to 
which 5 µl of the appropriate ABT-199 dilution or dimethylsulfoxide (DMSO) was added. The 
assays were performed with the Celltiter-Glo Luminescent Cell Viability Assay according to 
the manufacturer’s instructions (Promega). To determine the half maximal inhibitory 
concentration (IC50), 6 to 8 concentration points (twofold increase) were chosen for each cell 
line so that the IC50 point was approximately in the middle of the concentration range. The 
IC50 values were calculated using the CalcuSyn software (Biosoft, Cambridge, MA). The 
experiment was performed 2 or 3 times independently and in every experiment, each 
concentration was tested in duplicate for every cell line. 
For the apoptosis assay, cells were plated at 10 000 cells per well in 96-well plates. The cells 
were incubated for 24 hours in 95 µl medium with 10% FBS to which 5 µl of the appropriate 
ABT-199 dilution or DMSO was added. The assay was performed with the Caspase-Glo 3/7 
Assay according to the manufacturer’s instructions (Promega). The experiment was 
performed 3 times and every concentration point was each time tested in duplicate for each 
cell line. 
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For the treatment of primary T-ALLs, enriched mononuclear cells or full bone marrow from 
primary leukemia samples were suspended in complete culture medium  supplemented with 
10% FBS. Cells were plated at 50 000 cells per well in 96-well plates to which 5 µl of the 
appropriate ABT-199 dilution (9 to 13 concentrations) or DMSO was added (total volume 100 
µl). Cell viability was measured 16 hours after adding the compound and the IC50 values 
were calculated. Each concentration was tested in duplicate for every patient sample. The 
Lck-Lmo2 mouse tumor T-cells were thawed and treated with ABT-199 in medium with 10% 
FBS for 16 hours. The IC50 values were determined as described above (50 000 cells per 
well). Two independent experiments were performed in which each concentration was tested 
in duplicate. 
Quantitative real-time reverse transcription polymerase chain reactions (qRT-PCR) 
Total RNA was isolated using the miRNeasy mini kit (Qiagen) and the RNAse-Free Dnase 
set (Qiagen). The iScript cDNA synthesis kit (Bio-Rad) was used to synthesize cDNA. The 
qRT-PCRs were performed using the SsoAdvanced SYBR Green Supermix (Bio-Rad) and 
were run on the LightCycler 480 (Roche, model LC480). Every sample was analyzed in 
duplicate and the gene expression was standardized against at least 3 reference genes. The 
primer sequences are listed in Supplementary Table 2. 
Western blotting  
Cells were lysed with radioimmunoprecipitation assay (RIPA) buffer and protein 
concentration was measured with the Pierce BCA protein assay kit. Denatured protein was 
loaded on a 10% polyacrylamide gel and the sodium dodecyl sulfate-polyacrylamide gel 
electrophoresis was run followed by western blotting on a nitrocellulose membrane. The 
used primary antibodies were: Bcl-2 antibody (C-2) (sc-7382; Santa Cruz Biotechnology; 
dilution 1:1000), BCL-XL antibody (#2762; Cell Signaling Technology; dilution 1:1000) and 
anti-β-actin antibody (Clone AC-75; A2228; Sigma-Aldrich; dilution 1:2000). The protein 
bands were densitometric analyzed using ImageJ software (National Institutes of Health). 
In vivo treatment of xenografts with ABT-199  
Luciferase-positive LOUCY cells were generated by infecting the LOUCY cell line with PWPI-
LUC lentiviruses. Nonconcentrated virus was produced in HEK293TN cells using JetPEI 
polyplus reagent with pMD2.G (envelope plasmid), psPAX2 (packaging plasmid) and pWPI-
LUC (target plasmid) in 0.1/0.9/1 ratios. Transduced cells expressing enhanced green 
fluorescent protein were selected 72 hours after infection by cell sorting on a S3 cell sorter 
(Bio-Rad). 
Nonobese diabetic/severe combined immunodeficient γ (NSG) mice were injected at 6 weeks 
of age in the tail vein with 150 µl phosphate-buffered saline containing 5 x106 luciferase-
labeled LOUCY cells. At regular time points, the bioluminescence was measured using the 
IVIS Lumina II imaging system (PerkinElmer). At 6 weeks, the cells were engrafted and the 
mice were randomly divided into 2 groups (with an equal number of males and females in 
both groups), and the treatment was started on day 0. Mice were treated with 100 mg ABT-
199/kg body weight or with vehicle via oral gavage for four 4 consecutive days. ABT-199 was 
formulated in 60% phosal 50 propylene glycol, 30% polyethylene glycol 400 and 10% ethanol. 
At days 0, 2 and 4 the bioluminescene was measured. Before imaging, the mice were 
injected intraperitoneally with 200 µl of a 15 mg/ml firefly D-luciferin potassium salt solution 
and anesthetized by inhalation of 5% isoflurane. The mice were imaged 10 minutes after 
luciferin injection. The total bioluminescence signal in each mouse was calculated via the 
region of interest tool (total counts) in the Living Image software (PerkinElmer).  
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A xenograft of primary human T-ALL cells from patient 3 was established in NSG mice by 
retro-orbital injection21. Upon establishment of disease, human leukemic cells were isolated 
from the spleen and retransplanted into secondary recipients. Next, tertiary xenograft 
injections were performed in a cohort of 10 NSG mice and leukemia engraftment was 
monitored by human CD45 staining (CD45-FITC antibody; Miltenyi Biotec) in peripheral 
blood using FACS analysis with the S3 cell sorter (Bio-Rad). Upon detection of human 
CD45+ leukemic blasts in peripheral blood, mice were randomized in 2 groups and treated 
with vehicle or 100 mg ABT-199/kg body weight for 7 consecutive days. After treatment, 
animals were sacrificed and the percentage human CD45 (hCD45)-positive leukemic blasts 
in bone marrow were determined by FACS as described above. 
The ethical committee on animal welfare at Ghent University Hospital approved all animal 
experiments. 
Combination treatment of cells with ABT-199 and chemotherapeutic agents  
T-ALL cell lines were plated at 20 000 cells per well in 96-well plates, and twofold dilution 
series of ABT-199 and the chemotherapeutic were made around the IC50 point for every cell 
line. For the combination therapy, 5 µl of each compound dilution was added at a constant 
concentration ratio and every concentration point was tested in duplicate within 1 experiment. 
The final concentration of solvent was equal for all the concentrations of a particular 
compound. Cell viability was assessed 48 hours after adding the compounds by CellTiter-Glo 
Assay and Calcusyn was used to calculate the combination index (CI). The 
chemotherapeutics used were: doxorubicin hydrochloride (D1515, solvent dimethylsulfoxide; 
Sigma-Aldrich), L-asparaginase (Erwinase, PL 01511/0272, solvent NaCl 0.9%) and 
dexamethasone (Aacidexam; NV Organon; solvent water). 
Statistical analysis  
GraphPad Prism 5.04 (La Jolla, CA) was used for statistical analyses. 
 
Results 
BCL-2 expression in genetic subtypes of human T-ALL and normal T-cells  
To evaluate BCL-2 as a potential therapeutic target in human T-ALL, we analyzed BCL-2 
expression levels in T-ALL patients and sorted subsets of normal human thymocytes. Here, 
we performed microarray gene expression profiling on a panel of 64 primary T-ALL samples 
and used these gene expression signatures to define different molecular-genetic subtypes of 
human T-ALL as previously described6. Notably, this analysis revealed that high expression 
of anti-apoptotic BCL-2 is a hallmark of immature subtypes of T-ALL (Figure 1A). Moreover, 
BCL-2 levels were variable in TLX1, TLX3 and HOXA driven T-ALLs and predominantly low 
in TAL1 rearranged T-cell leukemias (Figure 1A). Importantly, these findings were validated 
and confirmed in an independent cohort of 117 genetically well-characterized human T-ALL 
samples for which gene expression signatures are publically available5 (Figure 1B). In this 
validation series, the average BCL-2 expression in the HOXA subgroup was similar to the 
one in the immature T-ALL subgroup. 
As normal T-cell development serves as the conceptual framework for the understanding of 
T-ALL biology23, we hypothesized that high BCL-2 expression in immature T-ALL is a 
reflection of the spatiotemporal regulation of BCL-2 during normal T-cell development. 
Indeed, BCL-2 expression was high in CD34+ T-cell progenitors and gradually decreased 
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during differentiation with the lowest values in CD4+CD8+ double-positive T-cells 
(Supplementary Figure 1A). Interestingly, BCL-2L1 (the gene encoding BCL-XL) expression 
showed an inverse trend (Supplementary Figure 1A). Furthermore, BCL-2 and BCL-XL 
expression in CD34+ T-cell progenitors as compared to sorted CD4+/CD8+ and TCRγδ+ T-cell 
fractions was confirmed at the protein level (Supplementary Figure 1B). 
 
 
Figure 1. BCL-2 expression in malignant human T-cells. (A) Differential gene expression profiling of primary 
immature T-ALLs vs T-ALLs from other subgroups (log2[fold change]>2; P<.05). A heat map of the top 50 
differentially expressed genes is shown. Genes in the heat map are shown in rows and each individual leukemia 
sample is shown in 1 column. Expression levels are visualized as color-coded differential expression from the 
mean in standard deviation units with red indicating higher levels and blue lower levels of expression. This 
primary T-ALL cohort has previously been investigated
21
 and hierarchical clustering was used to define molecular-
genetic subtypes of human T-ALL, as previously described
6
. (B) BCL-2 expression levels (probe 203685_at) in an 
independent cohort of 117 human T-ALL samples. Molecular-genetic subtypes of human T-ALL have been 
defined as previously described
5
. nBM: normal bone marrow. P = 0.0051. 
 
ABT-199 sensitivity in human T-ALL cell lines   
Next, we determined IC50 values for ABT-199 in a panel of 11 human T-ALL cell lines. Mature 
T-ALL cell lines, including ALL-SIL, CUTLL1, TALL-1, KOPTK1, DND-41, PF-382, KARPAS-
45, PEER, JURKAT and CCRF-CEM, showed modest responses towards ABT-199 
treatment with IC50 values ranging from 0.2 to 10 µM (Figure 2A). Most notably and in line 
with a previous report24, the T-ALL cell line LOUCY, which shows a transcriptional program 
related to early immature T-ALLs25, was highly sensitive toward ABT-199 treatment (IC50 = 
13.9nM). As expected, induction of apoptosis upon treatment of LOUCY with 20 nM ABT-199 
for 24 hours was associated with increased caspase activity (Figure 2B). This induction at 
low ABT-199 concentration was significantly higher (P = 0.0088; 2-sided t test) in LOUCY 
cells as compared with ALL-SIL, the second most ABT-199 sensitive T-ALL cell line (Figure 
2B). Moreover, we observed a negative correlation between ABT-199 IC50 values and BCL-2 
mRNA (Spearman ρ = -0.855; P = 0.0015) and BCL-2 protein (Spearman ρ = -0.7; P = 
0.0204) levels in human T-ALL cell lines (Figure 2C-F). 
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Figure 2. ABT-199 response in human T-ALL cell lines. (A) The effect of 48 hours ABT-199 treatment on the 
viability of human T-ALL cell lines relative to cells treated with dimethylsulfoxide (100%). The results represent the 
average and standard deviation for at least 2 independent experiments. SD, standard deviation. (B) Caspase 3/7 
activity was measured 24 hours after adding ABT-199 and was plotted relative to the DMSO control. The average 
and standard deviation of 3 independent experiments is shown. The caspase activity after treatment with 20 nM of 
ABT-199 was significantly higher in LOUCY than ALL-SIL (P=0.0088; 2-sided t test), PEER (P=0.0008; 2-sided t 
test) or JURKAT (P=0.0119; 2-sided t test with Welch's correction). (C) BCL-2 and BCL-2L1 expression measured 
with quantitative real-time polymerase chain reactions in a panel of T-ALL cell lines. The graph shows the 
calibrated normalized relative quantities values and corresponding standard error as calculated with qbasePLUS. 
The gene expression was standardized against HMBS, TBP and UBC. (D) Correlation between the IC50 values for 
ABT-199 and BCL-2 mRNA expression in human T-ALL cell lines. (E) Western blot of BCL-2 and BCL-XL in T-
ALL cell lines with β-actin as the loading control. (F) Correlation between the IC50 values for ABT-199 and BCL-2 
protein levels in human T-ALL cell lines. 
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To test the efficacy of ABT-199 in vivo, we performed xenograft experiments using luciferase 
positive LOUCY cells in immune-deficient NSG mice (Figure 3). Treatment of established 
xenografted tumors with 100 mg ABT-199/kg for 4 days resulted in a significant reduction of 
leukemic burden (P = 0.0048; 2-sided t test), suggesting that BCL-2 inhibition can selectively 
restrain leukemic cell growth of the T-ALL cell line LOUCY in vivo.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. ABT-199 sensitivity in a mouse xenograft model of the T-ALL cell line LOUCY. Thirteen mice 
xenografted with luciferase positive LOUCY cells were vehicle treated or ABT-199 treated (100 mg/kg body 
weight) for 4 days. The bioluminescence was measured before the start of the treatment (day 0) and after 2 and 4 
days of treatment. Each column with pictures represents 1 individual mouse. The total bioluminescence signal 
after 4 days of treatment is plotted relative to the start value at day 0 for each mouse.  
 
Mouse model of immature T-ALL responds to ABT-199  
To further study the association between ABT-199 sensitivity and tumor immune phenotype 
in T-ALL, we used the Lck-Lmo2 transgenic mouse model. Overexpression of the Lmo2 
oncogene in the thymi of these Lck-Lmo2 mice results in the development of murine T-cell 
tumors with an average latency of 10 months (K.R. and T.H.R., manuscript in preparation), 
comparable to the CD2-Lmo2 transgenic strain11,26. Interestingly, the resulting Lck-Lmo2 
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driven murine tumors show considerable immunophenotypic tumor heterogeneity, providing 
an opportunity to study the potential connection between tumor immunophenotype and ABT-
199 response in a homogeneous genetic background. 
For this, we determined ABT-199 IC50 values in leukemic blasts obtained from 2 
immunophenotypically different Lck-Lmo2 murine tumors that sustained their phenotype 
during transplantation. One Lck-Lmo2 tumor (#39365) showed an immature phenotype with 
about 90% CD4/CD8 double-negative blasts, whereas the second tumor (#39354) presented 
with a more mature phenotype consisting of about 30% CD4/CD8 double-positive and 40% 
CD4 single-positive leukemic blasts. Interestingly, we identified a 100-fold difference in ABT-
199 IC50 value between the immature (#39365; IC50 = 2.2 nM) (Figure 4A) and mature murine 
T-cell tumor (#39354; IC50 = 214 nM) (Figure 4A), and this differential ABT-199 response was 
associated with enhanced levels of BCL-2 in the immature murine T-cell tumor (Figure 4B). 
 
Figure 4. BCL-2 expression and ABT-199 sensitivity in the Lck-Lmo2 transgenic mouse model. (A) ABT-
199 response of tumor cells obtained from Lck-Lmo2 transgenic mice. T-cell tumor #39365 consists of 
approximately 90% double-negative T-cells (approximately 40% double-negative 1, 60% double-negative 2), 
whereas tumor #39354 consists of about 30% double-positive and 40% CD4
+
 single-positive T-cells. The viability 
(average and standard deviation of 2 independent experiments) is shown relative to the cells incubated with 
dimethylsulfoxide (100%). Based on these data, the IC50 values were calculated. (B) BCL-2 expression in the Lck-
LMO2 mouse tumors. The top panel shows the mRNA expression (quantitative real-time polymerase chain 
reactions, calibrated normalized relative quantities values and corresponding standard errors) and the bottom 
panel shows the protein expression with β-actin as loading control. The messenger RNA gene expression was 
standardized against Hmbs, Tbp and Ubc. 
 
ABT-199 response in primary T-ALL samples  
To define ABT-199 sensitivity in primary patient material, we subsequently selected a panel 
of 17 pediatric primary T-ALL samples that represent major immunophenotypic maturation 
stages and molecular genetic subtypes of T-ALL (Figure 5A; Supplementary Figure 2). 
Leukemic samples belonging to the early stages of maturation based on the EGIL criteria12 
were predominantly sensitive to ABT-199 treatment with all CD4- CD8- double negative T-
ALL samples showing an IC50 lower than 300 nM. In contrast, mature T-ALL patient samples 
showed modest ABT-199 responses with most SIL-TAL1-positive T-ALLs showing an IC50 > 
800 nM. Although only few HOXA and TLX3 rearranged T-ALLs were included in this patient 
Chapter 3: Results 
79 
  
series, some TLX3- or HOXA- positive leukemias were also highly sensitive to BCL-2 
inhibition (Figure 5A; Supplementary Figure 2). 
 
Figure 5. ABT-199 sensitivity in primary human T-ALL patient samples. (A) ABT-199 IC50 values for a panel 
of primary T-ALL samples. Patient samples are classified based on their immunophenotype in pro-, pre-, cortical, 
intermediate between cortical and mature and mature T-ALL with markers scored on the blast gate. Molecular 
classification is based on fluorescence in situ hybridization and/or expression analysis. (B) Cell viability of 
diagnostic and relapse material from T-ALL patient 16 after 16 hours of ABT-199 treatment using different 
concentrations relative to cells incubated with dimethylsulfoxide (100%). (C) BCL-2 expression (quantitative real-
time polymerase chain reactions, calibrated normalized relative quantities values and corresponding standard 
errors) analysis of diagnostic and relapse material obtained from T-ALL patient 16. The expression was 
standardized against B2M, HPRT1, RPL13A and TBP. (D) Percentage of human CD45 in the bone marrow of 
NSG mice injected with a patient-derived xenograft from T-ALL #3 (MLL rearranged, HOXA-positive) after 7 days 
of treatment with vehicle or ABT-199. /, not known; BM, bone marrow;  cCD3, cytoplasmic CD3; p+, partial 
positive; R, relapse; s, surface; v, variable; w, weak. *P = 0.0498. 
 
Interestingly, the putative relation between tumor immunophenotype and ABT-199 sensitivity 
was further strengthened by a unique T-ALL sample that presented with a mature T-ALL at 
diagnosis, but suffered from an immature/biphenotypic T-ALL at relapse 11 months after 
initial diagnosis (Supplementary Figure 3). Notably, the leukemic clone with an 
immature/biphenotypic immunophenotype that eventually gave rise to the relapse was 
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already detected at day 15 and day 35 after induction therapy. Notably, in vitro analysis of 
these paired samples obtained at diagnosis and relapse revealed marked differences in 
ABT-199 sensitivity. The immature leukemic cells at relapse were highly sensitive to ABT-
199 treatment (IC50 = 7.32 nM), whereas the mature leukemic cell population at diagnosis 
barely responded to ABT-199 (IC50 > 800 nM) (Figure 5B). Interestingly, the marked 
difference in ABT-199 sensitivity was accompanied by a notable difference in BCL-2 
expression between the diagnostic and relapse sample (Figure 5C). 
Finally, we established a patient-derived xenograft (PDX) in NSG mice from the HOXA-
positive (MLL rearranged) T-ALL patient sample #3 that showed ABT-199 sensitivity in vitro 
(Figure 5A; Supplementary Figure 2). ABT-199 treatment of this PDX for 7 consecutive days 
resulted in a significant lower percentage of human CD45-positive cells in the bone marrow 
(P = 0.0498; one-sided t test with Welch’s correction) as compared to the vehicle-treated 
mice (Figure 5D).  
Combination of ABT-199 and chemotherapeutics  
To evaluate potential synergism between ABT-199 and conventional chemotherapeutic 
agents, T-ALL cell lines were treated with combinations of ABT-199 and doxorubicin, L-
asparaginase (Erwinase) or dexamethasone (Aacidexam). LOUCY and ALL-SIL displayed 
higher synergism with doxorubicin and L-asparaginase as compared to the ABT-199-
insensitive JURKAT cell line (Figure 6A-B; Supplementary Table 3). In addition, the 
combination of ABT-199 with dexamethasone was strongly synergistic in LOUCY cells 
(Figure 6C; Supplementary Table 3) and could not be evaluated in JURKAT and ALL-SIL 
because of the high dexamethasone IC50 values in these cell lines. 
 
Discussion 
T-ALL is a genetically heterogeneous disease with cure rates in modern protocols 
reaching >80% in children and about 50% in adults27. The standard antileukemic therapy 
consists of intensive multiagent chemotherapy and is associated with considerable toxicities 
and long-term side effects. Therefore, novel molecularly driven therapeutic approaches 
should be developed to improve clinical care for T-ALL patients in the near future. 
Evasion of apoptosis is a hallmark of human cancer28 and is often mediated by 
overexpression of prosurvival BCL-2 family proteins, and can act as a major determinant of 
chemotherapy resistance29. Hence, the search for compounds that could target prosurvival 
BCL-2 family members has been actively explored30. ABT-73731 and its orally bioavailable 
derivative ABT-26332 (navitoclax) are BH3 mimetics that inhibit the anti-apoptotic proteins 
BCL-2, BCL-XL and BCL-W. Initial clinical trials using navitoclax have shown promising 
antitumoral effects particularly in CLL33. Unfortunately, navitoclax treatment was associated 
with dose-limiting thrombocytopenia, given the critical role of BCL-XL in platelet survival
32,34. 
As a consequence, ABT-19913 was developed as a highly specific inhibitor that only targeted 
BCL-2 and therefore spared platelets. 
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Figure 6. ABT-199 in combination with chemotherapeutic agents in human T-ALL cell lines. The effect of 
monotherapy or combination therapy on the viability of T-ALL cell lines is visualized. Cell viability is expressed 
relative to cells treated with dimethylsulfoxide and the average and standard deviation of 2 independent 
experiments is plotted for each combination. Combination of ABT-199 with doxorubicin (A) or L-asparaginase (B) 
in the T-ALL cell lines LOUCY, JURKAT and ALL-SIL. (C) Combination of ABT-199 and dexamethasone is only 
shown for the LOUCY cell line. The combination index (CI) shown represents the average of the CIs at the ED50, 
ED75 and ED90 effect levels for each experiment. 0.9<CI<1.1: nearly additive; 0.85<CI<0.9: slight synergism; 
0.7<CI<0.85: moderate synergism; 0.3<CI<0.7: synergism; 0.1<CI<0.3: strong synergism; CI<0.1: very strong 
synergism. 
 
To evaluate BCL-2 as a molecular target for therapy in human T-ALL, we analyzed the 
pattern of BCL-2 expression across 181 primary T-ALL samples and documented high BCL-
2 expression in immature T-ALLs. Notably, these results are in line with a study by Ferrando 
et al.4 that reported high BCL-2 expression in so-called LYL1 positive T-ALLs, a molecular 
subtype of human T-ALL that closely resembles immature T-ALL5 and partially overlaps with 
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the more recently identified subclass of poor prognostic ETP-ALL. In addition, we observed 
intermediate BCL-2 expression in TLX1, TLX3 or HOXA driven T-ALLs, whereas mature T-
ALLs, which are often characterized by TAL1 or LMO2 oncogene activation, displayed low 
levels of BCL-2. 
In the past, transcriptional profiling studies have established a genetic classification of human 
T-ALL4-7. Collectively, these analyses showed that gene expression signatures of molecular 
genetic T-ALL subgroups are closely related to those of normal thymocytes at distinct stages 
of T-cell development4. Given this, we analyzed BCL-2 expression in 11 subsets of human 
thymocytes that collectively reflect the chronological steps in human T-cell differentiation. 
Early T-cell precursors that enter the thymus from the bone marrow showed high BCL-2 
levels and this expression pattern was maintained until the CD28- immature single positive 
(ISP) stage. At this point, CD28-CD4+ ISP thymic precursors will undergo the process of β-
selection, which coincides with loss of BCL-2 expression as the cells move into the αβ 
lineage. Hence, we observed the lowest levels of BCL-2 in CD3-CD4+CD8+ T-cells. In 
contrast, BCL-2L1 showed an opposite pattern of expression with high BCL-2L1 levels in 
CD4+CD8+ T-cells, suggesting an anti-apoptotic switch from BCL-2 to BCL-2L1 during human 
T-cell maturation. Finally, CD28-CD4+ ISP cells that rearrange their TCRδ and TCRγ loci into 
functional TCRδ and TCRγ chains will develop into the γδ lineage, and these were shown to 
retain most of their BCL-2 expression. Altogether, BCL-2 expression analysis in 2 genetically 
well-defined primary T-ALL patient cohorts and sorted subsets of T-cells confirmed the tight 
association between normal and malignant T-cell development and provided a rationale for 
targeting BCL-2 in immature subtypes of human T-ALL. 
In vitro analysis of human T-ALL cell lines showed marked differences between cell lines that 
reflect different molecular genetic T-ALL subtypes and unraveled a significant association 
between ABT-199 sensitivity and BCL-2 expression levels. Most notably, the T-ALL cell line 
LOUCY showed the highest BCL-2 expression and was highly sensitive to BCL-2 inhibition 
by ABT-199 both in vitro24 and in vivo using xenografts of human LOUCY cells. Although the 
gene expression profile of the T-ALL cell line LOUCY closely resembles the gene signature 
observed in lymphoblasts from primary immature human T-ALLs25, this cell line shows 
characteristic activation of HOXA expression due to the presence of the SET-NUP214 
(nucleoporin 214) fusion oncogene35, which has been associated with corticosteroid and 
chemotherapy resistance36. In addition, the LOUCY cell line is TCRγδ+-positive, suggesting 
that it combines immature transcriptional features with a mature TCRγδ immunophenotype. 
Therefore, its high BCL-2 expression mimics normal T-cell development where BCL-2 levels 
remain high in T-cells that differentiate along the γδ lineage. All together, these data suggest 
that BCL-2 levels could predict ABT-199 sensitivity in human T-ALL and suggest that BCL-2 
inhibition might be particularly relevant as a novel therapeutic strategy in immature and 
HOXA-positive T-ALL.   
To obtain further evidence for the close association between tumor immune phenotype, BCL-
2 expression and ABT-199 sensitivity, we used the Lck-Lmo2 transgenic mouse model (K.R. 
and T.H.R., manuscript in preparation). The Lck-Lmo2 transgenic shows similar 
characteristics as the CD2-Lmo2 mouse model11,26, in which Lmo2 promotes self-renewal of 
preleukemic thymocytes and sets the stage for the accumulation of additional genetic 
mutations required for leukemic transformation37. In this model, BCL-2 expression was 
associated with the differentiation arrest of the tumor cells and defined the ABT-199 
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response of these murine tumors. Therefore, the tumor susceptibility towards BCL-2 
inhibition is initially dictated by the tumor cell of origin and is conserved in mice. 
In a next step, ABT-199 was able to affect the viability of primary T-ALL samples in vitro. 
Especially CD4- CD8- samples and samples belonging to the pro-T, pre-T and cortical T 
immunophenotypic maturation stages were responsive to ABT-199 treatment, whereas 
mature subtypes that differentiate along the αβ lineage were largely insensitive. Intriguingly, a 
T-ALL patient that was characterized by an immunophenotypic switch between diagnosis 
and relapse further exemplified the association between ABT-199 sensitivity and tumor 
immunophenotype. Notably, immature therapy-resistant leukemia cells at relapse were highly 
sensitive to ABT-199 in vitro, suggesting that BCL-2 inhibition could also serve as a 
promising therapeutic strategy for refractory T-cell leukemias. In addition, and as previously 
shown38, in vitro sensitivity of an MLL rearranged T-ALL patient corresponded with reduced 
tumor burden upon ABT-199 treatment in vivo using a PDX with material from that HOXA-
positive T-ALL. Based on these observations, we hypothesize that immunophenotypic 
features and BCL-2 expression levels largely determine ABT-199 sensitivity in human T-ALL. 
Importantly, our study confirms the recent work from Ni Chonghaile et al.39, which was mainly 
focused on the potential use of ABT-199 for the treatment of human ETP-ALL. However, our 
study suggests that genetic subtypes of human T-ALL that might benefit from ABT-199 
treatment might extend beyond ETP-ALL and could also include TLX1, TLX3 or HOXA-
positive T-ALLs as well as mature TCRγδ+-positive leukemias. 
Most conventional chemotherapeutic agents execute their action via the mitochondrial 
pathway of apoptosis by activation of pro-apoptotic or inactivation of anti-apoptotic BCL-2 
family proteins. Whether malignant cells are sensitive to a chemotherapeutic agent may 
depend on their pretreatment priming (ie. the proximity of a malignant cell to an apoptotic 
threshold)40. Given this, the combination of ABT-199 and chemotherapeutic agents could 
increase the chemosensitivity of malignant cells by reduction of their anti-apoptotic reserve40. 
Moreover, the combination of ABT-199 with chemotherapeutic agents or other targeted 
therapies could avoid the emergence of therapy resistance and result in reduced cytotoxic 
side effects due to lower chemotherapy dosage. In myeloid and ALL cell lines, ABT-737 was 
shown to increase sensitivity towards chemotherapeutic agents40,41. In addition, a strong 
synergism between ABT-199 and cytarabine has been previously reported in the T-ALL cell 
line LOUCY24. These findings were further extended in our study, in which we showed 
synergistic effects between ABT-199, doxorubicin, L-asparaginase and dexamethasone 
mainly in T-ALL cell lines with low ABT-199 IC50 values. 
Altogether, our study defines BCL-2 as an attractive molecular target in human T-ALL and 
provides a rationale for including T-ALL patients in clinical trials for the BH3-mimetic ABT-
199 in combination with conventional chemotherapeutics.  
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Supplementary Figures 
 
 
Supplementary Figure 1. BCL-2 expression in normal human T-cells. (A) BCL-2 (probe 203685_at) and BCL-
2L1 expression (probe X212312_at) in sorted subsets of human thymocytes. Average expression and standard 
deviation of two donors is shown. (B) Western blot analysis of BCL-2 and BCL-XL (encoded by BCL-2L1) in 
CD34+, CD4+ CD8+ double-positive and TCRγδ+ thymocytes. β-actin was used as loading control. For the CD4+ 
CD8+ double-positive cells only the lower band on the BCL-2 blot was quantified. 
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Supplementary Figure 2. In vitro ABT-199 sensitivity in primary human T-ALL samples. The viability of 15 
primary T-ALL samples after 16h treatment with different concentrations of ABT-199 is shown relative to cells 
incubated with DMSO (100%). The results represent the average and standard deviation of one experiment in 
which every concentration was tested in duplicate for every sample. The IC50 value for every primary sample is 
mentioned. Sample#2 was analyzed in three independent experiments, sample #3 and #8 in two independent 
experiments. For these samples the average and standard deviation of the independent experiments is shown. 
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Supplementary Figure 3. Clinical course of a primary T-ALL patient. Primary T-ALL patient #16 was diagnosed with leukemic T-cells with a characteristic mature 
immunophenotype. At day 15 and day 35 post induction therapy, resistant leukemic cells with an immature/biphenotypic immunophenotype persisted. At 7 months, the patient 
received a bone marrow transplantation (BMT). Eleven months after initial diagnosis, the patient relapsed with a leukemic burden that consisted of the presumably therapy-
resistant clone that showed the immature/biphenotypic immunophenotype. 
 
 
 
. 
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Supplementary Tables 
Supplementary Table 1. Characteristics of human T-ALL cell lines.  
Cell line Karyotype TCR Immunology Fusion transcript/molecular 
subgroup 
LOUCY1 hypodiploid karyotype with 16% polyploidy 45<2n>X, -X, 
del(1)(p3?2p3?4), del(5)(q14-15q34-35), t(16;20)(p1?1;q1?3) - 
sideline with del(6)(q23) - 1p32, 1p34 and 6q- recurrent in T-ALL 
αβ- γδ+ 
 
CD2- CD3+ CD4- CD5+ CD6+ 
CD7+ CD8- CD13- CD19- 
CD34- 
SET-NUP214 fusion/ 
expression of MEF2C 
 
ALL-SIL1 hypertetraploid karyotype - 90-95<4n>XX/XXYY,  
+6, +8, +8, t(1;13)(p32;q32)x2, del(6)(q25)x2, 
del(9)(?p23p24)x2, t(10;14)(q24;q11.2)x2, add(17)(p11)x2 -  
sideline with idem, -20, -20 - carries t(10;14) effecting TLX1-
TRD@ (HOX11-TCRD) juxtaposition 
αβ- γδ- 
 
cyCD3+ CD3- CD4+ CD5+ 
CD6+ CD7+ CD8+ CD13- 
CD19- CD34- 
 
NUP214-ABL1 fusion/ 
TLX1 expression 
 
 
PEER1 pseudodiploid karyotype with 7% polyploidy - 46(42-47)<2n>XX, 
der(4)?dup ins(4;4)(?p11;?q21q25), del(5)(q22q31), 
del(6)(q13q22), del(9)(p11p22), del(9)(q22) 
αβ- γδ+ 
 
CD2- CD3+ CD4+ CD5+ CD6+ 
CD7+ CD8+ CD13- CD19- 
CD34- 
NUP214-ABL1 fusion/ 
expression of NKX2-5 and 
MEF2C 
JURKAT1 flat-moded hypotetraploid karyotype with 7.8% polyploidy - 
87(78-91)<4n>XX, -Y, -Y, -5, -16, -17, -22, 
add(2)(p21)/del(2)(p23)x2 - sideline with additional 
der(5)t(5;10)(q11;p15), del(9)(p11) 
αβ+ γδ- 
 
CD2+ CD3+ CD4+ CD5+ CD6+ 
CD7+ CD8- CD13- CD19- 
 
High TAL1 expression 
KARPAS-451 hypotetraploid karyotype with 8% polyploidy - 87(84-
88)<4n>XX/XXY, -Y, -3, +6, -14, -18, +mar, t(X;11)(q13;q23), 
der(X)t(X;11)(q13;q23), t(1;5)(q21;q12.2)x2, del(4)(q22), 
der(X)t(X;11)(q13;q23)t(11;14)(p13;q11) - sideline with 
αβ- γδ- CD2+ CD3- CD4+ CD5+ 
CD6(+) CD7+ CD8+ CD13- 
CD19- CD34- 
MLL-AFX fusion 
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del(16)(q22)  
TALL-11 flat-moded hypertetraploid karyotype - 90-102<4n>XXY/XXYY, -
3, -9, -12, +13, +14, +14, -15, +20, +20, +21, +21, +2-4mar,  
der(X;1)(p10;p10)/add(1)(q11), add(1)(p11), add(5)(p1?5), 
del(2)(p22p24), del(12)(q24.1), dup(21)(q11qter)x3-4 
αβ+ γδ- 
 
CD2+ CD3+ CD4+ CD5+ CD6+ 
CD7+ CD8+ CD13- CD19- 
CD34- 
 
DND-411 flat-moded near-tetraploid karyotype with 12% polyploidy - 
92(86-98)<4n>XXYY, -9, -15, +20, +mar  
αβ- γδ- 
 
CD2+ CD3+ CD6- CD7+ CD8- 
CD13- CD19- CD34- 
CDKN2B and CDKN2A 
deletions and TP53 mutation 
TLX3 expression 
PF-3821 near-diploid karyotype with 9% near-tetraploid and 15% 
polyploid sidelines - 45/46(43-47)<2n>X/XX, -10, +14 - sideline 
with +add(?15)(p11), add(1)(p32) 
αβ- γδ- 
 
CD2+ CD3- CD4+ CD5+ CD6+ 
CD7+ CD8+ CD13- CD19- 
CD34+ 
 
CUTTL12 hyperdiploid karyotype [50, XY, t(7;9),+16,+18,+20,+21] with a 
characteristic t(7;9)(q34;q34) translocation 
αβ+γδ- CD1a(10%) CD2+ CD3+ CD4+ 
CD5+ CD7+ CD8+ CD34- 
TCRB-NOTCH1 fusion: 
aberrant NOTCH1 signaling 
CCRF-CEM1 near-tetraploid karyotype with extensive subclonal variation - 
90(88-101)<4n>XX, -X, -X, +20, +20, t(8;9)(p11;p24)x2, 
der(9)del(9)(p21-22)del(9)(q11q13-21)x2 - sideline with +5, +21, 
add(13)(q3?3), del(16)(q12) 
αβ+γδ- CD2- CD3+ CD4+ CD5+ CD6+  
CD7+ CD8- CD13- CD14-
CD15+ CD19- CD33- CD34- 
HLA-DR- 
expression of NKX2-5 
1Information taken from the website of DSMZ 
2Palomero et al. CUTLL1, a novel human T-cell lymphoma cell line with t(7;9) rearrangement, aberrant NOTCH1 activation and high sensitivity to gamma-
secretase inhibitors. Leukemia. 2006;20(7): 1279-87 . 
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Supplementary Table 2. Primer sequences used for qRT-PCR. 
Gene Forward primer Reverse primer 
Human and mouse BCL2 5’-CATGTGTGTGGAGAGCGTCAA-3’ 5’-GCCGGTTCAGGTACTCAGTCA-3’ 
Human BCL2L1 5’-TTTGTGGCCTCAGAATTGAT-3’ 5’-TTGCATCTTTATCCCAAGCA-3’ 
Reference genes   
Human HMBS 5’-GGCAATGCGGCTGCAA-3’ 5’-GGGTACCCACGCGAATCAC-3’ 
Human TBP 5’-CACGAACCACGGCACTGATT-3’ 5’-TTTTCTTGCTGCCAGTCTGGAC-3’ 
Human B2M 5’-GCTGTCTCCATGTTTGATGTATCT-3’ 5’-TCTCTGCTCCCCACCTCTAAGT-3’ 
Human RPL13A 5’-CCTGGAGGAGAAGAGGAAAGAGA-3’ 5’-TTGAGGACCTCTGTGTATTTGTCAA-3’ 
Human HPRT1 5’-TGACACTGGCAAAACAATGCA-3’ 5’-GGTCCTTTTCACCAGCAAGCT-3’ 
Human UBC 
Mouse Tbp 
Mouse Ubc 
Mouse Hmbs 
5’-ATTTGGGTCGCGGTTCTTG-3’ 
5’-CCCCACAACTCTTCCATTCT-3’ 
5’-GCAGATCTTTGTGAAGACCC-3’ 
5’-GAATTCAGTGCCATCGTCCT-3’ 
5’-TGCCTTGACATTCTCGATGGT-3’ 
5’-GCAGGAGTGATAGGGGTCAT-3’ 
5’-GAAGGTACGTCTGTCTTCCT-3’ 
5’-AATGCAGCGAAGCAGAGTTT-3’ 
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Supplementary Table 3. Combination index (CI) for combination of ABT-199 with doxorubicine, L-asparaginase or dexamethasone in T-ALL cell lines. 
Combination ABT-199 and doxorubicin           
LOUCY     JURKAT     ALL-SIL    
 CI values at    CI values at   CI values at 
 ED50 ED75 ED90   ED50 ED75 ED90   ED50 ED75 ED90 
Experiment 1 1.11574 
 
0.77131 0.58237  Experiment 1 1.00621 1.00595 1.00982  Experiment 1 0.95642 0.57942 0.4021 
Experiment 1 1.10649 0.73571 0.55409  Experiment 2 1.10958 1.04412 0.98304  Experiment 1 0.58748 0.40951 0.34317 
              
range ABT-199 3.475 - 55.6 nM  range ABT-199 655.5 – 20976 nM  range ABT-199 22.5 – 720 nM 
range doxorubicin 462.1 - 7393.6 nM  range doxorubicin 21.25 – 680 nM  range doxorubicin 21.25 – 680 nM 
Combination ABT-199 and L-asparaginase         
LOUCY     JURKAT     ALL-SIL    
 CI values at    CI values at   CI values at 
 ED50 ED75 ED90   ED50 ED75 ED90   ED50 ED75 ED90 
Experiment 1 0.69755 0.41294 0.25066  Experiment 1 0.66792 0.57169 0.55323  Experiment 1 0.3086 0.14291 0.0673 
Experiment 1 0.55506 0.39018 0.28453  Experiment 2 0.65231 0.63455 0.68977  Experiment 1 0.37071 0.12689 0.05161 
              
range ABT-199 1.75 – 56 nM  range ABT-199 655.5 – 20976 nM  range ABT-199 22.5 -720 nM 
range L-asparaginase 0.0875 – 2.8 U/l  L-asparaginase 7.5 – 240 U/l  range L-asparaginase 0.7 – 22.4 U/l 
Combination ABT-199 and doxorubicin           
LOUCY              
 CI values at        
 ED50 ED75 ED90           
Experiment 1 0.4284 0.1511 0.06867           
Experiment 1 0.49285 0.40344 0.33497           
              
range ABT-199 1.75 – 56nM       
range dexamethasone 15 - 480 µM       
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Abstract 
Inhibition of anti-apoptotic BCL-2 (B-cell lymphoma 2) has recently emerged as a promising 
new therapeutic strategy for the treatment of a variety of human cancers, including leukemia. 
Here, we used T-cell acute lymphoblastic leukemia (T-ALL) as a model system to identify 
novel synergistic drug combinations with the BH3 mimetic venetoclax (ABT-199). In vitro 
drug screening in primary leukemia specimens that were derived from patients with high risk 
of relapse or relapse and cell lines revealed synergistic activity between venetoclax and the 
BET (bromodomain and extraterminal) bromodomain inhibitor JQ1. Notably, this drug 
synergism was confirmed in vivo using T-ALL cell line and patient-derived xenograft models. 
Moreover, the therapeutic benefit of this drug combination might, at least in part, be mediated 
by an acute induction of the pro-apoptotic factor BCL2L11 and concomitant reduction of 
BCL-2 upon BET bromodomain inhibition, ultimately resulting in an enhanced binding of BIM 
(encoded by BCL2L11) to BCL-2. Altogether, our work provides a rationale to develop a new 
type of targeted combination therapy for selected subgroups of high-risk leukemia patients. 
 
Introduction 
T-cell acute lymphoblastic leukemia (T-ALL) arises from the malignant transformation of T-
cell progenitors and accounts for about 15% of childhood and 25% of adult ALL cases1. The 
cure rate for childhood T-ALL has steadily increased over the past decades, with current 
survival rates reaching ∼ 85%2,3. Although these numbers are high, the clinical perspective 
for children who fail induction therapy or suffer from relapsed disease remains extremely 
poor, with only a 7–23% subset of relapsed T-ALL patients surviving beyond 3 to 5 years 
after the initial diagnosis4. Compared with childhood leukemia, the clinical picture for adult T-
ALL is even worse, with high relapse rates and long-term disease-free survival of ∼ 40%5–7. 
Altogether, these figures suggest that better and less toxic treatment strategies are urgently 
required to further improve the clinical management of childhood and adult T-ALL patients.  
Recently, we and other research groups reported promising therapeutic activity for 
venetoclax (ABT-199), a highly specific inhibitor of the anti-apoptotic protein BCL-2 (B-cell 
lymphoma 2), in immature subtypes of human T-ALL8–10. Nevertheless, venetoclax sensitivity 
is variable between different T-ALL patient samples and the emergence of resistance to 
venetoclax11–13 as well as the occurrence of dose-limiting toxicities14 provides a rationale for 
the evaluation of venetoclax as part of a combination therapy. Indeed, previous studies have 
shown that venetoclax can synergize with conventional chemotherapeutic agents in human 
T-ALL, including doxorubicin, L-asparaginase, dexamethasone and cytarabine8,9. Venetoclax 
has recently also been approved by the FDA (Food and Drug Administration) for the 
treatment of chronic lymphocytic leukemia. Indeed, clinical trials demonstrated progress-free 
survival in more than two-thirds of relapsed chronic lymphocytic leukemia patients14, 
including poor prognostic chronic lymphocytic leukemia patients who carry a 17p deletion15. 
Nevertheless, complete remission remained uncommon14, further reinforcing the need for the 
evaluation of combined therapeutic strategies.  
Bromodomains of the bromodomain and extraterminal (BET) protein family recognize ε-N-
acetylation of lysine residues on histone tails. BRD4 is an important BET protein that recruits 
the positive transcription elongation factor complex (P-TEFb) to acetylated chromatin16. The 
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transcriptional coactivators BRD4 and Mediator co-occupy enhancers and promoters of 
active genes and are enriched at large stretches of enhancer sequences, often termed 
super-enhancers17–19. Notably, these enhancers regulate the expression of critical 
oncogenes in a variety of human cancers, providing a rationale for the use of BET 
bromodomain inhibitors, such as JQ1, as powerful anticancer agents17–19. In addition, in T-
ALL, BET bromodomain inhibitors have shown therapeutic efficacy in a number of in vitro 
and in vivo model systems and were shown to inhibit the expression of the T-ALL oncogene 
MYC20–22. Furthermore, super-enhancers have been identified in a panel of T-ALL cell lines 
near putative oncogenes, including MYB, TAL1, CDK6 and NOTCH118.  
In this study, we identified synergistic drug combinations with the BH3 mimetic venetoclax in 
the context of human T-ALL. Most notably, we show that combined targeting of BCL-2 and 
BET bromodomain proteins synergistically affects leukemic tumor growth in T-ALLs that were 
resistant to conventional chemotherapeutic agents. 
 
Materials and methods 
Primary patient samples  
Primary human ALL cells were recovered from cryopreserved bone marrow aspirates of 
patients enrolled in the ALL-BFM 2000, 2009 and ALL-REZ-BFM 2002 study. Informed 
consent was given in accordance with the Declaration of Helsinki and the ethics commission 
of the Kanton Zurich (approval number 2014-0383). Samples were classified as standard 
risk, medium risk, high risk, very high risk or relapse samples according to the clinical criteria 
used in ALL-BFM 200023. 
Drug-screening platform  
The in vitro drug response of T-ALL primary patient samples was assessed in co-culture with 
hTERT-immortalized primary bone marrow mesenchymal stromal cells as described 
previously.23 Details are provided in the Supplementary Data.  
Cell lines   
Cell lines were purchased from the DSMZ repository (Braunschweig, Germany), except for 
CUTLL1 (gift from Professor Adolfo Ferrando, Columbia University, New York, NY, USA) and 
KOPTK1 (gift from Professor Hans-Guido Wendel, Memorial Sloan Kettering Cancer Center, 
New York, NY, USA). Cells were cultured in RPMI-1640 medium (52400-025; Life 
Technologies, Carlsbad, CA, USA) supplemented with 10 or 20% fetal bovine serum, 100 
U/ml penicillin, 100 μg/ml streptomycin (15140-148; Life Technologies), 100 μg/ml kanamycin 
sulfate (15160-047; Life Technologies) and 2 mM L-glutamine (25030024; Life Technologies) 
at 37 °C with 5% CO2.  
In vitro evaluation of synergism between venetoclax and JQ1 in human T-ALL cell 
lines and primary samples  
The 48h treatment of the cell lines with venetoclax (2253-1; BioVision, Milpitas, CA, USA) 
and/or (+)-JQ1 (27401; BPS Bioscience, San Diego, CA, USA) and viability measurements 
via the CellTiter Glo Viability assay (Promega, Madison, WI, USA) were done as described in 
Peirs et al.8 CalcuSyn software (Biosoft, Cambridge, UK) was used to calculate the 
combination index (CI) with the Chou–Talalay method. The reported CI is the average of the 
values obtained at the effective dose (ED) points ED50, ED75 and ED90. Primary patient 
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samples co-titration experiments were performed for selected drugs. T-ALL cell plates were 
prepared and handled in the same manner as for drug combination screening described 
above. Selected drugs in combination with venetoclax were dispensed using Tecan D300 
digital dispenser (Tecan Group, Männedorf, Switzerland) in a concentration matrix. The 
concentration range tested for venetoclax and JQ1 were determined for each patient based 
on initial drug response screening. CI was calculated using Chou–Talalay method as 
implemented in R package (https://github.com/xtmgah/DDCV). 
Western blot  
Western blot analysis was performed as previously described8. The primary antibodies used 
were Bcl-2 antibody (C-2) (1:500, sc-7382; Santa Cruz Biotechnology, Dallas, TX, USA), 
PARP-1 antibody (F-2) (1:1000, sc-8007; Santa Cruz Biotechnology), BIM antibody (1:1000, 
AB17003; EMD Millipore, Darmstadt, Germany), β-actin antibody (1:10 000, Clone AC-75, 
A2228; Sigma-Aldrich, St Louis, MO, USA) and α-tubulin antibody (1:10 000, T5168; Sigma-
Aldrich). The detection of the blots was done with ChemiDoc-It Imaging System (UVP, 
Upland, CA, USA). Densitometric analysis of the protein bands was performed using ImageJ 
(NIH, Bethesda, MD, USA). Images have been cropped for presentation. 
Annexin V/propidium iodide (PI) staining  
FITC Annexin V Apoptosis Detection Kit I (556547; BD Biosciences, San Jose, CA, USA) 
was used and samples were measured on the S3 cell sorter (Bio-Rad, Hercules, CA, USA).  
Mice experiments  
Female nonobese diabetic/severe combined immunodeficient γ (NSG) mice were injected in 
the tail vein with 150 μl phosphate-buffered saline containing 5 × 106 luciferase-positive 
LOUCY cells8, 5×106 ALL-SIL cells or 1 × 106 cells from a secondary xenograft of patient T-
VHR-26. Engraftment of the cells was followed by bioluminescence imaging as previously 
described8 or by measuring the percentage of leukemic cells in the blood. Once there was 
clear engraftment (day 0), mice were randomly divided into four groups (control, venetoclax, 
JQ1 and combination) and treatment was started. Mice received daily 50 mg venetoclax per 
kg body weight via oral gavage and/or 50 mg JQ1 per kg body weight via intraperitoneal 
injection. Venetoclax (Axon Medchem, Groningen, The Netherlands) was formulated in 60% 
phosal 50 propylene glycol, 30% polyethylene glycol 400 and 10% ethanol. (+)-JQ1 
(MedChem Express, South Brunswick Township, NJ, USA) was formulated in 10% dimethyl 
sulfoxide and 90% of a 10% 2-hydroxypropyl-β-cyclodextrin solution. At the end of the 
treatment period, blood was taken and mice were killed. The percentage of leukemic cells 
was analyzed by staining the cells with phycoerythrin-labeled antibody for human CD45 
(hCD45; 130-098-141; Miltenyi Biotec, Bergisch Gladbach, Germany), performing red blood 
cell lysis and measuring the percentage on a LSRII flow cytometer using FACSDiva software 
(BD Bioscience). The ethical committees on animal welfare at Ghent University Hospital and 
University Children’s Hospital Zurich approved all animal experiments. 
Gene expression profiling and GSEA  
LOUCY cells were treated with dimethyl sulfoxide or (+)-JQ1. Three biological replicates of 
this treatment were performed and RNA was isolated using the miRNeasy mini kit (Qiagen, 
Venlo, The Netherlands) with on-column DNase digestion. RNA quality was evaluated by the 
Experion RNA StdSens analysis kit (Bio-Rad). RNA was amplified and labeled using the Low 
Input Quick Amp Labeling Kit, One Color (5190-2305; Agilent Technologies, Santa Clara, 
CA, USA) and hybridized with the Gene Expression Hybridization Kit (5188-5242; Agilent 
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Technologies) to the SurePrint G3 Human Gene Expression Microarray G4851A (design ID 
028004, Agilent Technologies). Normalization of microarray intensities was done using the 
variance stabilization and calibration (VSN, Bioconductor release 3.30.0) package in R 
software (version 3.0.2)24. Only probes with a signal 10% higher than the negative control 
probes were considered for analysis. Differential expression analysis was performed using 
the limma package (Bioconductor release 3.18.13) with P-value adjustment using the 
Benjamini and Hochberg method. The design matrix took into account the pairing information 
of the data. Enrichment analysis was performed with the Molecular Signatures database 
(MSigDB) c2 gene sets collection using the GSEA (Gene Set Enrichment Analysis) desktop 
application (version 2.2.0, Broad Institute, Cambridge, MA, USA)) run with the default 
parameters and with gene set permutations. The data have been deposited in NCBI Gene 
Expression Omnibus (GEO)25 and are accessible through GEO Series accession number 
GSE81918. 
qRT-PCR  
The miRNeasy mini kit (Qiagen) and the RNase-Free DNase set (Qiagen) were used to 
isolate RNA. For determination of mRNA levels, complementary DNA (cDNA) synthesis was 
performed with the iScript Advanced cDNA synthesis kit (Bio-Rad). The SsoAdvanced 
Universal SYBR Green Supermix (Bio-Rad) was used for the PCR reactions. Every sample 
was analyzed in duplicate and the gene expression was normalized against three 
housekeeping genes. For quantification of mature microRNAs, the miScript II RT kit (Qiagen) 
and target-specific miScript Primer Assays (Qiagen) together with the miScript SYBR Green 
PCR Kit were used. All real-time quantitative PCR reactions were run on the LightCycler 480 
(Roche, Vilvoorde, Belgium) and qBasePLUS software (Biogazelle, Zwijnaarde, Belgium) 
was used for analysis. Primer sequences and miScript Primer Assays are listed 
Supplementary Table 5. 
Co-immunoprecipitation 
Protein lysates were incubated with 2 μg of antibody. After 4 h of rotation at 4 °C, 20 μl of 
Protein A UltraLink Resin (53139; Thermo Scientific, Waltham, MA, USA) was added for 
overnight incubation at 4 °C. Beads were washed 3 times with RIPA buffer and 
immunoprecipitates were eluted by heating the beads at 95 °C in 2 × SDS loading buffer (62 
mM Tris-HCl (pH 6.8), 4% SDS, 20% glycerol, 0.01% BFB (bromophenol blue) and 2.5% β-
mercaptoethanol) for 10 min. A part of the original lysates were similarly denaturated by 
heating at 95 °C for 10 min after adding 5 × SDS loading buffer (155 mM Tris-HCl (pH 6.8), 
5% SDS, 32% glycerol, 0.025% BFB and 2.5% β-mercaptoethanol). 
Modulation of BIM expression  
The pENTR223-BCL2L11 (LMBP ORF81079-A09) plasmid was available from the 
BCCM/LMBP Plasmid Collection26 and was used to clone BCL2L11 in the pInducer21 
plasmid27. The MISSION lentiviral shBCL2L11 TRCN0000001051 (Sigma-Aldrich) vector 
(BCCM/LMBP Collection26), in which the puromycin resistance cassette was replaced by 
eGFP (enhanced green fluorescent protein), was used to perform BIM knockdown. As 
nontargeting small hairpin RNA control, MISSION pLKO.1-puro Non-Mammalian small 
hairpin RNA Control Plasmid (SHC002), in which puro was also replaced by eGFP, was 
used. Virus production was performed in HEK293TN cells using JetPEI polyplus with 
pMD2.G (envelope plasmid), psPAX2 (packaging plasmid) and target plasmid in 0.1:0.9:1 
ratios. Transduced KARPAS-45 cells expressing GFP (green fluorescent protein) were 
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selected by cell sorting. BCL2L11 expression was induced by adding doxycyclin (1 μg/ml) 
and sensitivity to venetoclax was evaluated by adding venetoclax together with or without 
doxycycline for 48 h to the cells. To evaluate the effect of BIM knockdown, cells were treated 
with venetoclax, JQ1 or the combination for 48 h. Viability was evaluated with CellTiter Glo 
as described above. 
Statistics 
GraphPad Prism 5.04 (La Jolla, CA, USA) was used for statistical analyses. 
 
Results 
Identification of synergistic drug combinations with venetoclax in primary human T-
ALL 
Previous studies have shown promising antitumor activity for venetoclax in the context of 
human T-ALL8–10. However, drug responses have been variable across patients both in vitro 
and in xenografts, suggesting the need for predictive biomarkers and further investigation 
toward synergistic drug combinations with venetoclax. Given this, we took advantage of a 
drug-profiling platform28,29 (Figure 1a) to test 21 clinically relevant compounds 
(Supplementary Table 1) for their ability to synergize with venetoclax in six primary human T-
ALLs, including five diagnostic and one relapse specimen. Notably, the selected patient 
samples represented different molecular genetic subtypes of human T-ALL and displayed a 
variety of tumor immunophenotypes. In addition, they displayed variable levels of BCL-2 and 
BIM protein expression (Supplementary Figure 1a) and most of these high-risk T-ALL patient 
samples experienced significant levels of minimal residual disease upon first-line therapy 
(Supplementary Table 2). 
 
First, we generated venetoclax response curves for each T-ALL sample and selected a 
sublethal dose of venetoclax for screening purposes (Figure 1a). Two T-ALL samples were 
sensitive at concentrations below 100 nM, whereas the remaining cases were more resistant 
to venetoclax (Supplementary Figure 1b). This variability in venetoclax sensitivity amongst T-
ALL patient samples corresponded to large differences in the area under the curve, a 
parameter that captures both IC50 (half-maximal inhibitory concentration) and Emax (maximal 
efficacy) as relevant end points of drug activity (Figure 1b). Next, we generated dose 
response curves (1 nM, 10 nM, 100 nM, 1 μM and 10 μM) for the 21 compounds in the 
presence or absence of a sublethal dose of venetoclax (Figure 1a). The results of this initial 
screening are visualized by scatterplots of area under the curve values, in which decreased 
area under the curve upon addition of venetoclax is indicative of increased antileukemic 
activity (Figure 1b and Supplementary Figure 2). In line with previous studies, the 
combination of venetoclax with conventional chemotherapeutic agents including vincristine, 
dexamethasone and etoposide increased therapeutic efficacy in some of the T-ALL cases 
analyzed (Figure 1b). The strongest effects, however, were observed for the combination of 
venetoclax with JQ1 that resulted in reduced leukemic tumor growth in 5 out of 6 primary T-
ALL patient samples (Figure 1b). As a confirmation, we validated responsive (Figure 1c) as 
well as nonresponsive (Supplementary Figure 3) drug interactions identified in this initial 
screen. Altogether, this screening effort identified clinically relevant drugs that could increase 
the therapeutic efficacy of venetoclax in the context of T-ALL. 
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Figure 1. Drug-screening platform to identify novel synergistic combinations of venetoclax and other 
drugs. (a) In a panel of primary T-ALL samples the effect of venetoclax treatment on cell viability was measured 
by flow cytometry using 7-aminoactinomycin D (7-AAD) 72 h after venetoclax treatment. Six representative 
samples (blue curves: sensitive to venetoclax; red curves: more resistant to venetoclax) were selected. For each 
sample, an optimal sublethal dose of venetoclax was calculated based on area under the curve (AUC) 
calculations of venetoclax as single agent. A single venetoclax dose was combined with selected clinically 
relevant compounds and the response change was compared with the control plate. Promising single compound 
combinations were validated in co-titration experiments. (bi) Scatterplots representing response of T-ALL samples 
(N=6) to venetoclax alone, shown as AUC. (bii) Responses of T-ALL patient samples to combination of a 
sublethal venetoclax dose and indicated chemotherapeutic agents. AUC values of dose response curves from 
individual drug treatments (circles) or combined with venetoclax (triangles) are shown. (c) Representative 
examples of co-titration assays for compounds found to synergize with venetoclax in preselected T-ALL samples 
from initial combination screening: topoisomerase I inhibitor topotecan (left), dual PI3K and mTOR inhibitor 
dactolosib (middle) and BRD4 inhibitor JQ1 (right). 
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Combined targeting of BCL-2 and BET bromodomain proteins in human T-ALL  
Given that our initial screen pointed toward increased efficacy of venetoclax upon BET 
bromodomain inhibition in a significant proportion of T-ALLs, we subsequently analyzed the 
synergistic potential of this drug combination in more detail by performing co-titration 
experiments with individually optimized concentration ranges in primary leukemias and a 
panel of human T-ALL cell lines. 
 
First, we determined the CIs for the six primary T-ALLs that were also used for the initial 
screening and identified synergistic activities (CI<1) between venetoclax and JQ1 in five out 
of six cases analyzed (Figure 2a). Notably, similar results were obtained using OTX015 (MK-
8628), another BET bromodomain inhibitor currently being tested in clinical trials for various 
tumor entities30,31 (Supplementary Figure 4).  
 
Next, we determined dose response curves in a panel of 13 human T-ALL cell lines with 
different BCL-2 levels and varying sensitivities toward venetoclax (Figure 2b and 
Supplementary Figure 5). Notably, T-ALL cell lines displayed variable levels of synergism 
with the lowest CI values (strongest synergism) detected for tumor lines with high BCL-2 
expression (Figure 2b). Indeed, the CI showed a negative correlation with BCL-2 protein 
levels in T-ALL cell lines (Figure 2c). Moreover, synergistic activity of this drug combination 
corresponded to increased cell death induction in T-ALL cell lines with low CI values 
(Supplementary Figure 6). 
 
Evaluation of the venetoclax and JQ1 combination therapy in xenograft models   
To evaluate the therapeutic potential of combined BCL-2 and BET bromodomain inhibition in 
human T-ALL, we subsequently performed in vivo drug treatment experiments using 
xenograft models. At 4 weeks after injection of luciferase-positive LOUCY cells8 in 
immunodeficient mice, successful engraftment was confirmed by bioluminescence imaging 
and daily drug treatment was initiated (days 1–13). Leukemia still progressed under JQ1 
monotherapy (n = 5), although to a lesser extent as compared with vehicle-treated control 
mice (n = 8; Figure 3a and Supplementary Figure 7). Mice treated for 13 days with 
venetoclax alone (n=5) initially showed disease regression, but this therapeutic response 
was not durable (Figure 3a and Supplementary Figure 7). In contrast, combination of 
venetoclax with JQ1 (n = 5) resulted in durable disease regression (Figures 3a and b). In line 
with these results, analysis of the percentage of human leukemic cells in peripheral blood 
and bone marrow as well as examination of the spleen size confirmed the superior 
therapeutic effect of this combination treatment (Figure 3c and d and Supplementary Figure 
8). Of note, mice receiving JQ1 alone or in combination with venetoclax displayed significant 
weight loss (Supplementary Figure 8), a putative side effect of BET bromodomain inhibition. 
The synergistic effect of combined BCL-2 and BET bromodomain inhibition was also 
confirmed in the TLX1-positive T-ALL cell line ALL-SIL (Supplementary Figure 9). The 
genetic characteristics of LOUCY and ALL-SIL are summarized in Supplementary Table 3. 
 
Finally, we performed a similar in vivo drug treatment experiment using a primary patient-
derived xenograft. For this, leukemic cells from the very high risk T-ALL patient (T-VHR-26) 
were engrafted and treated with a similar drug regimen as mentioned above. Notably, this 
experiment confirmed the superior therapeutic effect of combined BCL-2 and BET 
bromodomain inhibition for the treatment of this high risk T-ALL patient sample (Figure 4 and 
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Supplementary Figure 10). Of note, in this experiment, no significant weight loss was 
observed in any of the treatment groups (Supplementary Figure 10c). 
 
 
Figure 2. In vitro synergism between venetoclax and JQ1 in primary patient samples and T-ALL cell lines. 
(a) Dose response curves are given for co-titration assays in primary T-ALL samples treated for 72h with 
increasing concentrations of both venetoclax and the BRD4 inhibitor JQ1. CIs indicate synergism for five of the six 
cases, and additive activity for the remaining sample. (b) Overview of CIs between venetoclax and JQ1 in a panel 
of human T-ALL cell lines treated for 48h with indication of the degree of synergism. Mean and s.d. of at least 
three independent experiments per cell line are represented. Western blot (bottom panel) indicates the BCL-2 
protein levels in this cell line panel with β-actin as loading control. (c) Scatterplot demonstrating the correlation 
between BCL-2 protein level and CI in the T-ALL cell lines. 
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Figure 3. Combination treatment of mice xenografted with luciferase-positive human LOUCY cells. (a) 
Leukemic burden was followed during the experiment on the basis of the luminescence of the leukemia cells. For 
each treatment group, one mouse is represented from day 0 (that is, the day before the treatment started) till day 
14 (that is, the end of the experiment). The graph shows the average and s.d. of the total flux of luminescence for 
all the mice in the group relative to the signal on day 0. (b) Total flux of each mouse within a treatment group on 
day 14 relative to day 0. (c) Percentage of hCD45+ leukemic cells in the peripheral blood for each mouse. All 
viable cells after red blood cell lysis were selected based on the forward and side scatter parameters. One sample 
from the control group could not be analyzed correctly. (d) Percentage of hCD45+ leukemic cells in the bone 
marrow for each mouse. All the viable cells after red blood cell lysis were selected based on the forward and side 
scatter parameters. The one-tailed Mann–Whitney test was used to compare the treatment groups statistically. 
NS, not significant, *P<0.05, **P<0.01, ***P<0.001. Horizontal lines on the graph indicate the median for each 
group. 
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Figure 4. Combination treatment of patient (T-VHR-26)-derived xenograft. (a) Percentage of hCD45+ 
leukemic cells in the peripheral blood for each mouse after 14 days of treatment. (b) Percentage of hCD45+ 
leukemic cells in the bone marrow for each mouse after 14 days of treatment. (c) Percentage of hCD45+ leukemic 
cells in the liver for each mouse after 14 days of treatment. The one-tailed Mann–Whitney test was used to 
compare the treatment groups statistically. NS, not significant, *P<0.05. Horizontal lines on the graph indicate the 
median for each group. 
 
Mechanistic insights into the synergistic activities of venetoclax and JQ1 in human T-
ALL 
To understand how BET bromodomain inhibition might synergize with the BCL-2 inhibitor 
venetoclax, we subsequently analyzed the transcriptional consequences of JQ1 treatment in 
the T-ALL cell line LOUCY by microarray analysis. Short-term exposure to a low dose of JQ1 
(4 h, 250 nM) provided insights into the genes whose expression was immediately affected 
by BET bromodomain inhibition (Figure 5a, left). In contrast, sustained exposure at a higher 
concentration (48 h, 1 μM) revealed broader transcriptional effects with more than half of the 
expressed probe sets showing significant up- or downregulation (adjusted P-value<0.05; 
Figure 5a, right). Significantly downregulated genes upon shortterm drug treatment included 
stem-cell associated genes and putative oncogenes such as BAALC, WT1, MN1 
(meningioma 1), MEF2C, LMO1 and LMO2, whereas other oncogenic factors, including 
BCL2, IGFBP7 (insulin like growth factor binding protein 7), ZEB2, GFI1B, MYB and LYL1, 
only changed significantly after 48 h. 
 
In line with previous reports17–19, these JQ1-responsive genes were regulated by strong and 
active enhancer elements characterized by broad binding of the H3K27ac histone mark in 
LOUCY cells32 (Figure 5b). Indeed, genes associated with the 500 highest ranked enhancer 
regions in LOUCY were significantly enriched in genes downregulated after JQ1 treatment 
(Figure 5c). Moreover, enrichment analysis using gene sets from the MSigDB revealed that 
genes upregulated after JQ1 in LOUCY cells significantly overlapped with genes activated 
upon histone deacetylase (HDAC) inhibition (Figure 5d). In line with this notion, the LINCS 
(Library of Integrated Cellular Signatures) revealed a strong connection between the JQ1-
induced expression signature in LOUCY and gene signatures induced by HDAC inhibitors 
(Supplementary Table 4). 
 
Given that binding of the pro-apoptotic BIM (encoded by BCL2L11) to the BH3 domain of 
BCL-2 is an important mediator of venetoclax activity33–36, we subsequently focused on the 
transcriptional effects of JQ1 on the expression of both factors. Notably, in LOUCY cells, 
BCL2L11 expression was induced after short-term JQ1 exposure (Figure 5a, left), whereas 
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downregulation of BCL2 expression was only detected at later time points (Figure 5a, right). 
In addition, the expression of the miR17-92 cluster, a known negative regulator of BIM37, was 
not affected after 4 h of JQ1 treatment but was clearly downregulated after 48 h 
(Supplementary Figure 11a). Upregulation of pro-apoptotic BCL2L11 and concomitant 
downregulation of anti-apoptotic BCL2 could be confirmed in all T-ALL cell lines that 
displayed strong synergy (CI<0.5) for the ABT199/JQ1 drug combination. As a result, BET 
bromodomain inhibition triggered an increased BIM to BCL-2 ratio (Figure 6a and 
Supplementary Figure 11b), providing a putative explanation for the improved therapeutic 
efficacy of venetoclax upon JQ1 treatment. Indeed, co-immunoprecipitation experiments 
demonstrated an increased BIM to BCL-2 binding (Figure 6b) upon JQ1 treatment. Finally, 
doxycycline-inducible overexpression of BIM in the KARPAS-45 cell line mimicked the effect 
of JQ1 and resulted in an increased sensitivity toward venetoclax (Figure 6c), whereas 
knockdown of BIM lowered the sensitivity to ABT-199, JQ1 and combination treatment 
(Figure 6d). 
 
Discussion 
Venetoclax is a promising new molecular therapy that is currently being evaluated in clinical 
trials for different hematological malignancies14,15,38. However, the limited number of complete 
remissions14 and the emergence of resistance with venetoclax as single agent prompts for a 
systematic evaluation of combinations with rationally designed small molecules to assess its 
true therapeutic potential. Indeed, synergistic cytotoxic effects have been described for the 
combination of venetoclax with Bruton tyrosine kinase (BTK)39–41, galectin42, aurora kinase 
A43, cyclin-dependent kinase44,45 and PI3K/AKT/mTOR (phosphatidylinositol-3-
kinase/AKT/mammalian target of rapamycin) inhibition13,46. 
 
Given the promising single-agent activity of venetoclax in human T-ALL subsets8–10, we 
systematically evaluated clinically relevant drugs in order to identify synergistic combinations 
with venetoclax. The strongest and most consistent effect was detected for the combination 
with the bromodomain inhibitors JQ1 and OTX015, both targeting critical mechanisms that 
are deregulated in cancer cells. This effect could be validated in vivo using leukemia 
xenograft models. Notably, this concept has recently been suggested as an experimental 
therapy for double-hit lymphoma, triple-hit lymphoma and mantle cell lymphoma in which 
both MYC and BCL2 are deregulated47–49. Interestingly, our preclinical data indicate that 
relevant activity can be obtained with this combination of agents irrespective of their activity 
as single agent that may possibly broaden the cohort of eligible cancer types (or subsets) for 
clinical translation. However, the challenge will be to identify useful biomarkers to better 
define patients who may benefit from such experimental combinations. Interestingly, an 
increase of BCL-2 protein levels in human T-ALL cell lines correlated with synergism 
between venetoclax and JQ1. Nevertheless, the value of additional methodologies such as 
BH3-profiling50 should also be taken into consideration in future studies of this therapeutic 
rationale. 
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Figure 5. Transcriptional effects of JQ1 on LOUCY. (a) Volcano plots displaying the differentially expressed 
genes in LOUCY after 4 h of treatment with 250 nM JQ1 (left) and 48 h of treatment with 1 μM JQ1 (right). In case 
multiple probes for one gene were present on the array, the differentially expressed probe with largest fold 
change was plotted. (b) Hockey-stick plot showing the ranked H3K27Ac-seq signal of all enhancers in LOUCY. 
Super-enhancers are indicated with blue dots. The red dots are examples of enhancers associated with 
interesting downregulated genes upon JQ1 treatment. (c) GSEA showing a significant enrichment of the genes 
associated with the top 500 superenhancers in LOUCY among the downregulated genes after treatment with 250 
nM JQ1 for 4 h (top) or 1 μM JQ1 for 48 h (bottom). The nearest transcriptionally active gene (TSS) to each 
super-enhancer was determined via Peak Analyzer (OriginLab, Northampton, MA, USA). This list of super-
enhancerassociated genes was then used as a gene set for GSEA. (d) GSEA showing a significant enrichment of 
gene sets containing upregulated genes after HDAC inhibition among the upregulated genes after treatment of 
LOUCY with 250 nM JQ1 for 4 h. (d, left) DALESSIO_TSA_RESPONSE, that is, top genes upregulated in 
HEK293 cells in response to trichostatin A (TSA). (d, right) PEART_HDAC_PROLIFERATION_CLUSTER_UP, 
that is, cell proliferation genes upregulated by HDAC inhibitors SAHA and depsipeptide. 
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Figure 6. Molecular insights into the mechanism of synergism. (a) Western blot showing the increase of the 
BIM/BCL-2 protein ratio in synergistic T-ALL cell lines upon treatment with 1 μM JQ1 for 48 h. Only the upper 
band of BIM was quantified. (b) Immunoprecipitation with anti-BIM antibody illustrates the increased binding of 
BIM to BCL-2 after JQ1 treatment. (c) Induction of BIM expression in KARPAS-45 pInducer21-BCL2L11 cells 
increases the sensitivity to venetoclax. The average and s.d. from three independent experiments is plotted. 
Western blot shows BIM induction for three independent replicates. The doublet seen for BIMEL (largest isoform) 
may represent phosphorylation. (d) Knockdown of BIM in KARPAS-45 affects sensitivity to venetoclax, JQ1 and 
combination treatment. The average and s.d. from two independent experiments is plotted. Western blot shows 
knockdown of BIM in the cells. 
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The importance of BRD4 in processes that lead to abnormal activation of cancer driving 
genetic programs is increasingly being understood17–19. The proof of concept in T-ALL was 
provided by studies of BET bromodomain inhibitors with a focus on MYC inhibition20–22. Given 
the central importance of super-enhancer deregulation in cancer18,19, a similar principle may 
apply to many different transcriptional programs in leukemia cells. However, the broad 
transcriptional effects of these inhibitors on T-ALL cells remain largely unexplored. Gene 
expression profiling of LOUCY cells treated with JQ1 confirmed that BET bromodomain 
inhibition results in reduced expression of super-enhancer-associated oncogenes as 
previously described by Lovén et al.17. Similar effects have also previously been reported for 
the T-ALL cell line ALL-SIL51. Although there is some overlap between superenhancers in 
different T-ALL cell lines18,51, each cell line seems to have a pretty unique spectrum of super-
enhancer sequences. However, we also observed acute gene activation within 4 h of JQ1 
treatment. In the gene signature that was activated upon JQ1 treatment in LOUCY cells, 
HDAC inhibitor-associated gene sets were enriched. This is in accordance with Bhadury et 
al.52 who describe a large overlap between genes induced by BET and HDAC inhibitors. 
 
BCL2L11 (encoding BIM) is one of the genes that showed such an acute induction of gene 
expression upon JQ1 treatment in the context of T-ALL. BIM is an activator BH3-only pro-
apoptotic protein that can directly interact with BAX and/or BAK to induce apoptosis. BCL-2 
can prevent apoptosis by sequestering pro-apoptotic proteins such as BIM53. Studies 
demonstrated the requirement for BCL-2 complexed to the pro-apoptotic activator BIM in 
order to sensitize lymphoid cells to BCL-2 inhibition by venetoclax or ABT-73733–36. In our 
study, BET bromodomain inhibition increased BIM to BCL-2 binding, and could provide a 
putative explanation for the observed synergism between venetoclax and JQ1/OTX015 in the 
context of human T-ALL. Importantly, upregulation of pro-apoptotic BIM upon JQ1 treatment 
has also been described in a variety of other tumor entities47,54–56, suggesting that the 
synergistic activity between these molecules might not be restricted to human T-ALL. Xu et 
al.57 attributed the upregulation of BCL2L11 in response to JQ1 to the downregulation of the 
miR17-92 cluster. We also observed a downregulation of the miR17-92 cluster but not yet 
after 4 h of JQ1 treatment, a time point with already significant upregulation of BCL2L11 in 
LOUCY. Therefore, this mechanism does not explain the acute upregulation of BCL2L11 but 
this could definitely contribute to sustain the upregulation of BCL2L11. 
 
In summary, our study provides a rationale to select patients with treatment-resistant T-ALL 
for an innovative combination treatment based on mechanisms that are not exploited by 
conventional chemotherapy regimens. Interference with the balance between pro- and anti-
apoptotic proteins in BCL2-dependent T-ALL using the combination BET bromodomain 
inhibition and the BCL-2 inhibitor venetoclax should be considered in future clinical trials for 
this indication. 
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Supplementary Figures 
 
 
Supplementary Figure 1. BCL-2 and BIM protein levels and venetoclax dose response curves for the 6 
primary T-ALL patient samples. (A) Western blot with BCL-2 and BIM levels in panel of T-ALL patients. Protein 
samples were obtained from primary, secondary or tertiary mice xenografts. (B) In vitro response of six T-ALL 
samples to the BCL-2 inhibitor venetoclax in co-culture with mesenchymal stromal cells (MSC) and used for 
combination screening. Cell viability was measured by flow cytometry using 7-AAD after 72h of treatment and 
normalized to DMSO-treated controls. Sensitive and resistant cases were defined by a mixture model fit of the 
distribution of IC50 (log[nM]) measured after 72h. 
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Supplementary Figure 2. Effect of adding venetoclax on area under the curve (AUC) for 21 compounds in 
6 primary T-ALL patient samples.Plot showing the AUC for 21 compounds in 6 primary T-ALL samples without 
and with the addition of a sub-lethal dose of venetoclax. Indicated are the AUC values for dose response curves 
with (triangles) or without (circles) venetoclax. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 3: Results 
116 
  
 
Supplementary Figure 3. Validation of some of the non-responsive drug interactions identified in the 
initial screen. Representative examples of co-titration assays for compounds detected to not synergize with 
venetoclax in preselected T-ALL samples from initial combination screening.  
 
 
 
Supplementary Figure 4. Synergistic activity of venetoclax with BRD4 inhibitors OTX-015 and JQ1. (A) 
Titration assay of venetoclax with OTX-015 or JQ1 for 2 primary T-ALL samples. (B) Combination index 
determined by Chou-Talalay method. 
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Supplementary Figure 5. Cell viability curves and combination indexes (CI) for T-ALL cell lines treated with venetoclax and/or JQ1. The effect of venetoclax and JQ1 
monotherapy and combination therapy on the viability of T-ALL cell lines is visualized. Cell viability is expressed relative to cells treated with dimethylsulfoxide (DMSO) and the 
average and standard deviation of at least 3 independent experiments is plotted for each cell line.  
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Supplementary Figure 6 Induction of cell death in human T-ALL cell lines. (A) Induction of cell death 
represented by Western blot of PARP-1. Treatment with venetoclax, JQ1 and especially with the combination of 
both induced the cleavage of PARP-1. Half of the IC50 dose was used to treat the cell lines for 48h. (B) 
Percentage of cells in early apoptosis and late apoptosis based on Annexin V/PI staining after 48h treatment with 
the half of their IC50 dose. Average and standard deviation for 3 independent experiments is shown. Two-tailed t 
tests were used to compare the total apoptotic cells between the monotherapies and combination therapy.  * 
P<0.05, ** P<0.01, *** P<0.001. 
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Supplementary Figure 7. Bioluminescence photographs of all mice xenografted with LOUCY during 
the treatment period. Overview of the luminescence photographs taken during the experiment of each 
mouse. Day 0 is the day before the treatment started while day 14 is the day after the last dose was given. 
The luminescence scale is for all the photographs within a treatment group the same.
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Supplementary Figure 8. Spleen size and evolution of body weight in treated mice xenografted with 
LOUCY. (A) Spleens of all the mice after 13 days of treatment. (B) Spleen-to-body weight percentage at the end 
of the experiment for each mouse in a particular treatment group. The one-tailed Mann-Whitney test was used to 
compare the treatment groups statistically. ns not significant, * P<0.05, ** P<0.01, *** P<0.001. Horizontal lines on 
the graph indicate the median for each group. (C) The weight of each mouse on the day before the treatment 
started (day 0) and at the end of the experiment (day 14) is plotted. One-tailed Wilcoxon signed rank test was 
used to compare the weight loss within a group. ns not significant, * P<0.05, ** P<0.01, *** P<0.001. 
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Supplementary Figure 9. Treatment of mice xenografted with ALL-SIL. (A) Percentage hCD45+ leukemic 
cells in bone marrow for each mouse after 7 days of treatment. The one-tailed Mann-Whitney test was used to 
compare the treatment groups statistically. ns not significant, * P<0.05, ** P<0.01, *** P<0.001. Horizontal lines on 
the graph indicate the median for each group. (B) The weight of each mouse on the day the treatment started 
(day 0) and at the end of the experiment, after 7 days of treatment (day 7), is plotted. One-tailed Wilcoxon signed 
rank test was used to compare the weight loss within a group. ns not significant, * P<0.05, ** P<0.01, *** P<0.001. 
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Supplementary Figure 10 Leukemic burden in spleen and evolution of body weight in treated patient-
derived (T-VHR-26) xenografts. (A) Percentage hCD45+ leukemic cells in the spleen for each mouse after 14 
days of treatment. Spleens were not a lot enlarged in the control mice. Spleen weights were for all mice less than 
100mg. The one-tailed Mann-Whitney test was used to compare the treatment groups statistically. ns not 
significant, * P<0.05, ** P<0.01, *** P<0.001. Horizontal lines on the graph indicate the median for each group. (B) 
Spleen-to-body weight percentage for each mouse after 14 days of treatment. Spleens were not a lot enlarged in 
the control mice. Spleen weights were for all mice less than 100mg. The one-tailed Mann-Whitney test was used 
to compare the treatment groups statistically. ns not significant, * P<0.05, ** P<0.01, *** P<0.001. Horizontal lines 
on the graph indicate the median for each group. (C) The weight of each mouse on the day the treatment started 
(day 0) and at the end of the experiment, after 14 days of treatment (day 14), is plotted. One-tailed Wilcoxon 
signed rank test was used to compare the weight loss within a group. ns not significant, * P<0.05, ** P<0.01, *** 
P<0.001. 
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Supplementary Figure 11 Effect of JQ1 on miR17-92 cluster and knockdown of BIM. (A) Quantification of 
the miR17-92 cluster in LOUCY treated with DMSO or JQ1. These samples were the same as the one used for 
the microarray-based expression profiles. 3 independent replicates of each treatment were performed. Calibrated 
normalized relative quantities (CNRQ) and their standard error are plotted. (B) The BCL2L11 (coding for 
BIM)/BCL2 mRNA ratio increases in synergistic T-ALL cell lines upon treatment with 1µM JQ1 for 48h. The 
average and standard deviation of the ratio of calibrated normalized relative quantities (CNRQ) from three 
independent experiments is plotted. The two-tailed t test was used to compare the DMSO and JQ1 treatment. * 
P<0.05, ** P<0.01, *** P<0.001. 
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Supplementary Tables 
 
Supplementary Table 1. Overview of compounds used in drug-screening. 
Compound Drug class 
Clinical 
stage 
Availability for ALL/clinical trial 
number 
Thioguanine 
Antimetabolites 
Clinical Standard ALL drug 
Cytarabine Clinical Standard ALL drug 
Methotrexate Clinical Standard ALL drug 
Docetaxel 
Antimitotics 
Clinical Pediatric ALL, phase II, NCT00021242 
Vincristine Clinical Standard ALL drug 
JQ-1 BRD4 inhibitor No 
 
Dexamethasone 
Glucocorticoids 
Clinical Standard ALL drug 
Prednisolone Clinical Standard ALL drug 
Givinostat 
HDAC inhibitors 
Phase II CLL, NCT00792831 
Entinostat Phase I-II Adult ALL, NCT00462605 
Panobinostat Phase I-II Pediatric ALL, phase I, NCT01321346 
PU-H71 HSP90 inhibitor Phase I Lymphoma, NCT01393509 
Dactolisib 
Kinase inhibitor 
(PI3K//mTOR) 
Phase I-II Terminated, NCT01756118 
Imatinib 
Kinase inhibitors 
(PDGFR, c-Kik, 
BCR-ABL1) 
Clinical 
 
Bortezomib 
Proteasome 
inhibitor 
Clinical Pediatric ALL, phase III, NCT02112916 
Doxorubicin 
Topoisomerase 
inhibitors and 
anthracyclines 
Clinical Standard ALL drug 
Etoposide Clinical Pediatric ALL, Phase I, NCT00991133 
Idarubicin Clinical Pediatric ALL, Phase IV, NCT01990807 
Mitoxantrone Clinical Pediatric ALL, Phase III, NCT02101853 
Topotecan Clinical Pediatric ALL, Phase II, NCT00003735 
Birinapant SMAC mimetic Phase I-II AML and ALL, phase I-II, NCT01486784 
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Supplementary Table 2. Characteristics of primary T-ALL patient samples. No matched diagnosis sample was available for the relapsed sample. 
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T-R-18 Relapse 
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80 
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1 1 2 2 
   
     8.4 male 9 P CCR 90 
 
 
 
 
 
SR – standard risk;  
MR – medium risk;  
HR – high risk; 
VHR – very high risk; 
R – relapse;  
1 – heterozygous;  
2 – homozygous deletion,  
Y – yes. 
7 –  Pre-T-ALL; 
8 –  Cortical T-ALL; 
9 –  Mature T-ALL. 
G – good; 
P – poor. 
CCR – complete responder; 
R – relapsed 
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Supplementary Table 3. Characteristics of T-ALL cell lines used for xenograft experiments. 
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LOUCY Diagnosis (no remission achieved) 
    
1 1  1  
 
Y      38 female     * 
ALL-SIL Relapse 
  
2 2    Y  Y    Y   17 male  8 
 
 
 
 
1 – heterozygous;  
2 – homozygous deletion,  
Y – yes. 
7 –  Pre-T-ALL; 
8 –  Cortical T-ALL; 
9 –  Mature T-ALL. 
*  is considered to be a model for immature T-ALL 
because it has a transcriptional program highly related 
to early immature T-ALLs (Van Vlierberghe et al., J 
Exp Med 2011). However, immunophenotypically this 
cell line has sCD3 and TCRγδ expression. 
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Supplementary Table 4. Top 30 compound connections (LINCS).The Library of Integrated Cellular Signatures 
(LINCS), accessed via the website lincscloud.org, was used to search for the most connected compounds with 
our JQ1-induced signature in LOUCY. Using the up- and downregulated genes after 4h of JQ1 treatment 
(adjusted p-value<0.01), 10 known HDAC inhibitors were found in the top 30 of compound connections. The 
compound connections are ranked according to the score_best4, i.e. the mean connectivity score across the four 
cell lines in which the perturbagen connected most strongly to the query. 
Rank Name of perturbagen Type of perturbagen Score_best4 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
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TG-101348 
XMD-1150 
BRD-K52163391 
THM-I-94 
BI-2536 
ISOX 
XMD-885 
BRD-A11087911 
BRD-K10361096 
JWE-035 
trichostatin-a 
HC-toxin 
XMD-1185H 
scriptaid 
XMD-892 
BRD-K75081836 
XMD-16144 
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KM-00927 
KU-0060648 
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panobinostat 
LY-303511 
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Unknown? 
Unknown? 
Unknown? 
Unknown? 
Unknown? 
HDACi 
HDACi 
Unknown? 
HDACi 
ERK5/BMK1 inhibitor 
Unknown? 
Unknown? 
HDACi 
Unknown? 
inhibitor of DNA-PK and PI3Kα, PI3Kβ, PI3Kδ 
HDACi 
HDACi 
blocks voltage-gated potassium channels, inhibits IL-
1β-stimulated NF-κB activation and inhibits the BET 
bromodomain proteins BRD2, BRD3 and BRD4 
HDACi 
Unknown? 
HDACi 
HDACi 
HDACi 
Unknown? 
Unknown? 
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99.802 
99.708 
99.63 
99.606 
99.243 
98.986 
98.895 
98.64 
98.512 
98.478 
98.46 
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98.015 
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97.845 
97.831 
97.83 
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97.796 
97.482 
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95.531 
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Supplementary Table 5. Primer sequences and miScript Primer Assays. Sequences of all the primers used 
for the qRT-PCR reactions and miScript Primer Assays to quantifiy mature miRNAs. 
Gene Forward primer Reverse primer 
BCL2 5’-CATGTGTGTGGAGAGCGTCAA-3’ 5’-GCCGGTTCAGGTACTCAGTCA-3’ 
BCL2L11 (BIM) 5’-TGGCAAAGCAACCTTCTGATG-3’ 5’-GCAGGCTGCAATTGTCTACCT-3’ 
 
Reference genes   
HMBS 5’-GGCAATGCGGCTGCAA-3’ 5’-GGGTACCCACGCGAATCAC-3’ 
RPL13A 5’-CCTGGAGGAGAAGAGGAAAGAGA-3’ 5’-TTGAGGACCTCTGTGTATTTGTCAA-3’ 
YWHAZ 5’- ACTTTTGGTACATTGTGGCTTCAA -3’ 5’- CCGCCAGGACAAACCAGTAT -3’ 
   
   
miRNA miScript Primer Assay (Qiagen)  
miR-17-5p MS00029274  
miR-18a-5p MS00031514  
miR-19a-3p MS00003192  
miR-19b-3p MS00031584  
miR-20a-5p MS00003199  
miR-92a-3p MS00006594  
   
Assays used for normalization  
miR-16-5p MS00031493  
miR-26a-5p MS00029239  
miR-26b-5p MS00003234  
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Supplementary Materials and Methods 
Drug-screening platform  
MSC (2,500 cells/well) were plated in 384-well plates (Greiner, REF781090) in 30µL serum-
free medium (AIM-V®, Life Technologies). After 24h incubation at 37°C, 5% CO2, 2.5x104 
viable leukemia cells were suspended in 27.5µL medium and incubated for an additional 24h. 
All compounds used in the screening (Supplementary Table 1) had been diluted in DMSO to 
reach a 10mM concentration and stored at -80°C. Serial dilutions were performed from a 
starting dose of 1x105 nM diluted 10x over four additional points using an epMotion 5070 
robot (Eppendorf). Compounds were tested in duplicate. For combination screening two 
plates had been prepared: one as control (DMSO) and second with selected sub-lethal 
venetoclax dose in all wells. After 72h of incubation with compounds, live cell numbers were 
evaluated using CyQUANT® live cell staining (Life Technologies). 20μL staining mix (AIM-V 
medium, CyQUANT (1:300), Repressor (1:20)) was added into each well and incubated for 
1h at 37°C, 5 % CO2. Automated imaging was performed using the ImageXpressMicro 
microscope (Molecular Devices) equipped with a CoolLSNap HQ camera (Photometrics) and 
a 10x Plan Fluor objective with 0.3 NA (Nikon). Nine images were taken per well 
(MetaXpress), covering 50% of the well surface. Images were processed using the 
CellProfiler software (Broad Institute). Cells were classified and counted using the Advanced 
Cell Classifier software (1, 2). This software uses the random forest classification method to 
identify T-ALL cells from MSCs. More information on the two imaging processing programs 
used can be found on http://acc.ethz.ch/. 
1. Horvath P, Wild T, Kutay U, Csucs G. Machine learning improves the precision and 
robustness of high-content screens: using nonlinear multiparametric methods to 
analyze screening results. J Biomol Screen. 2011;16(9):1059-67. 
2. Misselwitz B, Strittmatter G, Periaswamy B, Schlumberger MC, Rout S, Horvath P, et 
al. Enhanced CellClassifier: a multi-class classification tool for microscopy images. 
BMC Bioinformatics. 2010;11:30. 
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PART II Pharmacological inhibition of LSD1/KDM1A for the treatment of 
T-ALL 
 
Paper 3: Oncogenic ZEB2 activation drives sensitivity towards KDM1A inhibition in T-cell 
acute lymphoblastic leukemia (published in Blood, 2017) 
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Key Points 
 ZEB2, a novel driver of immature T-cell acute lymphoblastic leukemia (T-ALL), 
interacts with the Lysine-specific demethylase KDM1A  
 KDM1A function is critical for leukemic survival of T-ALL cells with high ZEB2 levels 
 
Abstract 
Elevated expression of the Zinc finger E-box binding homeobox transcription factor-2 (ZEB2) 
is correlated with poor prognosis and patient outcome in a variety of human cancer subtypes. 
Using a conditional gain-of-function mouse model, we recently demonstrated that ZEB2 is an 
oncogenic driver of immature T-cell acute lymphoblastic leukemia (T-ALL), a heterogenic 
subgroup of human leukemia characterized by a high incidence of remission failure or 
hematological relapse after conventional chemotherapy. Here, we identified the Lysine-
specific demethylase KDM1A as a novel interaction partner of ZEB2 and demonstrated that 
mouse and human T-ALLs with increased ZEB2 levels critically depend on KDM1A activity 
for survival. Therefore, targeting the ZEB2 protein complex through direct disruption of the 
ZEB2-KDM1A interaction or pharmacological inhibition of the KDM1A demethylase activity 
itself, could serve as a novel therapeutic strategy for this aggressive subtype of human 
leukemia, and possibly other ZEB2-driven malignancies. 
 
Introduction 
ZEB2 is a member of the Zinc finger E-box binding homeobox transcription factor family that 
mediates epithelial to mesenchymal transition (EMT) events during development and 
disease1. Induced expression of ZEB2 in epithelial cancer cell lines results in the repression 
of a wide range of genes responsible for cellular adhesion, allowing these cells to become 
motile and upon xenotransplantation disseminate into the surrounding tissue and 
metastasize2. Moreover, increased expression of EMT transcription factors (EMT-TFs), such 
as ZEB2, is associated with the acquisition of cancer stem cell (CSC) properties that have 
the potential to self-renew and form secondary tumors upon transplantation3-5. Currently, little 
is known about how EMT-TFs regulate CSC properties at the molecular level. It has been 
proposed that targeting EMT-TFs is a promising novel therapeutic strategy that not only 
prevents EMT-mediated spreading of tumor cells but also targets radio/chemoresistent 
cancer stem cells6.  
Using a conditional loss of function approach, we have demonstrated that ZEB2 is an 
essential transcription factor during embryonic and adult hematopoiesis7, 8. In contrast, 
conditional Zeb2 overexpression leads to the spontaneous formation of an immature early 
thymic progenitor subtype of T-cell acute lymphoblastic leukemia (ETP-ALL)5. ETP-ALL is a 
refractory and aggressive form of leukaemia, characterized by the co-expression of early T-
cell and myeloid progenitor cell gene expression profiles9.  Zeb2-overexpressing primary T-
ALL cells show significant overlap with the expression profile of human ETP-ALL, and exhibit 
a marked increase of hematopoietic stem cell markers and leukemia-initiation potential5.  
ZEB2 is a large multidomain homeobox transcription factor that recognizes bipartite E-box 
motifs through its amino- and carboxyterminal Zinc finger domains10. The domains outside 
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the Zn-finger clusters have been shown to be essential for the recruitment of various tissue-
specific co-activators/repressors, which ultimately regulates ZEB2’s tissue-specific activity11. 
Therefore, identification and targeting of novel interaction partners that are essential for 
ZEB2’s oncogenic properties in the context of T-ALL, represents a feasible option for the 
development of novel therapeutics to treat aggressive leukemia. 
Recent studies have shown the importance of epigenetic changes during cancer 
initiation/progression. Clonal evolution studies have suggested the existence of pre-leukemic 
epigenetic changes within hematopoietic progenitors that allows clonal expansion and 
accumulation of genetic lesions that eventually results in overt leukemia12-14. KDM1A is a 
flavin-containing amino oxidase that specifically catalyzes the demethylation of mono- and di-
methylated lysines on histone 3 (H3K4 and H3K9, typically associated with gene repression 
and activation respectively). KDM1A regulates the balance between self-renewal and 
differentiation of pluripotent stem cells15 and its expression is upregulated in various cancers. 
Pharmacological inhibition of KDM1A has emerged as a promising novel therapy to treat and 
kill cancer stem cells and novel potent inhibitors are being tested in clinical trials16, 17. Within 
the hematopoietic system, conditional loss of KDM1A results in a pancytopenia with impaired 
HSC self-renewal and differentiation potential18. Inversely, KDM1A gain-of-function results in 
enhanced self-renewal and skewing towards the T-cell lineage, eventually leading to the 
development of T-cell lymphoblastic leukemia19. Although KDM1A inhibition has been 
identified as a promising novel epigenetic therapy for various subtypes of human cancers 
including acute myeloid leukemia (AML), the molecular mechanisms that drive susceptibility 
to KDM1A inhibition and/or biomarkers that could predict KDM1A sensitivity remain to be 
further explored. 
Here, we identify KDM1A as a novel interaction partner for ZEB2 in T-ALL and demonstrate 
that increased ZEB2 expression can drive sensitivity towards KDM1A inhibition. 
 
Methods 
Pull-downs, Mass Spectrometry   
Mouse T-ALL cells were washed once with phosphate-buffered saline and nuclear extracts 
were prepared as described previously20 and in supplements. Anti-FLAG M2 agarose beads 
(Sigma) were used to pull down FLAG-ZEB2 containing protein complexes overnight at 4°C, 
rotating. Beads were washed five times and eluted four times with 0.6 mg/ml FLAG tripeptide 
(Sigma) for 15 min at room temperature. Fractions were loaded onto a 10% Mini-Protean 
TGX precast gel (BioRad) and silver stained (Thermo Fisher Scientific). Elutions containing 
the majority of FLAG-ZEB2 were loaded onto a 10% SDS-PAA gel (Thermo Scientific) and 
separated by a short SDS-PAGE gel run. Entire lanes were excised and subjected to in-gel 
tryptic digestion and liquid chromatography tandem mass spectrometry (LC-MS/MS) analysis 
as previously described21. Raw data were processed and searched by MaxQuant software 
(version 1.5.2.8)22. Database searching was done against mouse protein sequences 
downloaded from Uniprot (03/2015 release) using MaxQaunt default settings. Significance of 
specific protein–protein interactions was performed using Perseus analysis software23. 
Co-immunoprecipitations 
For FLAG-ZEB2 pull-downs, anti-FLAG M2 agarose beads (Sigma) were used as above. For 
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KDM1A pull-downs, the rabbit polyclonal anti-KDM1A (LSD1) antibody (Abcam) was used in 
combination with the Rabbit TrueBlot IP-set (Rockland). Western blot analysis was 
performed according to standard protocols and primary antibodies are listed in 
Supplementary information. 
Chromatin immunoprecipitation (ChIP)  
ChIPs were performed using the SimpleChIP Enzymatic Chromatin IP kit with magnetic 
beads (Cell Signaling Technology) using H3K4me2-specific mouse monoclonal Antibody 
(MABI 0303, Active Motif). The enriched DNA was quantified by qPCR with SimpleChIP 
Human CD11b Promoter Primers (#14271, Cell Signaling Technology). 
Cell culture  
T-ALL cell lines were grown as previously described5 and in supplements. For the generation 
of KARPAS-45 cells overexpressing ZEB2, virus production was performed in HEK293TN 
cells using JetPEI polyplus with pMD2.G (envelope plasmid), psPAX2 (packaging plasmid) 
and pSIN-TRE-GW-3xHA hZEB2 (target plasmid) in 0.1/0.9/1 ratios. Transduced KARPAS-
45 cells were selected by puromycin (1µg/ml). 48h before the start of the KDM1A inhibitor 
experiment, doxycyclin (1µg/ml) administration was started. GSK2879552 (ActiveBiochem) 
was dissolved in DMSO at a concentration of 10 mg/ml and diluted further in medium as 
indicated. Further cell culture details are listed in supplements.  
SiRNA knockdown  
For siRNA-mediated knockdown experiments, LOUCY was electroporated with 400nM of 
ZEB2-specific siRNAs (siZEB2-01: ON-TARGETplus Human ZEB2 siRNA J-006914-07, 
Dharmacon; siZEB2-02: Silencer Select Pre-designed Human ZEB2 siRNA s19034, 
ThermoFisher Scientific) or 400nM of scrambled siRNAs (ON-TARGETplus Non-targeting 
pool D-001810-10-05, Dharmacon). Also electroporation without adding siRNAs was 
performed as control. For the electroporation, an exponential decay pulse (300V, 1000mF; 
Genepulser MxCell, Bio-Rad) was used. After 72h and 120h, RNA was isolated and 
evaluated by qRT–PCR.  
Cell viability assays  
Cell viability was determined by combination of CellTiter Glo Luminiscent viability assay 
(Promega) and flow cytometric analysis on LSRII or Fortessa (BD Biosciences) and 
FACSDiva or FlowJo software (BD Biosciences). For viability, we used combination of 
AnnexinV/DAPI stain or the fixable viability Dye eFluor450 (eBioscience). 
qRT-PCR was performed according to standard protocols and used primer sets are listed in 
supplements.  
Allo/Xenotransplantations 
T-ALL cell lines were intravenously injected in NOD scid gamma (NSG) mice. For the 
recipients transplanted with the mouse T-ALL cell lines, 1 X 106 cells were transplanted into 
8-10 week-old male recipients via tail-vein injection and the KDM1A inhibitor treatment was 
started the day after cell injection with 1.5mg GSK2879552/kg body weight (or vehicle only) 
via oral gavage and was continued for 3 weeks. Mice were monitored for illness and 
leukemia development. 
For the NSG mice injected with LOUCY or PEER cells, KDM1A inhibitor treatment was 
started when the first signs of engraftment were detected (hCD45+ cells in periphery). Mice 
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were treated (1.5 mg GSK2879552/kg body weight or vehicle via oral gavage) for 17 (PEER) 
or 18 (LOUCY) consecutive days. Mice were weighed daily and monitored. The percentage 
of leukemic cells in the blood was analyzed by staining the cells with an PE-labeled antibody 
(Miltenyi Biotec) for human CD45 (hCD45), red blood cell lysis and measuring the 
percentage with S3e cell sorter (Bio-Rad).  
RNA sequencing and Bioinformatics  
RNA was prepared using either the RNeasy mini Plus kit (Qiagen) or the miRNeasy mini kit 
(Qiagen). Library preparation was performed using the Illumina TruSeq RNA sample Prep 
Kit. Enriched cDNA libraries were sequenced using an Illumina NextSeq 500 sequencer 
instrument. Reads were aligned to GRCm38 and GRCh38 using STAR2.4.2a. Genes were 
quantified on Ensembl38_v81 and Gencode v23 respectively. Pathway analysis was 
performed by KEGG using standard settings. Finally, pre-ranked GSEA was performed with 
the c2 MSigDB gene sets collection using the GSEA desktop application (Broad Institute, 
version v2.2.0). Further details are provided in supplements. 
 
Results 
ZEB2 interacts with KDM1A   
We derived 4 T-ALL cell lines from murine thymomas from our Zeb2 overexpression mouse 
model that had been intercrossed onto a conditional p53-null tumor-prone background5: two 
p53 null primary T-ALL cell lines with Zeb2 overexpression (further annotated as P53/R26-
Zeb2tg/tg) and two p53 null control cell lines without Zeb2 overexpression (further annotated 
as P53/R26+/+). In the P53/R26-Zeb2tg/tg tumor cell lines, the ZEB2 transgene contains an 
aminoterminal 3xFLAG/Strep-tag, providing a useful in vitro model system to isolate ZEB2-
containing protein complexes and identify ZEB2 interaction partners in the context of T-ALL. 
We performed protein complex pull-down experiments on nuclear extracts of P53/R26-
Zeb2tg/tg and P53/R26+/+ T-ALL cell lines using anti-FLAG beads (Figure 1A), followed by 
mass spectrometry. Importantly, known ZEB2 interaction partners, such as CTBP124 and 
multiple subunits of the NuRD chromatin remodelling complex (i.e. CHD4/Mi-2β, MTA2 and 
HDAC1)25, were co-purified in the FLAG-ZEB2 expressing tumor lines, confirming the validity 
of our approach (Table 1). We also identified novel putative ZEB2 interaction partners 
including the hematopoietic transcription factor RUNX1, MYB binding protein 1A 
(MYBBP1A), multiple proteins involved in pre-mRNA processing and RNA biogenesis 
(Hnrnph1, Snrpb/n, Snrpd2, Snrnp70, Ddx21), NUMA1 (nuclear mitotic apparatus protein 1) 
as well as the Lysine-specific demethylase-1 KDM1A (Table 1). Here, we focused on the 
ZEB2-KDM1A interaction for several reasons: 1) there is a significant overlap between the 
phenotypes observed after KDM1A and ZEB2 gain/loss in vitro (i.e. EMT phenotype 
switching10, 26, regulation of the balance between self renewal and differentiation in 
embryonic stem cells15, 27, as well as regulating proliferation and differentiation of acute 
myeloid leukemia cells28, 29) and in vivo (i.e. pancytopenia with loss of HSC differentiation 
potential upon loss of function7, 18 and spontaneous T-ALL formation upon gain of function5, 
19, association with EMT and solid tumor metastasis10, 26) ; 2) KDM1A has previously been 
identified as being part of both the NuRD26 and CTBP1 co-repressor complexes30, known 
interactors of ZEB2 and also identified here, and 3) the existence of potent KDM1A 
inhibitors16, 17, 31 that are presently being used in Phase I clinical trials . 
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We confirmed this ZEB2-KDM1A interaction using bidirectional co-immunoprecipitation 
experiments, with FLAG/ZEB2- and KDM1A-specific antibodies (Figure 1B-C). Finally, to 
prove that this interaction was not an overexpression artifact in our mouse T-ALL cell lines, 
we further confirmed this interaction in nuclear extracts from LOUCY cells (Figure 1D), a 
human T-ALL cell line with an immature expression profile and high ZEB2 expression5.  
 
Table 1. Mass spectrometric analysis of peptides identified after pull down of FLAG-ZEB2 containing 
protein complexes in P53/R26-Zeb2
tg/tg
 versus control P53/R26
+/+
 mouse T-ALL cell lines. 
Protein Name Gene name peptides  
P53/R26
+/+
 
control #1 
peptides 
P53/R26
+/+
 
control #2 
peptides   
P53/Zeb2
tg/tg          
TG/TG #1 
peptides 
P53/Zeb2
tg/t
g 
TG/TG #2 
Gelsolin Gsn 0 0 21 6 
F-actin-capping protein subunit beta Capzb 0 0 22 2 
Zinc finger E-box-binding homeobox 2 Zeb2 0 0 13 4 
Major vault protein Mvp 0 0 10 3 
Nuclear mitotic apparatus protein 1 Numa1 0 0 9 4 
Actin-related protein 2/3 complex subunit 4 Arpc4 0 0 9 3 
Heterogeneous nuclear ribonucleoprotein H Hnrnph1 0 0 8 3 
Small nuclear ribonucleoprotein-associated protein B/N Snrpb;Snrpn 0 0 9 1 
Histone deacetylase 1 Hdac1 0 0 7 3 
Metastasis-associated protein MTA2 Mta2 0 0 7 2 
Small nuclear ribonucleoprotein Sm D2 Snrpd2 0 0 8 1 
Actin-related protein 3 Actr3 0 0 8 1 
Myb-binding protein 1A Mybbp1a 0 0 5 2 
RuvB-like 1 Ruvbl1 0 0 5 2 
Chromodomain-helicase-DNA-binding protein 4/5 Chd4;Chd5 0 0 6 1 
U1 small nuclear ribonucleoprotein 70 kDa Snrnp70 0 0 5 1 
Runt-related transcription factor 1 Runx1 0 0 5 1 
Tropomyosin alpha-3 chain Tpm3 0 0 4 2 
Lysine-specific histone demethylase 1A Kdm1a 0 0 4 1 
C-terminal-binding protein 1 Ctbp1 0 0 3 3 
Spectrin beta chain, non-erythrocytic 1 Sptbn1 0 0 4 2 
Nucleolar RNA helicase 2 Ddx21 0 0 3 2 
Unconventional myosin-Ic Myo1c 0 0 4 1 
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Figure 1. ZEB2 interacts with KDM1A in T-ALL cell lines. (A) Silverstain of SDS-Page after pull downs of 
FLAG-ZEB2 protein complex (B) Co-immunoprecipitation of KDM1A after pull down of FLAG-ZEB2 protein 
complex in mouse T-ALL cell lines (C) Co-immunoprecipitation of ZEB2 after pull down of KDM1A protein 
complex in mouse T-ALL cell lines (D) Co-immunoprecipitation of ZEB2 after pull down of KDM1A protein 
complex in the human T-ALL cell line LOUCY, using 2 antibodies that recognize human ZEB2.  
 
Mouse T-ALL cell lines with high ZEB2 levels are sensitive to KDM1A inhibitors  
To validate the functional relevance of this ZEB2-KDM1A interaction, we tested the effects of 
KDM1A inhibition on the mouse T-ALL cell lines with and without Zeb2 overexpression. 
Strikingly, both Zeb2-overexpressing P53/R26-Zeb2tg/tg cell lines showed high sensitivity 
towards KDM1A inhibition (Figure 2A, Supplementary Figure 1). More specifically, T-ALL 
cells with enhanced Zeb2 levels were sensitive to treatment with the commercially available 
KDM1A inhibitor GSK2879552 with an average IC50 at day 4 of 10.39nM (Figure 2A, 
Supplementary Figure 1). In contrast, no effects were observed for the control P53/R26+/+ 
mouse T-ALL cell lines using these inhibitors (Figure 2A, Supplementary Figure 1). Both 
P53/R26+/+ and P53/R26-Zeb2tg/tg expressed similar protein levels of KDM1A, illustrating that 
altered levels are not determining their sensitivity towards pharmacological KDM1A inhibition 
(Supplementary Figure 2A). 
To obtain molecular insights into the pathways involved in ZEB2-driven KDM1A inhibitor 
sensitivity, we subsequently performed RNA-sequencing on two P53/R26+/+ and two 
P53/R26-Zeb2tg/tg cell lines. As previously described5, this analysis revealed that the 
P53/R26+/+ and P53/R26-Zeb2tg/tg tumor lines displayed a very distinct gene expression 
signature under baseline (DMSO) conditions, with 6675 significantly differentially expressed 
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genes (adj. p-value<0.05; Supplementary Figure 3; Supplementary Table 1). KEGG pathway 
analysis revealed increased expression of AML related transcripts, decreased expression of 
NOTCH pathway genes involved in T-cell differentiation combined with activation of JAK-
STAT/MAPK (mitogen-activated protein kinase 1) signalling in ZEB2-derived tumor lines 
(Supplementary Table 2). These differential gene patterns are in line with our previous 
observations that Zeb2 driven thymomas reflect an immature T-ALL subtype with increased 
stem cell markers and activated IL7R/JAK-STAT signaling5. Given the pro-survival effects of 
activated IL7R/JAK-STAT signalling in the context of Zeb2-driven T-cell leukemogenesis, we 
wondered whether exogenous IL7 could partially rescue the apoptotic phenotype observed in 
these cells. Indeed, analysis of Zeb2 transgenic cells in IL7-supplemented culture conditions 
revealed that IL7 inclusion could decrease the sensitivity to KDM1A inhibition in the 
P53/R26-Zeb2tg/tg cell lines (Figure 2B).  
 
Figure 2. Mouse T-ALL cell lines with high ZEB2 levels are sensitive to KDM1A inhibition. (A) Percentage of 
viable cells (CellTiter-Glo Luminescent Cell Viability Assay) in P53/R26-Zeb2
tg/tg
 Zeb2 overexpressing mouse T-
ALL cell lines compared to control P53/R26
+/+
 cell lines treated with different concentrations of the KDM1A 
inhibitor GSK2879552 for 4 days. The average of three independent experiments and standard deviation is 
plotted. (B) Effects of exogenous IL7 on the sensitivity of P53/R26-Zeb2
tg/tg
 Zeb2 overexpressing mouse T-ALL 
cell lines to KDM1A inhibition (CellTiter-Glo Luminescent Cell Viability Assay). Average of technical triplicates are 
plotted. Similar effects are observed with the second independent mouse T-ALL cell lines (C) Differential gene 
expression after KDM1A inhibition (24h, 100nM GSK2879552) in P53/R26
+/+
 and P53/R26-Zeb2
tg/tg
 mouse T-ALL 
cell lines (adjusted P-value < 0.05, triplicates). (D) Overlap between the KDM1A responsive gene signatures in 
P53/R26
+/+
 and P53/R26-Zeb2
tg/tg
 mouse T-ALL cell lines.  
 
Next, we analysed the transcriptional response upon short-term KDM1A inhibition (100nM 
GSK2879552 for 24h) in the absence of exogenous IL7 in both murine tumor entities. 
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Notably, and in line with the drug response phenotypes, KDM1A inhibition in control 
P53/R26+/+ cell lines only caused limited effects on overall transcription with 62 differentially 
expressed genes (adj. p-value<0.05; Figure 2C). In contrast, gene transcription was more 
severely affected by KDM1A perturbations in the P53/R26-Zeb2tg/tg lines with significant 
changes in the expression of 413 transcripts (315 up- and 98 down-regulated; adj. p-
value<0.05; Figure 2C; Supplementary Table 3). Notably, all 62 genes that showed 
differential expression upon KDM1A inhibition in P53/R26+/+ cell lines, were also altered in the 
P53/R26-Zeb2tg/tg tumor lines (Figure 2D). All together, these results demonstrate that Zeb2 
overexpression modulates murine T-ALL responsiveness to KDM1A inhibitors. 
Human T-ALL cell lines with high ZEB2 levels are sensitive to KDM1A inhibitors  
To study the human relevance of our findings, we subsequently evaluated the putative 
correlation between ZEB2 expression levels and KDM1A inhibitor sensitivity in a panel of 
human T-ALL cell lines. Interestingly, human T-ALL cell lines characterized by high (LOUCY) 
or moderate (PEER) ZEB2 expression (Figure 3A) were sensitive towards KDM1A inhibition 
with average IC50 values at day 12 of 112.91nM (LOUCY) and 43.83nM (PEER) for 
GSK2879552 (Figure 3B). In addition, a time-course experiment in LOUCY cells revealed 
that the first overt effects on leukemic cell survival appear around 5-7 days of KDM1A 
inhibition treatment (Supplementary Figure 4). Moreover, this KDM1A inhibitor sensitivity was 
found to be similar to what has been described for acute myeloid leukemia (AML) cell lines31 
(Supplementary Figure 5). In contrast, the survival or proliferation of ZEB2-negative T-ALL 
cell lines, such as JURKAT, TALL-1 and ALL-SIL, was not affected by KDM1A inhibition 
(Figure 3B). Nevertheless, and in line with recent work31, screening of additional T-ALL cell 
lines revealed that two other ZEB2-negative T-ALL cell lines, RPMI-8402 and HSB-2, were 
also highly sensitive to KDM1A inhibition, suggesting that alternative molecular mechanisms, 
independent of ZEB2, can also drive sensitivity towards KDM1A inhibition in the context of 
human T-ALL. Similarly, as seen in the mouse cell lines, no correlation was observed in the 
human T-ALL cell lines between KDM1A protein expression and KDM1A inhibitor sensitivity 
(Supplementary Figure 2B). 
Although previous studies have suggested that KDM1A prevents differentiation and 
apoptosis in the context of MLL rearranged leukemia28, we only observed minimal anti-
leukemic effects upon GSK2879552 treatment in the MLL-AFX positive T-ALL cell line 
KARPAS-45 (Figure 3B). Given that this MLL rearranged T-ALL cell line is characterized by 
low levels of ZEB2 (Figure 3A), we subsequently generated KARPAS-45 cells with 
doxycycline-inducible expression of ZEB2, to formally prove that ZEB2 can truly modulate 
KDM1A inhibitor sensitivity in the context of human T-ALL. Notably, doxycycline induced 
ZEB2 overexpression significantly increased KDM1A inhibitor sensitivity in this in vitro model 
system, as exemplified by decreased cell viability 12 days after the initiation of KDM1A 
inhibition (Figure 3C).  
Next, we analysed the transcriptional response of KDM1A inhibition in human T-ALL cell 
lines. For this, RNA sequencing was performed on biological triplicates of the ZEB2-positive 
LOUCY and PEER cells, and the ZEB2-negatives RPMI-8402 and HSB-2 treated for 48 
hours with 100nM GSK2879552 versus their corresponding DMSO treatment controls. Gene 
expression was affected by KDM1A inhibition in all sensitive T-ALL cell lines, but the effect 
was most pronounced in ZEB2-high LOUCY cells (Supplementary Figure 6A). 
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Figure 3. Human T-ALL cell lines with high ZEB2 levels are sensitive to KDM1A inhibition.  (A) Relative 
mRNA expression in a panel of human T-ALL cell lines analysed by qPCR (B) Cell viability (CellTiter-Glo 
Luminescent Cell Viability Assay) of human T-ALL cell lines with variable expression of ZEB2 mRNA after 12 
days administration of the KDM1A inhibitor GSK2879552. The average and standard deviation of two 
independent experiments is plotted (C) Cell viability (CellTiter-Glo Luminescent Cell Viability Assay) of KARPAS-
45 with dox-inducible overexpression of ZEB2 versus parental line after 12 days of GSK2879552 administration. 
Left, Western blot demonstrating level of dox-inducible ZEB2 overexpression; Right, % of cell viability. (D) 
Differential gene expression after KDM1A inhibition (48h, 100nM GSK2879552) in LOUCY (adjusted P-value < 
0.05, triplicates) (E) Pre-ranked Gene Set Enrichment Analysis (GSEA) using probe set of genes upregulated 
upon KDM1A inhibition by TCP in human AML cell lines
33
. (F) ZEB2 and ITGAM mRNA expression levels upon 
siRNA-mediated ZEB2 knockdown in LOUCY cells (72h after electroporation). (G) Analysis of CD11B protein 
expression by flow cytometry after KDM1A inhibition (100nM GSK2879552, 72h) correlated with increased 
H3K4me2 levels at ITGAM promoter analysed by ChIP.  
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Indeed, GSK2879552 treatment in LOUCY cells resulted in significant changes of 2800 
transcripts (1382 up- and 1418 down-regulated; adj. p-value<0.05, Figure 3D), whereas 
PEER, RPMI-8402 and HSB-2 only displayed significant transcriptional changes in 333, 769 
and 622 genes, respectively (Supplementary Table 4). In terms of overlap, only 41 genes 
were commonly differentially regulated in all 4 T-ALL cell lines (39 genes up and 2 genes 
down; Supplementary Figure 6B). Of note, cross-species comparison between LOUCY and 
P53/R26-Zeb2tg/tg murine tumor lines revealed a common KDM1A inhibitor response 
signature, which consisted of 87 genes (72 up and 15 down; Supplementary Figure 7). 
Interestingly, pre-ranked Gene Set Enrichment Analysis (GSEA) revealed a significant 
overlap between the transcriptional response after KDM1A inhibition in the human LOUCY T-
ALL cell line and the transcriptional response previously reported in the context of human 
AML32 (Figure 3E). For example, common responsive genes that are re-expressed upon 
KDM1A inhibition in both AML and LOUCY included GFI1, vimentin (VIM) and integrin 
subunit alpha M (ITGAM; encoding CD11B). Interestingly, recent work also demonstrated 
that loss of ZEB2 causes a similar re-induction of ITGAM expression in both mouse and 
human AML cell lines29. Most notably, siRNA-mediated ZEB2 knockdown experiments in the 
T-ALL cell line LOUCY also resulted in increased ITGAM expression (Figure 3F). In line with 
this notion, we showed that CD11b induction upon KDM1A inhibition in LOUCY cells is 
associated with increased binding of the H3K4me2 mark at the ITGAM promoter region, as 
evaluated by chromatin immunoprecipitation (ChIP) (Figure 3G). 
In vivo activity of KDM1A inhibition on high Zeb2 expressing murine and human T-ALL 
Given that promising in vivo responses have been reported for small cell lung cancer using 
the commercially available KDM1A inhibitor GSK287955217, we subsequently explored the in 
vivo potential of GSK2879552 to prevent or delay secondary leukemia formation of ZEB2-
overexpressing murine T-ALL cell lines. For this, Zeb2-overexpressing T-ALL cell lines were 
xenografted in immune deficient NOD scid gamma (NSG) mice and treated for 3 weeks with 
GSK2879552 (1.5 mg/kg bodyweight) or with vehicle (DMSO). Notably, although all mice 
eventually developed leukemia, KDM1A inhibition triggered a significant delay in tumor 
latency (Figure 4A). 
 
To further evaluate the therapeutic relevance of KDM1A inhibition in the context of human T-
ALL, we subsequently performed in vivo drug treatment experiments using T-ALL cell line 
xenografts. LOUCY (ZEB2 high) and PEER (ZEB2 moderate) were injected in the tail vein of 
NSG mice and treatment of established tumors (1.5 mg GSK2879552/kg bodyweight or 
vehicle) was initiated when the percentage of hCD45+ cells in peripheral blood reached 2% 
(3 weeks (PEER) and 4 weeks (LOUCY) after injection). Notably, KDM1A inhibition resulted 
in a decrease in the percentage of circulating hCD45+ for both cell lines, suggesting that 
GSK2879552 can trigger an in vivo effect on tumor burden and leukemia development 
(Figure 4B and Figure 4D). However, no changes in spleen weight (Figure 4C and Figure 4E) 
were observed and all animals showed signs of progressive disease, suggesting that KDM1A 
inhibition in human T-ALL might be particularly useful as part of a combination therapy. 
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Figure 4. In vivo activity of KDM1A inhibitors on high Zeb2 expressing murine and human T-ALL. (A) 
Kaplan-Meier survival curves of NSG mice injected with two P53/R26-Zeb2
tg/tg 
murine tumor lines with and without 
3 weeks of GSK2879552 administration (1.5 mg/kg bodyweight). (B) Percentage of hCD45+ T-ALL cells in 
peripheral blood of NSG mice xenotransplanted with LOUCY human T-ALL cells, before and after 18 days of 
GSK2879552 administration (1.5 mg/kg bodyweight) versus DMSO. (C) Percent spleen weight after 18 days of 
KDM1A inhibition (1.5 mg GSK2879552/kg bodyweight) versus DMSO. (D) Percentage of hCD45+ T-ALL cells in 
peripheral blood of NSG mice xenotransplanted with PEER human T-ALL cells, before and after 17 days of 
GSK2879552 administration (1.5 mg/kg bodyweight) versus DMSO (E) Percent spleen weight after 17 days of 
KDM1A inhibitor administration (1.5 mg/kg bodyweight) versus DMSO. 
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Discussion 
Relapsed T-ALL is a major clinical challenge. Therefore, current research efforts are focused 
on the development of more effective and less toxic anti-leukemic drugs, which will likely 
require an improved understanding of the molecular biology of chemotherapy-resistant 
residual tumor cells that eventually drive disease recurrence33, 34. In particular, immature T-
ALL patients, which have a unique gene expression signature enriched for transcripts found 
in hematopoietic stem cells35, have been associated with a poor response to current 
chemotherapy and significantly higher incidence of induction failure and hematological 
relapse9. 
 
We recently demonstrated that ZEB2 is up-regulated in a subset of human T-ALLs and that 
Zeb2 activation in the mouse results in the spontaneous formation of immature T-cell 
lymphoblastic leukemia with increased cancer stem cell properties and enhanced IL7 
receptor expression5. Therefore, determining ZEB2 interaction partners involved in this 
oncogenic driver role may open up novel therapeutic strategies to specifically target 
aggressive forms of leukemia. 
 
Here, we identified a number of novel putative ZEB2 interaction partners, including 
recurrently mutated proteins in T-ALL, such as the essential hematopoietic transcription 
factor RUNX135, the RNA processing protein HNRNPH136 and NUMA1, a protein involved in 
regulation of mitotic spindle organization and asymmetric/symmetric cell divisions37. More 
research is needed to confirm these novel ZEB2 interactions and to determine whether they 
are involved in the ZEB2-mediated T-ALL formation. The identification of known ZEB2 
interaction partners in this study, such as CtBP138 and the NuRD chromatin remodeling 
complex25, 39, confirms the validity of this approach and highlights their potential importance in 
T-ALL. 
 
In this report, we identified and confirmed the interaction of ZEB2 with the Lysine-specific 
histone demethylase KDM1A in T-ALL cells. Whether this interaction is direct or part of a 
larger complex remains to be determined. Nevertheless, given that KDM1A has no DNA 
binding capacity, it depends on the interaction with transcription factors and transcriptional 
complexes to perform its function as a locus-specific epigenetic modifier. In that context, 
KDM1A has previously been identified in the CTBP130 and NuRD co-repressor26 complexes, 
suggesting that these transcriptional complexes could also be functionally relevant in the 
context of T-cell transformation. 
 
Similar as for ZEB2, KDM1A has been found to be involved in regulating cellular 
differentiation/self-renewal properties and EMT26, 40. Also other EMT-TF have been shown to 
interact with KDM1A and recruit it as a molecular hook to their target promoters41, suggesting 
the presence of common regulatory mechanisms. Targeting either these interactions or the 
activity of KDM1A itself may therefore provide therapeutic avenues to prevent EMT and/or 
target chemo/radio-resistant cancer stem cells.  
 
Here, we demonstrated that mouse and human T-ALL cell lines with high Zeb2 mRNA 
expression levels are sensitive to KDM1A inhibition. Exactly how ZEB2 is capable of 
modulating KDM1A activity in the context of T-ALL remains to be determined. In AML cell 
lines, it was observed that KDM1A inhibition results in terminal differentiation by reactivation 
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of the all-trans-retinoic acid pathway, leading to a severe decline in proliferative capacity. 
Indeed, Li H. et al.29 recently demonstrated that high ZEB2 levels are essential for AML 
progression and loss of ZEB2 in mouse and human AML cells results in myeloid 
differentiation, similar to what has been observed for KDM1A inhibition. Also in AML cells, a 
ZEB2-KDM1A interaction could be demonstrated via co-immunoprecipitation experiments, 
thereby confirming this interaction in a separate leukemic setting. Interestingly, we also 
observed that KDM1A inhibition results in upregulation of the myeloid differentiation marker 
CD11B in the human T-ALL cell line LOUCY, suggesting overlapping molecular mechanism 
downstream of KDM1A inhibition in both leukemic settings. Nevertheless, our study also 
revealed that ZEB2-negative human T-ALL cell lines also showed strong KDM1A inhibitor 
sensitivity, suggesting that other mechanisms or oncogenic drivers/transcriptional factors, 
such as GFI1, might be able to bind and alter KDM1A activity and drive KDM1A inhibitor 
sensitivity in a ZEB2-independent manner41, 42. 
 
In this study, we have used a commercially available KDM1A inhibitor, GSK2879552, which 
was previously successfully used to analyze the in vivo effects of KDM1A inhibition on 
human small cell lung cancer xenografts. Here, in the context of T-ALL, we only observed a 
partial reduction of the leukemic burden in vivo. Therefore, T-ALL cell lines might need higher 
dosing or combinations with other chemotherapeutic agents (e.g. ATRA or HDAC inhibitors), 
as reported for other tumor entities43-45. The differences observed between the therapeutic 
efficacy of KDM1A inhibition in vitro and in vivo, suggests that paracrine factors might 
regulate compensatory pathways that prevent cell death upon KDM1A inhibition in vivo. 
Here, we demonstrate that exogenous IL7 can decrease the sensitivity to KDM1A inhibition 
in Zeb2 transgenic T-ALL cells. In line with this finding, human LOUCY T-ALL cells showed a 
similar up regulation of IL7R expression following KDM1A inhibition. Therefore, combination 
therapies inhibiting both KDM1A and the IL7R/JAK-STAT signalling pathway, e.g. using the 
JAK inhibitor Ruxolitinib, or inhibitors of the downstream effector BCL2, like ABT-199, may in 
vivo be more effective as compared to KDM1A monotherapy.  
 
It remains to be determined whether or not the KDM1A interaction is also important for the 
phenotypes observed upon ZEB2 loss in adult hematopoietic stem cells. These include 
multilineage differentiation blocks with skewing to the granulocyte lineage, and a 
myeloproliferative disorder-like phenotype with perturbed cytokine receptor signaling 
pathways8. Similarly, it is not yet known whether this interaction is essential for other recently 
demonstrated roles of ZEB2 in cytotoxic T-cell differentiation46, 47, NK terminal maturation48, 
dendritic cell differentiation49, as well as in other non-hematopoietic cell lineages such as 
melanocytes50, neurons and oligodendroglial cell fate and migration where Zeb2 has been 
previously demonstrated to play important roles51-53.  
 
To conclude, we have identified a novel ZEB2-KDM1A interaction in the context of T-ALL, 
which is essential for the survival of ZEB2 overexpressing cells. Also in human T-ALL cell 
lines we see increased KDM1A inhibitor sensitivity upon enforced ZEB2 expression, 
suggesting a putative novel therapeutic tool for the treatment of ZEB2-driven tumors. 
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Supplementary Figures 
 
 
 
 
 
 
 
 
 
Supplementary Figure 1. Sensitivity of two P53/R26-Zeb2
tg/tg
 Zeb2 overexpressing mouse T-ALL cell lines 
compared to two control P53/R26
+/+
 cell lines treated with 100nM GSK2879552 over a time period of 5 days. The 
CellTiter-Glo Luminescent Cell Viability Assay was used. 
 
 
Supplementary Figure 2. KDM1A protein levels in GSK2879552 sensitive and insensitive mouse and human T-
ALL cell lines. 
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Supplementary Figure 3. Differential gene expression pattern in P53/R26-Zeb2
tg/tg
 versus control P53/R26
+/+
 
mouse T-ALL cell lines (adjusted P-value < 0.05, triplicates).  
 
 
 
 
 
 
 
 
 
 
 
 
Supplementary Figure 4. Sensitivity of human T-ALL cell line LOUCY treated with increasing concentrations of 
GSK2879552 over a time period of 24 days. The CellTiter-Glo Luminescent Cell Viability Assay was used. 
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Supplementary Figure 5. Sensitivity of human T-ALL cell line (LOUCY and JURKAT) compared to the human 
AML cell lines (MEGAL, FKH1 and OCI-AML3) treated with increasing concentrations of GSK2879552 for 12 
days. The CellTiter-Glo Luminescent Cell Viability Assay was used. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Supplementary Figure 6. RNA sequencing results of human T-ALL cell lines (LOUCY, PEER, RPMI8402 and 
HSB2) after KDM1A inhibition (100nM, 48h). (A) Differential expression analysis represented by Volcano plots (B) 
List of common genes differentially expressed after KDM1A inhibition in all 4 human T-ALL cell lines.  
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Supplementary Figure 7.  Venn diagram indicating overlap between genes affected in the human T-ALL cell 
lines LOUCY and mouse T-ALL cell lines upon short-term KDM1A inhibition. Left, upregulated gene signature. 
Right, downregulated gene signature. 
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Supplementary Tables 
The Supplementary Tables can be consulted on the Leukemia website in the online version 
of the paper.  
 
Supplementary Table 1. Differential gene expression analysis between P53/R26+/+ and 
P53/R26-ZEB2tg/tg tumor lines. 
Supplementary Table 2. KEGG pathway analyses based on genes up- and downregulated 
in P53/R26-ZEB2tg/tg tumor lines. 
Supplementary Table 3. Differential gene expression analysis based on RNA sequencing of 
P53/R26-ZEB2tg/tg tumor lines upon KDM1A inhibition 
Supplementary Table 4. Differential gene expression analysis based on RNA sequencing of 
the human T-ALL cell lines LOUCY, PEER, RPMI8402 and HSB2 upon KDM1A inhibition 
 
Supplementary Materials and Methods 
Pull downs, Mass Spectrometry  
1.5 X 108 mouse T-ALL cells were washed once with phosphate-buffered saline and nuclear 
extracts were prepared using a high salt lysis buffer and douncer and subsequently dialyzed 
for 2 times 2 hours at 4°C with 100 mM KCl using a Slide-A-Lyzer dialysis cassette (Thermo 
Scientific). Finally, nuclear extracts were transferred to non-stick Eppendorf tubes (Alpha 
Laboratories) and cleared by centrifugation for 15 min, 13000rpm, at 4°C. A total of 60 μl of 
anti-FLAG M2 agarose beads (Sigma), washed and equilibrated in buffer C-100 (20 mM 
HEPES, pH 7.6, 10% glycerol, 100 mM KCl, 1.5 mM MgCl2, 0.2 mM EDTA, 1× complete 
EDTA-free protease inhibitor; Roche), was added to 1.5 ml of nuclear extract supplemented 
with 150U/ml Benzonase (Novagen) and incubated overnight at 4°C, rotating. Next day, 
beads were washed five times with 1 ml of C-100 buffer plus 0.02% NP-40 (C-100*) and 
eluted four times with C-100* containing 0.6 mg/ml FLAG tripeptide (Sigma) for 15 min at 
room temperature. Fractions were loaded onto a 10% Mini-Protean TGX precast gel 
(BioRad) and silver stained (Silverquest, Thermo Fisher Scientific). Western blot analysis 
confirmed that the most prominent band on silverstained gels is detected by anti-FLAG 
(Sigma) and anti-ZEB2 specific antibodies (Sigma). Elutions 1 and 2, containing the majority 
of FLAG-ZEB2 were loaded onto a 10% SDS-PAA gel (Thermo Scientific), the resulting 
proteins were separated by limited SDS-PAGE (5 minutes gel migration). For each sample 
the entire lane was excised and subjected to in-gel tryptic digestion and Liquid 
chromatography tandem mass spectrometry (LC-MS/MS) analysis as previously described1. 
Mass spectrometry raw data was processed and searched by MaxQuant software (version 
1.5.2.8)2.  Database searching was done against Mouse protein sequences downloaded from 
Uniprot (03/2015 release) using MaxQaunt default settings. Significance of specific protein–
protein interactions was performed using Perseus analysis software as described in Hubner 
and Mann, 20113. 
Co-immunoprecipitations and Western blotting  
Nuclear extracts were prepared as above. For FLAG-ZEB2 pull downs, anti-FLAG M2 
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agarose beads were used. For KDM1A pull downs, the rabbit polyclonal anti-KDM1A/LSD1 
antibody in combination with the Rabbit TrueBlot IP-set with beads (Rockland) was used 
according to manufacturer’s instructions. After 5 times washing and elution from the beads 
by denaturation, proteins were loaded on a 10% SDS-PAA gel (Thermo Scientific), followed 
by blotting on a PVDF membrane (Millipore). Non-fat milk was used as blocking before 
immunodetection. Primary antibodies used for detection: rabbit polyclonal anti-KDM1A/LSD1 
(1:1000; abcam), rabbit polyclonal anti-ZEB2 (1:1000, Sigma), rabbit polyclonal anti-SIP1 
(1:1000, Bethyl Laboratories), mouse monoclonal anti-FLAG M2 (1:500, Sigma). Secondary 
antibodies: HRP-conjugated TrueBlot anti-rabbit IgG (1:10000; Rockland) and HRP-
conjugated rabbit anti-mouse (1:10000; Merck). Detection was performed using Western 
Lightning ECL Substrate (Perkin Elmer). Images have been cropped for presentation.  
Cell culture  
The human T-ALL cell lines were purchased from the DSMZ repository (Braunschweig, 
Germany) and cultured in RPMI 1640 medium supplemented with 10% or 20% fetal bovine 
serum (FBS), 100 U/ml penicillin, 100 μg/ml streptomycin, 100 μg/ml kanamycin sulfate and 
2 mM L-glutamine at 37°C with 5% CO2. The mouse T-ALL cell lines were isolated and 
cultured as described before4 in RPMI 1640 medium supplemented with 15% heat-
inactivated FBS, 100 U/ml penicillin, 100 μg/ml streptomycin, 2 mM L-glutamine  and 5 ng/ml 
recombinant IL-7 (Peprotech) at 37°C with 5% CO2, 95% humidity. The commercially 
available KDM1A inhibitor GSK2879552 (ActiveBiochem) was dissolved in DMSO at a 
concentration of 10 mg/ml and diluted further in medium as indicated.  
Histone extractions  
For each histone preparation, 5x106 cells were harvested by centrifugation (1500 rpm, 4°C, 5 
min) and washed twice with ice cold PBS supplemented with 5mM Sodium Butyrate (NaB).  
Cell pellets were dissolved in 500µl TEB buffer (PBS supplemented with 5mM NaB, 
0.5%Triton X-100 and Halt Protease/Phosphatase inhibitor cocktails) and incubated for 10 
min on ice for nuclear extraction. Nuclei were collected via centrifugation (2000 rpm, 4°C, 10 
min) and washed once in 250µl TEB buffer. Nuclear pellets were resuspended in 25µl of 
freshly prepared 0.4M HCl and incubated 1 hour at 4oC. Histone preps were centrifuged 
(11000 rpm, 4°C, 10 min), supernatant transferred to new tube and neutralized by adding 10 
µl neutralizing buffer (0.5M Sodium phosphate dibasic, pH 12.5 NaOH supplemented with 
5nM NaB and Halt Protease/Phosphatase inhibitor cocktails). Protein concentration were 
measured using Bradford assay before further analysis using Western blotting according to 
standard protocols and as described above, using the following primary antibodies: total 
Histone 3 (1:1000, mouse mAb clone 1B1-B2, Active motif), H3K4me1 (1:1000, mouse mAb 
clone MABI0302, Active motif), H3K4me2 (1:1000, mouse mAb clone MABI0303, Active 
motif), H3K9me2(1:2000, rabbit pAb, Active motif). 
Generation of ZEB2 overexpressing KARPAS-45 cells  
The ZEB2 open reading frame (ORF) was shuttled using standard Gateway cloning (Life 
Technologies) from a pDONR207 entry clone into the doxycyclin-inducible lentiviral vector 
pSIN-TRE-GW-3xHA5, kindly provided by Prof. dr. Bart  Deplancke. Virus production was 
performed in HEK293TN cells using JetPEI polyplus with pMD2.G (envelope plasmid), 
psPAX2 (packaging plasmid) and pSIN-TRE-GW-3xHA hZEB2 (target plasmid) in 0.1/0.9/1 
ratios. Transduced KARPAS-45 cells were selected by puromycin selection (1µ/ml). Cells 
were cultured in medium with 20% tetracycline-free FCS. 48h before the start of the KDM1A 
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inhibition experiment, doxycyclin (1µg/ml) was added to induce ZEB2 expression. Every two 
or three days, the doxycylin was refreshed. 
qRT-PCR 
The miRNeasy mini kit (Qiagen) and the RNAse-Free Dnase set (Qiagen) were used to 
isolate RNA. cDNA synthesis was performed with the iScript Advanced cDNA synthesis kit 
(Bio-Rad). The SsoAdvanced Universal SYBR Green Supermix (Bio-Rad) was used for the 
PCR reactions while amplification and detection was done with the LightCycler 480 
instrument (Roche, model LC480). Every sample was analyzed in duplicate and the gene 
expression was normalized against 3 reference genes (B2M, HPRT1, YWHAZ or TBP). 
ZEB2 primers: (F) 5’ ATCAGATGAGCTTCCTACCA 3’, (R) 5’ GCAATTCTCCCTGAAATCCT 
3’; ITGAM (CD11B) primers: (F) 5’- GTGAAGCCAATAACGCAGC-3’, (R) 5’- 
TCTCCATCCGTGATGACAAC-3’; B2M primers: (F) 5’ TGCTGTCTCCATGTTTGATGTATCT 
3’, (R) 5’ TCTCTGCTCCCCACCTCTAAGT 3’; HPRT1 primers: (F) 5’ 
TGACACTGGCAAAACAATGCA 3’, (R) 5’ GGTCCTTTTCACCAGCAAGCT 3’; YWHAZ 
primers: (F) 5’ ACTTTTGGTACATTGTGGCTTCAA 3’, (R) 5’ CCGCCAGGACAAACCAGTAT 
3’; TBP primers: (F) 5’-CACGAACCACGGCACTGATT-3’, (R) 5’-
TTTTCTTGCTGCCAGTCTGGAC-3’ 
Xenotransplantations 
All animal experimentation was performed according to the regulations and guidelines of the 
Ethics Committee for care and use of laboratory animals of Monash University and Ghent 
University. The two P53/R26-ZEB2tg mouse T-ALL cell lines were intravenously injected in 6-
8 weeks old NOD scid gamma (NSG) mice. 2 X 106 cells in 150μl PBS were injected in 10 
recipient mice for each of the cell lines. The day after injection the mice were divided into two 
groups and the treatment was started with 1.5mg GSK2879552/kg body weight or with 
vehicle via oral gavage for 5 consecutive days. Mice were monitored for illness, leukemia 
development. NSG mice were injected at 6 weeks of age in the tail vein with 150μl PBS 
containing 5 X 106 LOUCY or PEER cells. At 3 (PEER) and 4 (LOUCY) weeks, the cells were 
engrafted and the mice were randomly divided into two groups and the treatment was started 
(day 0). Mice were treated with 1.5 mg GSK2879552/kg body weight or with vehicle via oral 
gavage for 17 consecutive days. Mice were daily weighted and monitored. The percentage of 
leukemic cells in the blood was analyzed by staining the cells with an PE-labeled antibody 
(Miltenyi Biotec) for human CD45 (hCD45), performing red blood cell lysis and measuring the 
percentage with S3e cell sorter (Bio-Rad). At the end of the experiment, all mice were 
sacrificed and spleens were collected. 
RNA sequencing  
Murine tumor cells were counted and seeded at a concentration of 5x105 cells/ml and half of 
the culture was treated with 200 nM of GSK2879552. 24 hours later cells were collected by 
centrifugation, lysed and RNA was prepared using RNeasy mini Plus kit (Qiagen) with an 
extra step for gDNA eliminitation.  For human cell lines, total RNA was extracted from 
LOUCY and PEER cells treated with GSK2879552 and DMSO vehicle control using the 
miRNeasy mini kit (Qiagen) according to the manufacturer's instructions. The RNA quality 
was evaluated using a RNA Nano chip on a Bioanalyzer (Agilent technologies). Library 
preparation for human and murine tumor samples was performed using the Illumina TruSeq 
RNA sample Prep Kit (San Diego, CA, USA) according to the manufacturer’s protocol. 
Library quality was checked using a DNA-1000 chip on a Bioanalyzer (Agilent technologies) 
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and enriched cDNA libraries were sequenced using an Illumina NextSeq 500 sequencer 
instrument. RNA sequencing data have been deposited to the GEO repository (GSE8312). 
Reads were aligned to mm38 reference genome using STAR2.4.2a. Genes were quantified 
on Ensembl38 GTF. DESeq2 was used to assess differential expression between various 
groups using a multifactorial design with 2 conditions and 2 genotypes including the 
interaction term. Functional annotation of differentially expressed genes was performed by 
DAVID gene ontology analysis using standard settings. Pathway analysis was performed by 
Reactome and KEGG using standard settings. Finally, pre-ranked GSEA was performed with 
the c2 MSigDB gene sets collection using the GSEA desktop application (Broad Institute, 
version v2.2.0). The analysis was run with the default parameters (1000 permutations) and 
classic enrichment statistic. A ranked list of all the genes detected in our RNA-seq 
experiment was given as input. As ranking metric, the sign of the fold change multiplied by 
the inverse of the adjusted p-value was used. 
1. Alonso H et al. Structural and mechanistic insights into alkane hydroxylation by 
Pseudomonas putida AlkB. Biochemical Journal. 2014;460(2):283-293. 
2. Cox J and Mann M. MaxQuant enables high peptide identification rates, individualized 
p.p.b.-range mass accuracies and proteome-wide protein quantification. Nature 
Biotechnology. 2008;26(12):1367-1372. 
3. Hubner NC and Mann M. Extracting gene function from protein-protein interactions 
using Quantitative BAC InteraCtomics (QUBIC). Methods. 2011;53(4):453-459. 
4. Peirs S et al. ABT-199 mediated inhibition of BCL-2 as a novel therapeutic strategy in 
T-cell acute lymphoblastic leukemia. Blood. 2014;124(25):3738-47. 
5.  Gubelmann C et al. Identification of the transcription factor ZEB1 as a central 
component of the adipogenic gene regulatory network. Elife. 2014.  
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1. The BCL-2 inhibitor ABT-199 as monotherapy and part of 
combination therapies for the treatment of T-ALL  
 
In our search for new therapies for the treatment of T-ALL, we noticed that the anti-apoptotic 
BCL2 gene is overexpressed in early immature T-ALLs. Inhibition of the BCL-2 protein with 
the BH3 mimetic ABT-199 proved to be a promising therapeutic strategy in certain T-ALLs. 
Especially the human T-ALL cell line LOUCY and primary T-ALLs with a developmental 
arrest at the early stages of T-cell development, were highly sensitive to ABT-199 (paper 1). 
Around the same time, Ni Chonghaile et al.1 performed BH3 profiling on a panel of human T-
ALL cell lines and primary T-ALL samples and demonstrated a dependency on BCL-2 for 
ETP-ALLs while the more mature T-ALLs depended upon BCL-XL for their survival. In line 
with this finding, they also tested the sensitivity to ABT-199 and identified LOUCY and ETP-
ALL patient samples to be sensitive, thereby confirming our results. Altogether, this means 
that T-ALL can be added to the growing list of cancers that could benefit from treatment with 
ABT-199.  
1.1. How to select T-ALL patients that may benefit from ABT-199 treatment 
 
Given the fact that ABT-199 is in clinical trials for several malignancies and already FDA-
approved to treat patients with CLL, conducting clinical trials with ABT-199 in T-ALL patients 
could be feasible in the near future. An important step in the design of such a trial will be the 
decision about the inclusion criteria. Similar to trials in other malignancies, including T-ALL 
patients that are refractory or relapsed following standard treatment could be a possibility. 
However, probably not all these patients will benefit from a treatment with ABT-199. Based 
on our study (paper 1) and the study of Ni Chonghaile et al.1, one could predict that 
especially patients with early immature T-ALL will favorably respond to treatment with ABT-
199 while patients with typical T-ALL would be better off with small molecules like navitoclax 
that also target BCL-XL. Interestingly, some T-ALL patient samples that did not have a very 
immature immunophenotype were also sensitive to ABT-199 in vitro1 (paper 1). As an 
example, an MLL-rearranged (MLLr) primary T-ALL sample showed high sensitivity to ABT-
199 in our panel (paper 1). With regard to this, two studies2, 3 recently demonstrated the 
potent in vitro and in vivo activity of ABT-199 in MLLr B-cell precursor ALL xenografts. In 
these MLLr ALLs, BCL2 expression was shown to be upregulated via DOT1-like histone 
lysine methyltransferase (DOT1L)-mediated H3K79me2/3 at the BCL2 locus3. In addition, 
Frismantas et al.4 performed ex vivo drug response profiling of 24 T-ALL patient-derived 
xenografts and reported high sensitivity to ABT-199 for some cortical and mature T-ALLs. 
Moreover, the treatment of mice xenografted with a very sensitive cortical T-ALL patient 
sample resulted in a significant delay of leukemia progression4. Altogether, these studies 
show that response to ABT-199 is not limited to early immature T-ALL.  
Having a biomarker that could predict whether a patient may benefit from treatment with 
ABT-199, would be of enormous value. Several studies, including ours (paper 1), found high 
BCL-2 levels as a potential predictive biomarker for ABT-199 sensitivity in a range of 
hematological malignancies2, 5-7. In contrast, high levels of the anti-apoptotic factors BCL-XL 
and MCL-1 can be inversely associated with response to ABT-1992, 5, 6, 8. Intrinsic 
mechanisms of resistance to ABT-199 include the binding of released BIM to stabilized MCL-
1 upon ABT-199 administration9. Moreover, high levels of phosphorylated BCL-2 can 
contribute to intrinsic resistance because phosphorylation alters the BH3-binding groove and 
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impedes ABT-199 binding10. These examples illustrate that quantifying individual BCL-2 
family members or ratios of selected proteins might not be reliable enough as a clinical 
biomarker since they do not capture the complex interactions between BCL-2 family 
members and do not take posttranslational modifications into account2, 6. Instead, BH3 
profiling could be used to predict ABT-199 response. Indeed, a strong correlation between 
mitochondrial BCL-2 dependence and ABT-199 sensitivity was observed in primary AML and 
T-ALL cells1, 6. On the other hand, the lack of dependence on BCL-XL and MCL-1 was a 
predictor of sustained response to ABT-199 rather than the dependence on BCL-2 in a 
phase II clinical trial of ABT-199 in AML11. BH3 profiling is a rapid and simple method that 
can be carried out in a couple of hours12. Treating a primary sample in vitro with ABT-199 is 
another possibility to predict the ABT-199 sensitivity of a patient. A treatment period of 16 
hours was used in our study (paper 1) but the fast killing of cells by ABT-199 allows the use 
of much shorter treatments (two to eight hours) to determine whether a sample is sensitive or 
not1, 6. 
1.2. Impact of ABT-199 on healthy blood cells 
 
Drugs targeting specific molecular targets are often referred to as “targeted therapies” or 
“precision medicine”. However, this does not necessarily mean that these drugs will only 
affect the cancer cells and won’t cause any side effects by inhibiting their target in healthy 
cells. The main side effects of ABT-199 are neutropenia, nausea, vomiting, diarrhea, 
hypokalemia and upper respiratory tract infections11, 13. Khaw et al.14 investigated the impact 
of ABT-199 on normal mature hematopoietic cell lineages and found that human peripheral 
blood B cells were highly sensitive compared to T cells and granulocytes. The normal B cells 
had even comparable in vitro sensitivities to ABT-199 as primary CLL patient cells14. Unlike 
Khaw et al.14, the study of Leverson and colleagues15 detected also an ABT-199-induced 
reduction in the granulocyte colony formation capacity of human bone marrow cells and a 
reduced amount of neutrophils in the blood of rats dosed with a selective BCL-2 inhibitor. 
This corresponds to the neutropenia observed in clinical trials with ABT-199. When ABT-199 
sensitivities were studied in isolated murine T cell subsets, DN thymocytes were more 
susceptible to ABT-199 than DP thymocytes14. This is in line with our expression profiles of 
human thymus subsets in which we noticed high levels of BCL2 in DN thymocytes and low 
levels in DP thymocytes (paper 1). Interestingly, ABT-199 did not affect CD34+ 
stem/progenitor cells purified from bone marrow of healthy persons16. 
1.3. Acquired resistance to ABT-199 and how to overcome it 
 
Over time, prolonged treatment with ABT-199 as single agent may result in the emergence of 
resistance. Indeed, although mice xenografted with the luciferase-positive LOUCY cells 
initially responded strongly to ABT-199 monotherapy, regrowth of the leukemia occurred 
already during the second week of treatment indicating the emergence of resistance (paper 
2). Similarly, Bodo and colleagues17 observed after 10 days of ABT-199 treatment a recovery 
of the tumors in a xenograft model of follicular lymphoma. By using resistant cell lines, 
generated by chronically exposing cells to increasing ABT-199 doses, several research 
groups studied the mechanisms of acquired resistance to ABT-199 in hematological 
malignancies. Common observations in cell lines with acquired ABT-199 resistance are 
reduced expression of the pro-apoptotic factor BIM and/or upregulation of the anti-apoptotic 
factors MCL-1 and BCL-XL
17-21. The increased levels of MCL-1 and BCL-XL can sequester 
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the released BIM from BCL-2 upon ABT-199 treatment and therefore prevent apoptosis19. 
The importance of these factors in driving the acquisition of resistance was further 
demonstrated by the increase in sensitivity to ABT-199 after knockdown of MCL-1 or BCL-XL 
in resistant cell lines19, 20. Moreover, c-Jun N-terminal kinase 1 or 2 (JNK1/2), AKT and/or 
ERK1/2 can be activated in response to ABT-199 and contribute to the acquired resistance17, 
19. As described in detail in the introduction of this PhD thesis, the PI3K/AKT/mTOR and 
RAF/RAS/MEK/ERK pathway can regulate pro- and anti-apoptotic factors. A schematic 
representation of how these pathways can contribute to the acquired resistance is given in 
Figure 1. Additionally, acquired selective mutations in BAX and BCL-2 have been 
described18, 21. The BAX mutation detected in an ABT-199-resistant human lymphoma cell 
line, was located in the transmembrane domain and hampered its anchoring in the 
mitochondrial membrane and subsequent induction of apoptosis upon ABT-199 treatment18. 
The BAX mutation in a resistant MM cell line resulted in a very short truncated protein21. 
Missense mutations identified in the BH3 domain of BCL-2 made binding of ABT-199 
impossible in resistant mouse lymphoma cells18.  
Unfortunately, T-ALL cell lines were not included in the above-mentioned studies. To study 
the mechanisms of acquired resistance to ABT-199 in the context of T-ALL, our LOUCY 
xenograft model could be used. Following a two-week treatment with ABT-199, hCD45+ 
leukemia cells could be isolated and compared to leukemia cells from vehicle-treated mice. 
Analyzing the mutation status and expression of BCL-2 family members and the activity of 
the PI3K/AKT/mTOR, IL7R/JAK/STAT and RAF/RAS/MEK/ERK pathway in these cells would 
provide valuable information. Furthermore, monitoring the acquisition of resistance to ABT-
199 during clinical trials via BH3 profiling could be useful to decide when to pause or stop 
treatment with ABT-199.  
Developing strategies to overcome or avoid the emergence of resistance to ABT-199 is very 
important. ABT-199 can be combined with inhibitors of proteins and pathways whose 
activation or upregulation is known to be involved in the acquisition of resistance. For 
example, the dual PI3K/mTOR inhibitor NVP-BEZ235 (dactolisib) is able to (re)sensitize B-
cell lymphoma cell lines to ABT-199 treatment via downregulation of MCL-119. Noteworthy, 
this inhibitor was also in our screen identified as a compound that could synergize with ABT-
199 in some T-ALL patient samples (paper 2). Another possible strategy is to combine ABT-
199 with a CDK inhibitor such as dinaciclib or flavopiridol. Members of the CDK family can 
regulate cell cycle progression (e.g. CDK1, CDK2 and CDK5) or transcription (e.g. CDK7, 
CDK8 and CDK9)22. Dinaciclib is a potent and selective inhibitor of CDK1, CDK2, CDK5 and 
CDK9. Since CDK9 phosphorylates RNA polymerase II to promote transcriptional elongation, 
its inhibition by dinaciclib results in transcriptional repression. Especially the downregulation 
of MCL-1 is known to be important for dinaciclib’s antitumor effects23, 24. Furthermore, 
dinaciclib also affects the protein stability of MCL-1 by inhibiting cyclinE/CDK2-mediated 
phosphorylation of MCL-125. As a logical consequence of this, dinaciclib synergizes with 
ABT-199 in DLBCL, a cancer in which BCL-2 and MCL-1 are frequently co-expressed23, 25.  In 
T-ALL, a broad sensitivity to the CDK7 inhibitor THZ-1 was found26. As CDK7 phosphorylates 
RNA polymerase II to initiate transcription and activates CDK9 as well27, this compound 
could be an alternative to use in combination with ABT-199. Moreover, in T-ALL cell lines 
treated with THZ1, the expression of the anti-apoptotic proteins MCL-1 and XIAP was 
reduced26. 
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Figure 1. Schematic representation of how the activation of the PI3K/AKT/mTOR and RAF/RAS/MEK/ERK 
pathway can contribute to the acquisition of resistance to ABT-199. (A) In cells that are sensitive to ABT-199 
treatment, BCL-2 is highly occupied with BIM. ABT-199 competes for the BH3 binding site on BCL-2 which results 
in the release of BIM. Next, BAX/BAK is activated and apoptosis is induced. (B) Cells that are for a long time 
continuously exposed to ABT-199 can acquire resistance. Activation of the PI3K/AKT/mTOR and/or 
RAF/RAS/MEK/ERK pathway results in the upregulation and stabilization of the anti-apoptotic factors MCL-1 and 
BCL-XL and in the downregulation and degradation of BIM. The downregulation of BIM will result in a lower 
occupation of BCL-2 while the high levels of MCL-1 and/or BCL-XL will sequester the released BIM. Therefore, 
ABT-199 can’t induce apoptosis anymore in these cells. 
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1.4. Combination therapies with ABT-199 in T-ALL 
 
Using ABT-199 in combination treatment schedules is not only interesting to avoid the 
emergence of resistance, it can also enhance the antileukemic effects.  Moreover, combining 
synergistic drugs allows to use lower drug doses and minimize side effects. Above all, ABT-
199 could be used to increase the chemosensitivity of T-ALL cells since most conventional 
chemotherapeutic agents trigger the intrinsic pathway of apoptosis28. Anderson et al.29 were 
the first to report synergistic activity between ABT-199 and a chemotherapeutic agent, 
cytarabine, in a T-ALL cell line. Next, we described synergism between ABT-199 and the 
chemotherapeutic agents doxorubicin, L-asparaginase and dexamethasone in human T-ALL 
cell lines (paper 1). In addition, several chemotherapeutic agents were included in our 
screen on T-ALL patient samples to identify promising combinations with ABT-199. ABT-199 
was able to enhance the effects of etoposide, vincristine, dexamethasone and prednisolone 
in some samples (paper 2). A limitation of our studies is the lack of in vivo experiments for 
these combinations. Ideally, to mimic more closely the clinical situation, where patients 
receive a cocktail of chemotherapeutic agents, we should evaluate the addition of ABT-199 
to the standard combination chemotherapy regimens instead of using only one 
chemotherapeutic agent in the combination experiments. This is exactly what Benito et al.3 
and Frismantas et al.4 successfully did in patient-derived xenograft models of BCP-ALL. 
Adding ABT-199 to a treatment with dexamethasone and vincristine prevented leukemia 
progression for more than 300 days in some BCP-ALL samples while treatment with ABT-
199 or chemotherapy alone resulted in a much shorter delay of disease progression4. 
On the other hand, we also tested combinations with clinically relevant targeted small-
molecule inhibitors (paper 2). The combination with the BET bromodomain inhibitor JQ1 was 
the most promising. Strong cell death was induced in cells treated with the combination and 
the observed response in xenograft models was superior to the response in mice treated with 
either of the drugs alone. However, bringing the combination of ABT-199 and a BET 
bromodomain inhibitor into clinical trials for patients with T-ALL might be challenging. Both 
drugs are not FDA-approved for the treatment of T-ALL and have never been used in T-ALL 
patients before. Moreover, there is no good biomarker to select patients that will likely 
respond to the combination of ABT-199 and a BET bromodomain inhibitor. Although the 
degree of synergism was correlated to the BCL-2 expression levels in human T-ALL cell 
lines, no correlation was observed in our 6 patient samples. Evaluation of this combination 
treatment in a larger panel of primary samples and extensive study of parameters that may 
influence the synergism would be necessary for this. Nevertheless, our study shed light on 
the working mechanism of BET bromodomain inhibitors and how they may enhance the 
sensitivity to ABT-199 in the context of T-ALL. In all T-ALL cell lines with clear synergism, 
JQ1 increased the levels of BIM and decreased the levels of BCL-2. By knocking down and 
overexpressing BIM in the T-ALL cell line KARPAS-45, we showed that increased BIM levels 
are important to enhance the antileukemic effect of ABT-199.     
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2. Pharmacological inhibition of LSD1/KDM1A for the treatment of T-
ALL 
 
As the transcription factor ZEB2 can drive the development of early immature T-ALL, 
targeting ZEB2 could be an interesting strategy to treat this group of patients. However, 
developing small molecules to directly target transcription factors is at present still very 
challenging. A more achievable strategy is to indirectly target transcription factors via their 
protein interactions30. We aimed to identify the protein interaction partners of ZEB2 in the 
context of T-ALL in order to learn more about the oncogenic function of ZEB2 and to find 
druggable targets (paper 3). One of the newly identified interaction partners was the lysine-
specific demethylase KDM1A. Noteworthy, previous studies have found the other ZEB family 
member ZEB1 as part of the CtBP-CoREST-KDM1A co-repressor complex in HeLa cells and 
pituitary cells31, 32. It is possible that the presence of ZEB1 or ZEB2 in this complex is cell-
type dependent.    
2.1. Limited in vivo activity of GSK2879552 in T-ALL xenograft models 
 
Pharmacological inhibition of KDM1A with the small molecule drug GSK2879552 in murine 
and human T-ALL cell lines demonstrated sensitivity in ZEB2-positive T-ALL. The treatment 
of mice xenografted with a Zeb2-overexpressing murine T-ALL cell line caused a significant 
delay in tumor latency. However, prolonging the survival for only some days is not 
spectacular. Moreover, when human T-ALL cell line xenografts were treated with 
GSK2879552, antileukemic effects were only seen in the blood and not in the spleen (paper 
3).  
Yet, Mohammad et al.33 obtained strong antitumor effects with the same drug in SCLC 
xenograft models. A substantial difference between both experimental setups was the 
location of the cancer cells in the body. While we used tail vein injection, allowing the cells to 
spread throughout the whole body (paper 3), Mohammad et al.33 injected the cancer cells in 
a matrigel subcutaneously in the flank. To rule out the possibility that GSK2879552 simply 
does not reach the leukemia cells in the spleen or that the dose is insufficient to treat T-ALL, 
we analyzed the effects on target genes and histone marks in leukemia cells isolated from 
the blood and spleen of LOUCY xenografts treated for 5 days (data not shown). The 
expression of CD11B, VIM and GFI1B was induced in leukemia cells located both in the 
blood and spleen compared to the expression in leukemia cells from vehicle-treated mice. 
Moreover, an increase in the H3K4me2 and H3K9me2 mark was detected in the spleen. 
Besides, higher doses had some added value in inducing the analyzed genes and histone 
marks. Altogether, daily treatment with 1.5mg GSK2879552/kg body weight was sufficient to 
provoke in vivo changes in transcription and histone marks, but insufficient to achieve strong 
antileukemic effects in our T-ALL xenograft models.  
Strikingly, the in vivo experiments carried out by Feng et al.34 in mice intravenously injected 
with the AML cell line MV4-11 yielded very nice results. The LSD1 inhibitor ‘Compound 1’ 
caused 80% less leukemia cells in the bone marrow, 81% less in the spleen and 92% in the 
blood.  
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Future experiments will need to sort out whether increasing the dose of GSK2879552 or 
using another KDM1A inhibitor can enhance the antileukemic effect of KDM1A inhibition in T-
ALL xenograft models.  
2.2. Combinations with KDM1A inhibitor that are worthwhile to test in the 
context of T-ALL 
 
Pharmacological inhibition of KDM1A in human T-ALL might be particularly useful as part of 
a combination therapy. In a first step, one could investigate whether adding a KDM1A 
inhibitor to standard chemotherapeutic agents would be useful. McGrath et al.35 reported 
synergism between the KDM1A inhibitor RN-1 and chemotherapeutic agent cytarabine in 
AML cell lines. Also chemotherapeutic agents that induce DNA damage might synergize with 
KDM1A inhibition. KDM1A is namely recruited to sites of DNA damage and promotes the 
DNA damage response36.  
Furthermore, combinations with some rationally chosen targeted small-molecule inhibitors 
could be evaluated. In AML, synergistic activity between a KDM1A and pan-HDAC inhibitors 
has been reported37. KDM1A is indeed linked to HDACs since it interacts with the CoREST 
and NuRD complexes, which contain HDAC1 and HDAC2. Moreover, KDM1A is 
downregulated by HDAC inhibitors38. A pan-HDAC inhibitor such as panobinostat or an 
HDAC1/2 specific inhibitor like romidepsin could be tested in combination with KDM1A 
inhibition. There even exists a small molecule named 4SC-202, developed by the company 
4SC, that inhibits both KDM1A and HDACs (1,2 and 3) and has been evaluated in a phase I 
clinical trial in patients with different types of blood cancer (ClinicalTrials.gov identifier: 
NCT01344707). Another option is the combination with a DNA methyltransferase inhibitor, 
such as the FDA approved decitabine. The rationale here is that KDM1A demethylates and 
increases the stability of DNMT139 and that synergism between decitabine and a KDM1A 
inhibitor has already been demonstrated in an AML cell line40. T-ALLs belonging to the HOXA 
molecular subgroup often have a MLL-AF10, MLL-AF4, MLL-ENL, CALM-AF10 or SET-
NUP214 fusion. The resulting fusion proteins recruit the methyltransferase DOT1L, leading to 
aberrant methylation of H3K7941. In this group of T-ALLs, combining KDM1A inhibition with 
DOT1L inhibition could be a good strategy since strong synergism between the DOT1L 
inhibitor SYC-522 and the KDM1A inhibitor ‘Compound 1’ was measured in MLLr AML cell 
lines34.  
Lastly, we demonstrated that exogenous IL7 decreases the sensitivity to KDM1A inhibition in 
Zeb2 transgenic T-ALL cells (paper 3). This suggests that paracrine factors, such as 
interleukin-7, might regulate compensatory pathways that prevent cell death upon KDM1A 
inhibition in vivo. Therefore, combination therapies inhibiting both KDM1A and the 
IL7R/JAK/STAT signalling pathway, e.g. using the JAK inhibitor Ruxolitinib, or inhibitors of 
the downstream effector BCL-2, like ABT-199, may in vivo be more effective as compared to 
KDM1A monotherapy. 
2.3. Understanding sensitivity towards KDM1A inhibition in ZEB2-negative T-
ALL 
 
The evaluation of the KDM1A inhibitor GSK2879552 on a panel of human T-ALL cell lines 
revealed that also some ZEB2-negative T-ALL cell lines strongly depend on KDM1A (paper 
3). Consequently, sensitive T-ALLs are not restricted to one particular T-ALL genetic subtype 
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or immunophenotype. The molecular mechanisms that drive susceptibility towards KDM1A 
inhibition in these ZEB2-negative T-ALLs are however still unknown. Future experiments will 
need to clarify which factors determine the sensitivity. 
In our study, we looked for protein interaction partners of ZEB2 and identified KDM1A (paper 
3). Doing the opposite, i.e. determining the interaction partners of KDM1A in both 
GSK2879552-sensitive and –insensitive cell lines, would be extremely interesting. Since 
KDM1A has no DNA binding capacity by itself, we hypothesize that KDM1A will bind to 
essential transcription (co)factors and/or putative oncogenic drivers in order to guide specific 
histone-modifying activity to their respective target genes. Cell line-specific expression of 
these essential factors may determine the KDM1A inhibition sensitivity. To confirm that these 
interaction partners critically mediate sensitivity towards KDM1A inhibition, knockouts of 
these protein partners could be made and used to check the influence on KDM1A inhibition 
sensitivity. This type of experiments could also help to identify predictive biomarkers. 
In a panel of SCLC cell lines, approximately 30% of the cell lines were sensitive to 
GSK287955233. In order to identify a predictive biomarker, Mohammad et al.33 studied the 
global DNA methylation in sensitive and insensitive SCLC cell lines. DNA hypomethylation 
correlated with sensitivity to GSK2879552 and a differentially methylated gene signature set 
was proposed as a predictive biomarker33. A similar strategy could be followed to identify a 
predictive biomarker in T-ALL. 
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3. General conclusions 
 
T-ALL is an aggressive and rare blood cancer. The chemotherapeutic agents that are 
commonly used to treat T-ALL patients are often associated with serious acute and long term 
side effects. Moreover, a significant part of the T-ALL patients can not be cured with the 
current treatment strategies. Therefore, there is a need for more effective and less toxic 
therapies. In this doctoral thesis, two new strategies to treat T-ALL were identified and 
evaluated in in vitro and in vivo models. 
In a first part of this work, high expression levels of the anti-apoptotic factor BCL2 were found 
in early immature T-ALL patients. Evaluation of the BCL-2 specific BH3 mimetic ABT-199 in 
human T-ALL cell lines, tumor cells from the Lck-Lmo2 mouse model and in primary patient 
samples indeed revealed high sensitivity to the BCL-2 inhibitor in immature T-ALLs. In 
mouse xenograft models, ABT-199 showed also promising anti-leukemic effects. In order to 
increase the efficacy of ABT-199 treatment and to avoid the emergence of resistance, 
combination strategies were searched for. ABT-199 synergized with standard 
chemotherapeutic agents. In addition, a screen in a panel of samples coming from patients 
with medium to very high risk T-ALL identified strong synergistic effects between ABT-199 
and the BET bromodomain inhibitors JQ1 and OTX-015. This synergism was also found in 
human T-ALL cell lines with high BCL-2 levels. Treatment of T-ALL cells with JQ1 resulted in 
the downregulation of super enhancer-associated genes and in the upregulation of the pro-
apoptotic factor BIM. Finally, the treatment of T-ALL xenograft models confirmed the superior 
effects of a combination treatment with ABT-199 and JQ1 compared to the treatment with 
each of the agents alone. 
Secondly, the lysine specific demethylase KDM1A was discovered as an interaction partner 
of the oncogenic driver ZEB2, a transcription factor that is often overexpressed in early 
immature T-ALL. Mouse and human T-ALL cell lines with high ZEB2 expression levels were 
sensitive to treatment with the KDM1A inhibitor GSK2879552. In addition, also some ZEB2-
negative human T-ALL cell lines were sensitive to this inhibitor. This indicates that also other 
factors than ZEB2 can determine the sensitivity to KDM1A inhibition. The treatment of human 
T-ALL cell line xenograft models elicited only limited anti-leukemic responses.      
Altogether, the studies performed as part of this doctoral thesis generated novel molecular 
insights and evaluated the use of two novel targeted therapeutics in T-ALL. The importance 
of combination therapies to increase the efficacy of these targeted agents was also 
illustrated. 
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Summary 
 
T-cell acute lymphoblastic leukemia (T-ALL) is a rare blood cancer that originates from the 
malignant transformation of T-cell progenitor cells (lymphoblasts). These malignant cells 
accumulate in the bone marrow where they hinder the production of normal blood cells. They 
can also infiltrate other organs such as the spleen, liver and central nervous system. The 
current treatment of T-ALL patients consists of high-dose multi-agent chemotherapy, 
potentially followed by hematopoietic stem cell transplantation. Over the past decades, the 
cure rate for childhood T-ALL has gradually increased and is nowadays approximately 85%. 
However, still a significant fraction of the children relapses and presents with very dismal 
survival perspectives. Furthermore, adults diagnosed with T-ALL have a much worse 
prognosis. On top of that, the chemotherapeutic agents often cause acute and long-term 
toxicities. Therefore, more effective and less toxic therapies are needed for the treatment of 
T-ALL. 
In this PhD thesis, we aimed to find new treatment strategies for T-ALL by investigating the 
molecular mechanisms that contribute to the development of T-ALL. The main focus was on 
early immature T-ALL, a subtype of T-ALL that is characterized by a developmental arrest at 
a very early stage of T cell development. Nevertheless, our findings appeared to be valuable 
for other T-ALL subtypes as well.  
In a first study (paper 1), we used gene expression profiling of a cohort of T-ALL patients to 
identify genes that are differentially expressed between early immature T-ALL and other T-
ALLs. The BCL2 gene, encoding the anti-apoptotic factor BCL-2, was found to be 
overexpressed in early immature T-ALL. Moreover, expression analysis of BCL2 in subsets 
of normal human thymocytes revealed a high expression in the CD34+ T cell progenitors and 
a gradual decrease in expression during T cell differentiation. These findings provided a 
rationale for targeting BCL-2 in immature T-ALL. Indeed, evaluation of the BCL-2 specific 
inhibitor ABT-199 in tumor cells from the Lck-Lmo2 mouse model and in a panel of human T-
ALL cell lines and primary patient samples, demonstrated especially in the more immature T-
ALL samples a high sensitivity to ABT-199. Sensitivity to ABT-199 was significantly 
correlated with BCL-2 expression in the human T-ALL cell lines. Next, strong antileukemic 
effects were measured upon ABT-199 treatment of mice xenografted with the immature T-
ALL cell line LOUCY. Altogether, our results indicated that T-ALL could be added to the 
growing list of cancers that may benefit from treatment with ABT-199. 
In order to increase the efficacy of the treatment and to lower the risk of developing 
resistance, combination strategies with ABT-199 were investigated. In a first phase, we 
tested whether adding ABT-199 to the current treatment schedule could be useful. 
Synergism between ABT-199 and the chemotherapeutic agents doxorubicin, dexamethasone 
and L-asparaginase was found in human T-ALL cell lines (paper 1). Next, combinations with 
clinically relevant compounds were tested in vitro on a panel of T-ALL patient samples. This 
screen confirmed that ABT-199 was able to enhance the antileukemic effects of several 
standard chemotherapeutics. However, the most promising combination was the one with the 
BET bromodomain inhibitor JQ1. In 5 out of 6 patient samples, this combination was 
synergistic to even very strong synergistic. Synergistic responses were also found in a panel 
of human T-ALL cell lines in which the combination treatment induced strong cell death. 
Moreover, the treatment of cell line- and patient-derived xenografts with the combination of 
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ABT-199 and JQ1 outperformed the treatment with the single agents. In addition, gene 
expression profiling of JQ1-treated cells yielded information about the transcriptional effects 
of JQ1 and provided insights in the mechanism of synergism with ABT-199. The increased 
expression of the pro-apoptotic factor BIM and its binding to BCL-2 in response to treatment 
with JQ1 contributed to the enhanced effects of ABT-199 (paper 2). 
Another important project in this thesis was about the transcription factor ZEB2 (paper 3). 
ZEB2 is an oncogenic driver of early immature T-ALL. Via pull down experiments followed by 
mass spectrometry, novel protein interaction partners of ZEB2 were identified in the context 
of T-ALL. We focused on the newly identified interaction with the lysine-specific demethylase 
KDM1A since inhibitors for this protein are available and in clinical trials for various human 
cancers. Both murine and human T-ALL cell lines with increased ZEB2 levels were sensitive 
to in vitro treatment with the KDM1A inhibitor GSK2879552. Interestingly, also several ZEB2-
negative human T-ALL cell lines were sensitive to KDM1A inhibition. Therefore, we believe 
that KDM1A could serve as a novel therapeutic target in a broad panel of human T cell 
leukemias. Surprisingly, the treatment of immunodeficient mice xenografted with 
GSK2879552-sensitive cell lines elicited only limited antileukemic responses. Hence, 
inhibition of KDM1A in human T-ALL might be particularly useful as part of a combination 
therapy.  
In conclusion, two new strategies to treat T-ALL were identified and evaluated in in vitro and 
in vivo models. First, the BH3 mimetic ABT-199 proved to be a promising drug to treat T-
ALLs that depend on the anti-apoptotic factor BCL-2 for their survival. Moreover, its efficacy 
was further improved in combination with standard chemotherapeutic agents or a BET 
bromodomain inhibitor. Secondly, KDM1A was found as an interaction partner of the 
oncogenic driver ZEB2 and T-ALLs with high ZEB2 expression were sensitive to 
pharmacological inhibition of KDM1A. However, the in vivo results with the KDM1A inhibitor 
GSK2879552 were not spectacular. Therefore, combination therapies with GSK2879552 
should be tested to overcome this problem. 
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Samenvatting 
 
T-cel acute lymfatische leukemie (T-ALL) is een zeldzame bloedkanker die ontstaat uit de 
kwaadaardige transformatie van voorloper T-cellen (lymfoblasten). Deze kwaadaardige 
cellen accumuleren in het beenmerg waar ze de productie van normale bloedcellen hinderen. 
Ze kunnen ook infiltreren in andere organen zoals de milt en lever en in het centraal 
zenuwstelsel. De huidige behandeling van T-ALL patiënten bestaat uit hoge dosissen van 
verschillende chemotherapeutica die eventueel gevolgd worden door een hematopoietische 
stamceltransplantatie. De voorbije decennia is de genezingskans voor kinderen met T-ALL 
geleidelijk aan gestegen tot ongeveer 85% momenteel. Desalniettemin zijn er nog steeds 
kinderen die hervallen en heel slechte overlevingskansen hebben. Volwassenen die de 
diagnose van T-ALL krijgen, hebben trouwens een veel slechtere prognose. Daarenboven 
veroorzaakt de chemotherapie vaak acute en lange termijn toxiciteit. Er is dus nood aan 
doeltreffendere en minder toxische behandelingen voor T-ALL. 
In dit doctoraat zochten we naar nieuwe behandelingsstrategieën voor T-ALL door de 
moleculaire mechanismen die bijdragen aan de ontwikkeling van T-ALL te onderzoeken. De 
nadruk lag op vroeg immature T-ALL, een subtype van T-ALL dat gekenmerkt wordt door 
een ontwikkelingsstop in een heel vroeg stadium van T-cel ontwikkeling. Onze bevindingen 
bleken echter ook waardevol te zijn voor andere T-ALL subtypes. 
In een eerste studie (paper 1) gebruikten we genexpressie profileringen van T-ALL patiënten 
om genen te identificeren die differentieel tot expressie komen tussen vroeg immature T-ALL 
en andere T-ALLs. We vonden dat het gen BCL2, dat codeert voor de anti-apoptotische 
factor BCL-2, hoog tot expressie kwam in vroeg immature T-ALL. Bovendien toonde 
expressie-analyse van BCL2 in subsets van normale humane thymocyten een hoge BCL2 
expressie aan in CD34+ voorloper T-cellen en een geleidelijke daling in expressie tijdens T-
cel differentiatie. Deze bevindingen leidden tot het idee om BCL-2 te inhiberen in vroeg 
immature T-ALL. Evaluatie van de BCL-2 specifieke inhibitor ABT-199 in tumorcellen van het 
Lck-Lmo2 muismodel en in een panel van humane T-ALL cellijnen en primaire 
patiëntenstalen liet inderdaad zien dat vooral de meer immature T-ALL cellijnen en primaire 
patiëntenstalen heel gevoelig waren voor ABT-199. Gevoeligheid voor ABT-199 was 
significant gecorreleerd met BCL-2 expressie in de humane T-ALL cellijnen. Vervolgens 
werden sterke anti-leukemische effecten gemeten na behandeling met ABT-199 in een muis 
xenograft model met de humaan immature T-ALL cellijn LOUCY. Kortom, onze resultaten 
gaven aan dat T-ALL kon toegevoegd worden aan de groeiende lijst met kankers die 
voordeel kunnen halen uit een behandeling met ABT-199. 
Om de doeltreffendheid van de behandeling te verhogen en om het risico op resistentie te 
verkleinen, werden combinatiestrategieën met ABT-199 onderzocht. In een eerste fase 
hebben we getest of het nuttig zou zijn om ABT-199 toe te voegen aan de huidige 
behandelingsschema’s. Er werd synergisme gevonden tussen ABT-199 en de 
chemotherapeutische agentia doxorubicine, dexamethasone en L-asparaginase in humane 
T-ALL cellijnen (paper 1). In een volgende stap werden combinaties met klinisch relevante 
compounds in vitro getest op een panel van T-ALL patiëntenstalen. Deze screen bevestigde 
dat ABT-199 in staat was om de anti-leukemische effecten van verschillende standaard 
chemotherapeutica te versterken. Echter, de meest belovende combinatie was die met de 
BET bromodomein inhibitor JQ1. In 5 van de 6 patiëntenstalen was deze combinatie 
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synergistisch tot zelfs sterk synergistisch. Synergistische responsen werden ook gevonden in 
een panel van humane T-ALL cellijnen waarin de behandeling met de combinatie sterke 
celdood induceerde. Daarenboven overtrof de behandeling van cellijn- en patiënt- afgeleide 
xenografts met de combinatie van ABT-199 en JQ1 de behandeling met de afzonderlijke 
agentia. Verder leverde de genexpressie profilering van JQ1-behandelde cellen informatie op 
over de transcriptionele effecten van JQ1 en inzichten in het mechanisme van het 
synergisme met ABT-199. De verhoogde expressie van de pro-apoptotische factor BIM en 
zijn binding aan BCL-2 als reactie op de behandeling met JQ1, droeg bij aan de versterkte 
effecten van ABT-199 (paper 2). 
Een ander belangrijk project in deze thesis ging over de transcriptiefactor ZEB2 (paper 3). 
ZEB2 is een oncogene driver van vroeg immature T-ALL. Via pull down experimenten 
gevolgd door massaspectrometrie werden nieuwe eiwit interactiepartners van ZEB2 
geïdentificeerd in de context van T-ALL. Wij focusten op de nieuw geïdentificeerde interactie 
met het lysine-specifieke demethylase KDM1A aangezien er inhibitoren beschikbaar zijn 
voor dit eiwit waarvan sommige in klinische studies geëvalueerd worden voor verschillende 
humane kankers. Zowel muizen als humane T-ALL cellijnen met verhoogde ZEB2 niveaus 
waren gevoelig voor in vitro behandeling met de KDM1A inhibitor GSK2879552. Interessant 
is dat ook meerdere ZEB2-negatieve humane T-ALL cellijnen  gevoelig waren voor inhibitie 
van KDM1A. Daarom geloven wij dat KDM1A zou kunnen dienen als een nieuw 
therapeutisch doelwit in een breed panel van humane T-cel leukemieën. Verrassend genoeg 
wekte de behandeling van immunodeficiënte muizen met xenograften met GSK2879552-
gevoelige cellijnen enkel beperkte anti-leukemische effecten op. Vandaar dat inhibitie van 
KDM1A in humane T-ALL vooral nuttig kan zijn als onderdeel van een combinatietherapie. 
In conclusie kunnen we stellen dat twee nieuwe strategieën om T-ALL te behandelen 
geïdentificeerd en geëvalueerd werden in in vitro en in vivo modellen. In de eerste plaats 
bleek de BH3 mimetic ABT-199 een veelbelovend geneesmiddel om T-ALLs te behandelen 
die afhankelijk zijn van de anti-apoptotische factor BCL-2 voor hun overleving. De 
doeltreffendheid van dit geneesmiddel werd verder verbeterd in combinatie met standaard 
chemotherapeutische agentia of met een BET bromodomein inhibitor. In de tweede plaats 
werd KDM1A geïdentificeerd als een interactiepartner van de oncogene driver ZEB2 en T-
ALLs met hoge ZEB2 expressie waren gevoelig voor farmacologische inhibitie van KDM1A. 
De in vivo resultaten met de KDM1A inhibitor GSK2879552 waren echter niet spectaculair. 
Om dit probleem op te lossen zouden combinatietherapieën met GSK2879552 getest 
moeten worden.  
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Belgium 
 Course on Molecular Aspects of Hematological Disorders, June 7th-8th, 2016, Rotterdam, The 
Netherlands 
 21th Congress of EHA, June 9th-12th, 2016, Copenhagen, Denmark.  
 
Supervision of students 
 Project Biomedical Biotechnology, 1st Master of Biochemistry and Biotechnology 2013-
2014: Jonas Van Damme, DOT1L inhibition in the treatment of SET-NUP214 rearranged 
leukemias. Supervision: Sofie Peirs, promotor: Bruce Poppe, co-promotor: Pieter Van 
Vlierberghe 
 Project Biomedical Biotechnology, 1st Master of Biochemistry and Biotechnology 2013-
2014: Robin Vanluchene, DOT1L inhibition in the treatment of SET-NUP214 rearranged 
leukemias. Supervision: Sofie Peirs, promotor: Bruce Poppe, co-promotor: Pieter Van 
Vlierberghe 
 Project Biomedical Biotechnology, 1st Master of Biochemistry and Biotechnology 2014-
2015: Wouter Versmessen, Testen van nieuwe compounds voor de behandeling van humane 
leukemie. Supervision: Sofie Peirs, promotor: Bruce Poppe, co-promotor: Pieter Van 
Vlierberghe 
 Z-lijn paper, 2nd Bachelor of Medicine 2014-2015: Hanne Vandevoort, Het anti-apoptotisch 
eiwit BCL-2 als doelwit voor therapie in kanker. Supervision: Sofie Peirs, promotor: Bruce 
Poppe  
 Z-lijn paper, 2nd Bachelor of Medicine 2014-2015: Jesse Demuytere, DNA methylatie 
inhibitoren in de behandeling van leukemie. Supervision: Sofie Peirs, promotor: Pieter Van 
Vlierberghe  
 Z-lijn paper, 2nd Bachelor of Medicine 2014-2015: Cédric De Landsheer, DNA methylatie 
inhibitoren in de behandeling van leukemie. Supervision: Sofie Peirs, promotor: Pieter Van 
Vlierberghe  
 Z-lijn paper, 2nd Bachelor of Medicine 2015-2016: Esthelle Colle, De anti-apoptotische 
eiwitten BCL-2 en MCL-1 als doelwitten voor de therapie van hematologische maligniteiten.  
Supervision: Sofie Peirs, promotor: Pieter Van Vlierberghe  
 Z-lijn paper, 2nd Bachelor of Medicine 2015-2016: Jeroen Dobbelaere, De anti-
apoptotische eiwitten BCL-2 en MCL-1 als doelwitten voor de therapie van hematologische 
maligniteiten.  Supervision: Sofie Peirs, promotor: Pieter Van Vlierberghe  
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Dankwoord (word of thanks) 
 
Mijn doctoraat is een geweldig boeiende periode geweest waarin ik heel veel heb bijgeleerd 
en fantastische mensen heb leren kennen. Door onderzoek te doen en door veel te lezen, 
besef ik meer en meer hoe complex maar ook hoe boeiend het menselijk lichaam is. Verder 
heb ik ook gemerkt dat experimenten soms meer vragen oproepen dan dat ze antwoorden 
opleveren. Als onderzoeker word je vaak geconfronteerd met tegenslagen en frustraties: 
ettelijke keren proberen om een techniek te doen werken, een toestel dat plots niet meer wil 
meewerken of slechte/onverwachte resultaten. Gelukkig zijn er ook veel momenten die grote 
voldoening geven. Zowel voor de leuke als de iets mindere momenten, is het fijn om die te 
kunnen delen met geweldige mensen. Ik zou daarom graag een aantal mensen bedanken, 
zonder wie ik dit onderzoek nooit tot een goed einde had kunnen brengen en zonder wie mijn 
doctoraatsperiode niet half zo leuk was geweest. 
Eerst en vooral moet ik mijn promotoren, prof. Bruce Poppe en prof. Pieter Van Vlierberghe, 
ontzettend bedanken. Dankzij de inspirerende lessen van Bruce kreeg ik interesse om 
onderzoek te doen in het Centrum voor Medische Genetica. Bruce, jij hebt me de kans en 
het vertrouwen gegeven om te komen solliciteren en om samen een FWO mandaat aan te 
vragen. Ondanks je drukke agenda maakte je steeds tijd en toonde je interesse om de 
lopende projecten te bespreken. Ik zal nooit vergeten hoe je met me kwam praten toen ik het 
tijdens mijn eerste jaar moeilijk had. Pieter, van jou heb ik onwaarschijnlijk veel geleerd. Ik 
bewonder je als onderzoeker: je zit vol ideeën, hebt een enorme kennis en kan als de beste 
verbanden leggen. Ik ben ook heel dankbaar dat ik aan veel verschillende projecten heb 
kunnen meewerken en kon samenwerken met internationale onderzoeksgroepen. Daardoor 
heb ik veel technieken geleerd en heb ik verschillende aspecten van T-ALL kunnen 
onderzoeken. Wat ik enorm fijn vind, is je positieve ingesteldheid. Als ik wat in de knoop zat 
met bepaalde experimenten of resultaten, had ik na een gesprek met jou toch altijd terug de 
volle goesting om het nog eens opnieuw of op een andere manier te proberen. 
Steven, jou moet ik ook bedanken om me te betrekken in je ZEB2-verhaal en voor de fijne 
samenwerking over KDM1A inhibitie in T-ALL. Je hebt zoveel ervaring en kennis waardoor ik 
al heel veel heb geleerd van jou. 
En, wat een geweldige collega’s en zelfs vrienden heb ik leren kennen tijdens mijn doctoraat! 
Eerst in MRB1, waar iedereen altijd bereid was om te helpen of om een babbeltje te slaan in 
de gang, en nu ook in MRB2. Jullie zijn met veel te veel om allemaal op te sommen, maar 
weet dat ik ervan genoten heb om samen met jullie in het labo te staan, samen aan de 
keukentafel te zitten en samen naar feestjes te gaan. Op congres gaan was altijd geweldig 
met jullie en we hebben samen toch een stukje van de wereld gezien. Vooral het extra 
weekje vakantie in Florida met Gloria en Renate was een topervaring. Béa, Filip, Gloria, Julie, 
Juliette, Lindy, Maaike, Morgan, Pieter R., Pieter VV., Renate, Sara, Steven en Tim, oftewel 
het superfantastische PVV team, bedankt voor de vele afterwork-drinks, -dinners, en –party’s, 
bedankt voor de beforework-breakfasts, bedankt voor de duringwork-breaks en bedankt voor 
de sfeer en lachmomenten. Béa, jij verdient een speciaal dankwoordje, want hoeveel werk 
heb jij niet verzet! Zonder jou had ik nooit zoveel goede resultaten gehad en waren de 
intense dagen op het einde van muizenexperimenten niet te doen geweest. Je bent dan ook 
niet voor niets verkozen tot beste “Lab Citizen” van de hele wereld! 
Chapter 6: Curriculum Vitae & Word of thanks 
186 
  
Wie ik ook niet mag vergeten, zijn mijn familie en vrienden. Jullie hebben voor de nodige 
afleiding gezorgd en me heel veel ontspannende momenten bezorgd. Mama en papa, 
dankjewel voor jullie onvoorwaardelijke steun. Tot slot, dankjewel lieve Arun om er altijd voor 
mij te zijn.  
 
 
 
 
 
 
 
 
 
 
 
 
